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I do not know what I may appear to the world, but to myself I seem to have 
been only like a child playing on the seashore, and diverting myself in now 
and then finding a smoother pebble or a prettier shell than ordinary, whilst the 
great ocean of truth lay all undiscovered before me. 
 
- Sir Isaac Newton 
 
 
 
 
To strive, to seek, to find, and not to yield. 
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ABSTRACT   
 
L-glutamate is the major excitatory neurotransmitter in the central nervous system of 
vertebrates. By playing a dual role as amino acid and neurotransmitter, glutamate fulfils a 
large array of physiological functions supporting neuronal development and cognitive 
performances. Consequently, the alteration of glutamate signaling entails profound 
detrimental effects that give rise to disease conditions, including excitotoxicity induced by 
cerebral ischemia. 
Although plenty of reports have so far investigated the effects of cerebral ischemia at 
postsynaptic sites, little is known concerning the mechanisms activated by the ischemic injury 
at the presynaptic terminal.  
NMDA receptors have been classically implicated in both postsynaptic and presynaptic 
pathways sustaining excitotoxicity. Recently, their intracellular association with the c-Jun N-
terminal kinase (JNK) has also been involved in such pathological mechanisms. 
Our previous findings already underlined a specific and unique involvement of the JNK2 
isoform as a pivot player in glutamate release, when focusing on presynaptic sites.  
In the present dissertation we furthermore unveil the selective protein-protein interaction 
between JNK2 and Syntaxin-1a (STX1a), emphasizing their unexplored contribution in the 
docking and release of synaptic vesicles at the basis of the NMDA-evoked excitotoxicity. 
On purpose, we have developed JGRi1, a cell-permeable peptide able to selectively disrupt 
JNK2/STX1a interplay and pharmacologically prevent the downstream ischemic cascade.  
To uphold our hypothesis, we tested JGRi1 in several experimental settings, achieving a 
convincing neuroprotective effect also in a murine model of ischemia over a conveniently 
long therapeutic window.  
Conclusively, we analysed the presence of three single nucleotide polymorphisms (SNPs) on 
the STX1A gene in a cohort of stroke patients, evidencing a haplotype correlated with 
increased susceptibility to cerebral ischemia. 
Overall, we here confirm JNK fundamental implication in glutamate release at presynaptic 
level, moreover presenting for the first time JGRi1, a selective inhibitor of the JNK2/STX1a 
interaction that may represent a new therapeutic tool able to modulate glutamate overflow in 
various conditions, including neurodegenerative diseases and ischemia-linked pathologies. 
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INTRODUCTION 
 
1. Ischemia: definition and classification 
Stroke is a medical condition characterized by a severe reduction of blood flow to the brain 
that impedes the attainment of a proper metabolic demand and the clearance of waste toxins.  
This emergency condition results in cerebral hypoxia and initiation of the ischemic cascade, 
ultimately leading to delayed neuronal vulnerability or cell death, depending on the severity 
and duration of the insult (https://www.nhlbi.nih.gov/health/health-topics/topics/stroke).  
In the 1970s the World Health Organization defined stroke as a "neurological deficit of 
cerebrovascular cause that persists beyond 24 hours or is interrupted by death within 24 
hours" (World Health Organisation, Geneva 1978). This statement was devised to reflect the 
potential reversibility of tissue damage in less severe and manageable conditions, although the 
time frame of 24 hours was chosen arbitrarily.  
Cerebral blood flow in healthy human brain is about 50–55 mL/100 g tissue/minute, although 
neurons can still survive in a quiescent state at 23 mL/100 g tissue/minute. Below this value, 
the ischemic cascade is set into motion. Dropping down to 12 mL/100 g tissue/minute cell 
death occurs rapidly and the injury gets irreversible (Harper, 1965). 
Two main types of stroke are diagnostically recognized (Fig. 1): 
 ischemic stroke, caused by decrease or lack of blood supply to the brain, 
possibly due to either thrombosis, embolism or systemic hypoperfusion. In this 
context, focal ischemia indicates a condition confined to a specific region of 
the brain whereas global ischemia, presumably due to cardiac arrest, 
encompasses wider areas. 
 hemorrhagic stroke, due to bleeding at either intracerebral or subarachnoid 
compartments. 
Roughly 90% of the strokes are ischemic while the others are hemorrhagic.  
Additionally, the hemorrhagic transformation of ischemic infarction is a well-recognized 
consequence of cerebral stroke (https://www.nhlbi.nih.gov/health/health-
topics/topics/stroke/types; Roger et al., 2011). 
To what concern this dissertation, the first type of stroke, i.e. ischemia, will be mainly taken 
into consideration, although both share common pathological mechanisms. 
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Fig. 1 
Ischemic vs. Hemorrhagic stroke. 
CT scans of a healthy control subject (A), and patients with ischemic (B) or hemorrhagic (C) stroke, as indicated 
by the arrows. 
D) Blockade of a blood vessel and lack of blood flow to a brain area is the major cause underlying ischemic 
stroke (left panel). Hemorrhagic stroke is instead due to the rupture of a blood vessel with subsequent blood 
leakage within the cerebral parenchyma (left panel).  
 
 
 
1.1 Epidemiology 
According to estimates from the ‘Global Burden of Diseases, Injuries and Risk Factors Study 
2010’, ischemic stroke is recognized as the second leading cause of premature death in the 
developed countries, responsible for substantial health care costs (3–7% of the total health-
care expenditure in high-income countries) and worldwide long-term disability (Wang et al., 
2016).  
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Basically, every 40 seconds an ischemic event occurs, every 4 minutes a person dies from 
stroke, more than 10% of deaths every year are due to stroke, and, among survivors, 
approximately half of people who have had a stroke live less than one year more (Mozaffarian 
et al., 2016). 
The NHLBI Framington Heart Study for stroke estimated a global prevalence and mortality 
respectively accounting for 33 million and 6.5 million cases annually, with an incidence 
supposed to more than double in each successive decade, especially for males over the age of 
55 (Bramlett and Dietrich, 2004; Wolf et al., 1977). 
Incidence is subjected to a large geographical variation, and is worryingly increasing in 
developing countries, due to lack of good health services and social policy for stroke 
prevention and/or care (i.e. smoking cessation, blood pressure control, proper dietary regimen, 
accessibility to health services in terms of treatment availability, rehabilitation strategies, 
secondary and long-term prevention). Consequently, although stroke mortality rates and 
mortality-to-incidence ratios have generally decreased in the past two decades, the global 
burden of stroke in terms of absolute number of people affected every year and related deaths 
is increasing and ultimately accounting for an epidemiological transition, with most of the 
burden actually gathered in developing countries (Fig. 2). 
Additionally, although stroke has been traditionally thought as a disease of elderly, the 
proportion in people younger than 65 years is substantial, and more than 83.000 children and 
youths younger than 20 years are affected by stroke annually.  
If these trends in stroke incidence and mortality will continue, by 2030 there will be almost 12 
million of stroke deaths per year (Feigin et al., 2014). 
 
 
 
A 
5 
 
 
 
 
Fig. 2 
Stroke epidemiology. 
A) Age-standardized stroke incidence per 100 000 person/year for 2010. 
B) Age-standardized stroke mortality per 100 000 people for 2010. 
C) Stroke mortality-to-incidence ratio (MIR) for 2010. 
(Adapted from Feigin et al., 2014). 
 
 
 
1.2       Risk factors and preventive care  
As a cardiovascular based disease, the main modifiable risk factors for stroke are chronic 
hypertension and atrial fibrillation, followed by thromboembolism and coagulation 
impairment, vascular disease and cerebral microangiopathology, hypercholesterolemia and 
dyslipidemia, obesity, diabetes mellitus, hyperhomocysteinemia, active and passive cigarette 
smoking, alcohol and amphetamine-like drugs abuse, lack of physical activity, and unhealthy 
diet, especially rich in processed red meat (Bailey, 2017; Meschia et al., 2014).  
B 
C 
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In addition, genetic predisposition (congenital heart defects, familial increased Von 
Willebrand factor), environmental factors and gender may undermine ischemia 
pathomechanisms, with premenopausal women presenting for instance lower stroke incidence 
and better recovery compared to men (Bramlett and Dietrich, 2004; Roof and Hall, 2000). 
Primary prevention is generally less effective than secondary prevention for recurrent 
episodes. However updated and detailed guidelines have been published for both conditions 
by the American Heart Association/American Stroke Association (Kernan et al., 2014; 
Meschia et al., 2014). 
35–50% of stroke risk is accounted only by high blood pressure, indeed a reduction of 10 
mmHg systolic pressure may lower ischemic occurrence up to 40% in both primary and 
secondary prevention.  
Statins were shown to reduce the risk of stroke by about 15% (O’Regan et al., 2008). On the 
other hand, although oral anticoagulants and antiplatelet drugs have been the mainstay of 
stroke prevention for over 50 years, they are by now mostly indicated in secondary 
prevention after stroke or transient ischemic attack, in order to avoid unsolicited bleeding. 
Among those drugs, warfarin and aspirin have been respectively the most used, with lower 
aspirin doses (50–150 mg daily) resulting as effective as higher daily doses, but with lesser 
unwanted side effects. Thienopyridines including clopidogrel and ticlopidine used in 
monotherapy might be slightly more effective than aspirin and showed a lower risk 
of gastrointestinal bleeding. Dipyridamole in association with aspirin provided tiny additional 
therapeutic benefits, therefore it is currently recognized as a secondary therapeutic option for 
the prevention of recurrent ischemic events (Diener, 2006; Kirshner, 2008).  
The recourse to carotid endarterectomy or carotid angioplasty can be ultimately evaluated to 
remove atherosclerotic stenosis of the carotid artery, particularly to prevent secondary 
occurrence (Rothwell et al., 2003).  
 
 
1.3 Causes 
Cerebral ischemia has been linked to a variety of diseases or abnormalities. Individuals with 
sickle cell anemia, compressed blood vessels, ventricular tachycardia, plaque build-up in the 
arteries, blood clots, extremely low blood pressure as a result of heart attack, and congenital 
heart defects have for instance a higher predisposition to brain ischemia in comparison to 
healthy counterparts (Sveinsson et al., 2014). 
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Overall, the main causes accounting for ischemic events, as reported above, have been 
identified in: 
- Thrombosis 
- Embolism 
- Cerebral hypo-perfusion 
Additionally, a small percentage of cases is represented by ischemic stroke of unknown 
etiology and therefore referred to as cryptogenic stroke (Bailey et al., 2012; Scullen et al., 
2015). 
Atherosclerosis may for instance disrupt the blood supply by narrowing arterial lumen, 
directly forming blood clots within the vessels, or indirectly promoting the release of small 
emboli through the disintegration of atherosclerotic plaques (Lyaker et al., 2013).  
Embolic infarction occurs when a thrombus in the circulatory system (typically in the heart as 
a consequence of atrial fibrillation or in the carotid arteries) breaks off, enters the cerebral 
circulation and lodges in, blocking brain perfusion and preventing oxygen or glucose in 
properly reaching brain areas.  
The fall of metabolic supply to the cellular milieu following those events leads to failure of 
energy-dependent processes and initiates a complex cascade of molecular pathogenic events 
that endanger cell survival and ultimately produce cell injury and death (see paragraph 2 – 
“Pathophysiology of cerebral ischemia”). 
On the other hand, silent strokes can also occur without any outward symptoms. Despite 
patients are typically unaware they have had a stroke, brain damage may obviously present 
and place the patient at increased risk for both transient ischemic attack and major stroke in 
the future. 
 
 
1.4 Signs and symptoms 
Sudden-onset face weakness, arm drift and abnormal speech are the warning signs mostly 
evaluated in order to correctly diagnose stroke. These assessments are rapid and easy to make, 
therefore they are deeply valuable in acute conditions. Apart from neurological and 
neuropsychiatric consequences, ischemia also induces immediate immune depression, 
generally reflected in the fever and sometimes pneumonia suffered within few days by about 
60% of patients. Additionally, association with severe headache or vomiting may occasionally 
present in case of hemorrhagic stroke.  
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A scoring system called ROSIER (Recognition of Stroke in Emergency Room) has been 
recommended in emergency settings to identify features belonging to the medical history and 
physical examination of the patient (Nor et al., 2005). 
Stroke symptomatology typically starts suddenly, over seconds to minutes, and strictly 
depends on the specific areas of the brain affected. Consequently, the wider the ischemic area, 
the higher the number of cerebral functions likely to be lost.  
If cerebral areas affected contain one of the three prominent central nervous system pathways, 
i.e. spinothalamic tract, corticospinal tract, and dorsal column (Fig. 3), symptoms may include 
hemiplegia and facial muscle weakness with initial flaccidity followed by spasticity, 
numbness, sensory depletion. A brainstem stroke may produce symptoms related to deficits in 
the cranial nerves, including altered smell, taste, hearing, or vision, nystagmus, ptosis and 
weakness of ocular muscles, decreased reflexes (i.e. gag, swallow, pupil reactivity to light), 
weakness in tongue, balance problems, altered breathing and heart rate. On the other hand, 
cortical ischemia may be responsible for aphasia, dysarthria, apraxia, visual field defects, 
memory deficits, disorganized thinking, confusion, lack of proprioceptive insight. Finally, 
cerebellum infarction is linked with ataxia, altered movement coordination, vertigo and 
disequilibrium.  
Most symptoms generally affect only one side of the body, usually contralateral with respect 
to the brain area where ischemia has occurred.  
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Fig.3  
The Circle of Willis and the cerebral vasculature. 
Inferior aspect of the arteries at the basis of the brain, depicting the Circle of Willis and its main vessels. 
The temporal lobe and the cerebellar hemisphere have been removed on the right side of the left image. 
According to the patient symptomatic presentation, it is possible to speculate the anatomical site where the 
ischemic insult has occurred. 
(Adapted from “Atlas and Text-book of Human Anatomy Volume III Vascular System, Lymphatic system, 
Nervous system and Sense Organs”). 
 
 
 
1.5 Diagnosis 
Diagnosis for stroke is typically assessed by imaging techniques, including MRI (Magnetic 
Resonance Imaging) and multimodal CT (Computed Tomography) scans, along with a 
neurological and physical examination (https://www.nhlbi.nih.gov/health/health-
topics/topics/stroke/diagnosis). 
Structural imaging has been classically used to assess the presence and extent of ischemia or 
to evaluate a differential diagnosis. At present, however, the improvement in functional 
imaging approaches including perfusion-CT or Diffusion-Weighted Imaging (DWI) has 
revolutionized both diagnosis and management of acute ischemic stroke that has thereby been 
redefined from an all-or-none process to a dynamic and evolving process.  
Particular concern is nowadays focused on the diagnostic discrimination between ischemic 
core and penumbra. Additionally, several studies have been converted into clinical practice, 
opening the possibility to select patients on the basis of imaging criteria for favourable 
clinical outcomes with conventional thrombolytic therapy (Leiva-Salinas and Wintermark, 
2010).  
As a matter of fact, the most important service that imaging provides is to rapidly identify 
those ischemic patients who are most likely to benefit from immediate treatment. This sub-
population includes patients with severe neurological symptoms due to an occlusion of a 
major artery and who are candidates for recanalization using intravenous thrombolysis or 
intra-arterial intervention to remove the occlusion. 
 Outcomes for these patients are determined by symptom severity, specific artery occluded, 
size of the infarct at the time of presentation, and overall treatment efficacy (Ginsberg, 2016; 
González, 2012) (Fig. 4). 
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Fig. 4   
Ischemic stroke to right middle cerebral artery (MCA) in 2 patients. 
(Top row) 38-year-old man with severe left-sided paralysis of unknown time of onset.  
A) CT angiography demonstrates occlusion of the right MCA (arrow).  
B) Diffusion MR imaging shows a small diffusion abnormality in the right hemisphere.  
C) Perfusion MR imaging displays abnormalities involving the entire right MCA territory. Because of the large 
diffusion/perfusion mismatch and the likely poor long-term outcome, the decision was made to proceed to intra-
arterial thrombolysis, which was successful.  
D) A follow-up head CT scan shows infarction in the region of the right corona radiata and a small portion of 
cerebral cortex. The patient made a complete recovery. 
 
(Bottom row). 61 year old male with mild left sided weakness that began 12.7 hours earlier. 
E) CT angiography demonstrates a proximal right MCA occlusion (arrow). 
F) Initial DWI reveals multiple punctate foci of diffusion abnormality in the right hemisphere. 
G) Mean transit time (MTT) MR perfusion map demonstrates a large volume of poor perfusion involving the 
majority of the right MCA territory. The patient did not undergo thrombolytic therapy because of the long time 
between stroke onset and imaging. 
H) The patient condition worsened to severe paralysis, and follow-up MRI showed a large area of infarction. 
(Adapted from González, 2012). 
 
 
 
Doppler ultrasound and arteriography, electrocardiogram, echocardiogram, and blood tests 
may be added to determine risk factors, confirm the supposed diagnosis or rule out other 
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possible underlying causes. For the assessment of stable strokes, SPECT (Single Photon 
Emission Computed Tomography) is used to evaluate cerebral blood flow whereas PET 
(Positron Emission Tomography) estimates the metabolic activity of neurons. 
The National Institute of Health Stroke Scale (NIHSS) is a validated tool used by healthcare 
providers to objectively quantify the impairment caused by acute stroke and document patient 
neurological status in order to predict lesion size as well as both short- and long-term 
disability. 
The NIHSS is composed of 11 items evaluating levels of consciousness, language, neglect, 
visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss, 
scoring each specific ability between 0 and 4. Higher scores are indicative of some level of 
impairment. The individual scores from each item are summed up in order to calculate the 
patient's total NIHSS score, with 42 being the highest value, correlated with higher stroke 
severity (Ortiz et al., 2008). 
 
 
1.6 Clinical management 
In auspicious situations wherein sufficient circulation is restored within short periods of time, 
symptoms may be transient. Conversely, if a significant amount of time passes before 
perfusion restoration, brain damage may be permanent.  
The management of acute ischemic stroke patients is driven by the catchphrase “time is 
brain”. Indeed, as reported in a renowned paper, an average of 1.8 million neurons is lost 
every minute that appropriate treatment is not given (Saver, 2006) (Fig. 5). 
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Fig. 5 
Time is brain, but each patient has his own time. 
Neuronal loss estimated from 68 patients who presented to the emergency room within 24 hours from stroke 
onset. The mean for all 68 patients is the dashed line (Adapted from González, 2012).  
The table shows indicative values of loss in terms of neurons, synaptic connections and years of life in relation to 
time window without therapeutic intervention. 
 
 
 
Immediate reperfusion appears essential to effectively provide neuroprotection, although 
reperfusion injury may occur when the restoration of blood supply is provided to the ischemic 
tissue (see paragraph 2.6 – “Reperfusion injury”) (Nour et al., 2013). 
When ischemic stroke is detected within 3 to 4 hours from the onset, the usage of systemic 
thrombolysis, i.e. intravenous administration of recombinant tissue plasminogen activator (rt-
PA; Alteplase
®
) might be beneficial in order to break down eventual clots formation (Hacke 
et al., 2008; Saver, 2006). Indeed, the administration of  thrombolytic drugs within the first 3 
hours from stroke onset provided neuroprotection and  improved functional outcomes versus 
placebo (i.e. a modified Rankin scale score of 0 or 1 at 3–6 months), although overall 
mortality was not affected. On the other hand, thrombolysis proved to worsen patients 
outcome if applied 4.5 hours after ischemia onset (Alper et al., 2015; Emberson et al., 2014; 
Wardlaw et al., 2014).  
Recent evidence moreover underlined the efficacy of mechanical endovascular thrombectomy 
over intravenous thrombolysis, due to the complete vessel recanalization showed in three of 
four treated eligible patients (Chamorro et al., 2016; Goyal et al., 2015; Jovin et al., 2015). 
Additionally, thrombolysis may not be ideal for various restrictions and complications, 
limiting to 10% or less the percentage of patients treatable within the appropriate time 
window. Surgical removal of the blood clot may also improve the outcome if done within 7 
hours from the onset, but again, only eligible patients could benefit (Saver et al., 2016). 
TIME NEURONS LOST SYNAPSES LOST ACCELERATED AGING 
1 second 32 000 230 million 8.7 ore 
1 minute 1.8 million 14 billion 3.1 weeks 
1 hour 120 million 830 billion 3.6 years 
Avg. stroke 1.2 billion 8.3 trillion 36 years 
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Recent evidence from randomized trials confirmed that aspirin is a key drug for reducing up 
to 13% the long-term risk of recurrent stroke (Diener, 2006; Rothwell et al., 2016). On the 
other hand, tight blood sugar and blood pressure control in the first few hours did not provide 
evidence for improved functional outcomes. 
Stroke rehabilitation has been formulated to support stroke patients in overcoming disabilities 
and possibly regaining the skills of everyday living. Moreover, rehabilitation helps stroke 
survivors to adapt to challenges, prevent secondary complications and educate family 
members to play a supportive role. 
The rehabilitation team is usually multidisciplinary and involves staff with different skills, 
including physicians trained to rehabilitation medicine, clinical pharmacists, nurses, 
physiotherapists, occupational therapists, speech and language therapists, orthotists and 
psychologists. 
Based on current experience, the rehabilitation should start as quickly as possible since 
important functional benefits have been mostly seen in the first few months, with little chance 
for further improvement after the sixth month. Physical exercise and a proper diet may 
positively contribute to the rehabilitation success, although a complete recovery is unusual 
(Barclay et al., 2015; Brady et al., 2016; Saunders et al., 2013).  
In this context, the modified Rankin Scale, introduced in 1957 by Dr. Rankin (Rankin, 1957) 
and subsequently modified to its currently accepted form by Prof. Warlow, is by now the 
commonly used scale to categorize the degree of disability in daily activities for patients who 
have suffered a stroke or akin neurological disabilities. The Rankin scale ranges from 0 to 6, 
running from perfect health to death. The evaluation has been recently implemented with a 
structured questionnaire during the interview process, becoming the most widely used clinical 
outcome measure for the assessment of ischemia in clinical trials (Bruno et al., 2010). 
Similarly, the Barthel Index, introduced in 1965 (Mahoney and Barthel, 1965) but lately 
updated, is an ordinal scale used to measure patients performances concerning their 
independence in activities of daily living (ADL). Each of the ten performance item describes 
ADL and mobility and is rated with a given number. Higher scores are associated with greater 
likelihood of being able to live at home with a respectable degree of independence following 
discharge from hospital. The scale is regarded as a reliable tool to predict the functional 
outcomes related to stroke for in-patient rehabilitation and occupational therapy. Its use 
in clinical stroke trials has been only recently reconsidered (Ohura et al., 2017). 
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Ultimately, novel virtual reality and video games for rehabilitation are under evaluation for 
potential future use (Balasubramanian et al., 2010). In addition, self-management programs 
are special trainings currently used to educate stroke survivors to cope with everyday 
challenges and meet their own goals during their recovery process (Fryer et al., 2016). 
 
 
1.7 Prognosis 
As reported above, ischemia is a severe condition with no cure at the moment, recognized as 
second leading cause of worldwide death, and accounting for a 0.35 mortality-to-incidence 
ratio (Wang et al., 2016). 75% of stroke survivors are limited by the  inability to employability 
due to disability at physical, mental, and emotional level, depending on the anatomical 
location and size of the ischemic lesion (Edwardson and Dromerick, 2017). 
In this frame, physical disability can include muscle weakness, numbness, incontinence, 
apraxia, pain, appetite, speech and vision loss. Cognitive deficits resulting from stroke include 
perceptual disorders, aphasia, dementia, anosognosia, impairments of attention and memory. 
Moreover, up to 10% of patients may develop seizures, therefore anticonvulsants may be a 
supportive therapeutic option (Gilad, 2012). 
Emotional problems may be due to direct damage of emotional centres in the brain or to 
frustration from adaptation to post-ischemic challenges. 30 to 50% of stroke survivors suffer 
post-stroke depression. Additionally, anxiety, panic attacks, sleep disturbances, flat affect, 
apathy, disruption of self-identity, social isolation, mania, and ultimately psychosis may 
thereby present (Dhamoon et al., 2010). 
 
 
 
2.  Pathophysiology of cerebral ischemia 
Cerebral ischemia results from the severe or prolonged decrease of blood flow supplying 
nervous tissues, following the transient or permanent occlusion of a cerebral artery.  
The consequent hemodynamic deprivation of oxygen and glucose thereupon elicits the 
transition to anaerobic metabolism, characterized by fall in the synthesis of high energy 
phosphate compounds such as ATP, and release of lactic acid by-products. Metabolic stress, 
energy depletion, ionic imbalances and build-up of potentially toxic substances follow. 
Furthermore, vascular perturbations, platelet aggregation, cerebral cells swelling, vasogenic 
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edema, tissue vulnerability and peri-infarct depolarization subsequently occur, promoting a 
complex cascade of biochemical and molecular pathogenic events finalized toward neuronal 
death (Bramlett and Dietrich, 2002; Danton et al., 2002; Dewar et al., 2003). 
The ischemic core is generally enclosed by an area known as penumbra, wherein still 
salvageable neurons do not receive enough blood to communicate, although they do receive 
sufficient oxygenation to avoid cell death for a limited period of time.  
As a consequence, the penumbra has become a milestone in stroke research, being a tissue 
potentially recoverable. Conversely, neurons from the central core of dense ischemia almost 
inexorably will die.  
Clinically, ischemic penumbra may be recognized through precise hemodynamic and 
electrophysiological parameters, being declaimed as a diagnostic territory for neuroprotection, 
neurorepair and brain plasticity, ultimately allowing an extension of the window for 
therapeutic intervention (Ramos-Cabrer et al., 2011).  
Neuroimaging devices are currently providing optimized functional thresholds to differentiate 
ischemic core and penumbra in acute ischemic stroke patients. Cerebral perfusion-CT has for 
instance recently allowed a fine discrimination comparing baseline profiles from both areas, 
in order to select eligible patients for efficacious reperfusion therapy (Yu et al., 2016) (Fig. 6). 
 
 
 
           
 
 
 
Fig. 6 
Human brain ischemia, ischemic core and penumbra. 
A) Cerebral infarction with liquefactive necrosis is shown in the upper right of this image, within the distribution 
territory of the middle cerebral artery.  
B) Schematic representation of ischemic core and penumbra, an area bearing potential to reverse neurologic 
impairment with post-stroke therapy 
 
A B 
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2.1 Molecular mechanisms underlying pathophysiology: excitotoxicity, inflammation, 
oxidative stress 
Although the adult human brain constitutes only 2% of total body weight, nerve cells account 
for 25% of basal metabolism and exhibit exceedingly high metabolic rates, consuming 20% of 
the total oxygen intake.  
Consequently, immediate loss of consciousness ensues already 10 seconds after oxygen 
deprivation, while any cerebral activity ceases if interruption of blood flow proceeds for more 
than 60 to 90 seconds. After few minutes of hypoxia neurons generally suffer irreversible 
injury and possibly death, as also detected by electroencephalographic demise (Lee et al., 
2000).  
Various pathological molecular mechanisms have been ascribed as potentially underlying the 
ischemic neuronal death, including oxidative stress and generation of reactive oxygen species 
(ROS), mitochondrial dysfunction, aberrant nitrosylation, delayed inflammation, and, 
ultimately, caspase3-driven apoptosis or necrosis (Chamorro et al., 2016; Iadecola and 
Alexander, 2001; Shi et al., 2013). In particular, the exact percentage of cells dying through 
apoptosis versus necrosis depends upon several factors including stroke severity and duration, 
with necrotic neuronal damage occurring early after severe ischemic insults, while apoptotic 
cell death may be observed with milder insults and longer survival periods (Bramlett and 
Dietrich, 2004). 
Besides those possible concomitant causes, scientific consensus presently recognizes a major 
culprit in excitotoxicity, a term coined by John Olney in 1970 to indicate the neuronal 
impairment specifically driven by glutamatergic storm persisting in the synaptic cleft 
(Borsello et al., 2003a; Lee et al., 2000; Olney, 1969) (Fig. 7). 
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Fig. 7 
Molecular mechanisms underlying the pathophysiology of ischemia, 
A) Schematic overview of the molecular mechanisms involved in brain ischemia, including excitotoxicity, 
inflammation and oxidative stress (see text for further details). 
B) (Top) Evolution of the expanding volume of the ischemic core over the salvageable penumbra, during 
ischemic cerebral demise. (Bottom) Time-course of the damaging events in focal cerebral ischemia, represented 
as a function of time and impact of the insult on final outcome. 
(Adapted from Dirnagl et al., 1999). 
 
 
 
2.2 Excitotoxicity 
Notwithstanding the ubiquitous nature of L-glutamate, excitotoxicity is a pathological state 
exclusively confined to the central nervous system.  
The massive shutdown of neural activity upon blood flow reduction is primarily induced by 
K
+
 efflux from neuronal voltage-gated potassium channels, leading to membrane 
hyperpolarization. The ensuing abrupt redistribution of ions results in anoxic depolarization, 
relief of Mg
2+
 block from N-methyl-D-aspartate (NMDA) receptors, intracellular free Ca
2+
 
influx and ultimately excessive release of excitatory neurotransmitters, especially glutamate.  
Due to its versatile and ubiquitous role in neuron-to-neuron communication, neuronal growth 
and axon guidance, differentiation, migration and survival, as well as in synaptic transmission 
and plasticity (Collingridge and Lester, 1989; Nisticò et al., 2015; Yang et al., 2012), the 
concentration of this abundant dicarboxylic amino acid in the cerebrospinal fluid is 
physiologically strictly regulated on the order of 10 µM. During ischemia, however, as a 
consequence of the transmembrane ion gradient rundown, both synaptic vesicles from nerve 
terminals and reversed glutamatergic transporters from astrocytes massively release glutamate 
in the extracellular space to a concentration up to 10-fold increased with respect to 
physiological conditions. 
This near-millimolar extracellular glutamate overflow turns out to be deeply harmful yet 
neurotoxic, indeed producing overactivation of ionotropic glutamate receptors, especially 
the NMDA subtype. The further induction of K
+
 efflux together with a rapid Ca
2+
 influx 
relentlessly trigger neuronal death, waving from the ischemic core out toward the margins of 
the ischemic penumbra (Dirnagl et al., 1999; Zipfel et al., 2000). Conclusively, the spreading 
of membrane shunting exacerbates both metabolic demand and energy failure, further 
enhancing glutamate release and breaking into harmful cytotoxic cascades, in a vicious 
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downward spiral that leads to neuronal cell body swelling and eventually death, either 
apoptotic or necrotic (Fig. 8). 
In addition to these damaging effects, ischemia also results in loss of structural integrity of 
cerebral tissue, blood vessels and blood brain barrier (BBB) architecture. The release of 
proteases including matrix metalloproteases, namely zinc- and calcium-dependent enzymes 
that break down collagen, hyaluronic acid, and connective tissue, may indeed contribute to 
cerebral edema and inflammation, secondarily exacerbating ongoing brain injury (Lakhan et 
al., 2013; Yang and Rosenberg, 2015). 
 
 
 
 
Fig. 8 
Excitotoxicity: the insult driven by glutamate spillover. 
A) Schematic representation of the excitotoxic cascade within a neuronal cell (see text for further details). 
B) Micrographs show Hoechst-stained neurons 24 h after treatment with NMDA 100 µM. Cellular death is 
evidenced by the decreased level of cellular nuclei (Adapted from Borsello et al., 2003a). 
 
 
 
2.3 Glutamate and NMDA receptors 
Interest in excitotoxicity arose almost sixty years ago when the food additive monosodium 
glutamate was found to be neurotoxic. Starting from the pioneering work conducted by Van 
Harreveld in 1959 (Harreveld, 1959), further evidence subsequently corroborated and then 
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unequivocally confirmed the hypothesis that glutamate is not only the primary excitatory 
neurotransmitter in the adult brain, responsible for neuronal depolarization and action 
potentials firing, but also that glutamate-mediated excitotoxicity is a primary contributor to 
ischemic neuronal death (Lai et al., 2014; Mangia et al., 2012). 
Glutamate exerts its biological activity mainly through the activation of the ionotropic 
glutamate-gated NMDA receptor (NMDAR), a cerebral hub that detects and processes 
extracellular glutamate signals into diverse intracellular signaling outputs (Green and 
Nayeem, 2015). NMDARs are calcium-permeable ion channels that also allow the entry of 
monovalent cations such as Na
+
 and K
+
. As a result, NMDARs activation mostly produces 
excitatory postsynaptic responses, generally slower but longer-lasting than those produced by 
AMPA or kainate receptors. 
To be opened, beside the two agonist molecules of glutamate, NMDARs additionally require 
the presence of a co-agonist (the amino acid glycine) as well as the removal of the Mg
2+
 block 
within the pore channel, achieved by postsynaptic neuronal depolarization following 
repetitive firing of the presynaptic cell (Fig. 9). 
 
 
 
 
 
Fig. 9 
NMDA receptor model illustrating important binding and modulatory sites.  
Activation of NMDA receptors requires binding of glutamate with the co-agonist glycine for the efficient 
opening of the ion channel. The most relevant modulatory sites are the magnesium (Mg
2+
) site within the ion 
channel and an S-nitrosylation site located toward the extracellular N-terminal of the receptor. Other modulatory 
sites include binding sites for Zn
2+
, polyamines, and drugs like phencyclidine (PCP), memantine, MK-801. 
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NMDAR exhibits therefore a dual input requirement (both a sufficiently strong depolarization 
and a presynaptic release of glutamate) that together with the slow activation and deactivation 
kinetics allow the accurate integration and codification of incoming patterns of synaptic 
activity and the consecutive transduction into enduring alterations in synaptic strength.  
These events are at the basis of NMDARs pivotal activity in regulating physiological synaptic 
plasticity and cognitive processes, as well as in NMDARs association with psychiatric 
disorders, neurodegenerative diseases, and neurodevelopmental dysfunctions (Gonda, 2012). 
Since ‘80s, studies performing intracerebral injection of the NMDAR blockers such as 2-
amino-7-phosphonoheptanoic acid (AP-7) evidenced a prevention of neuronal death following 
cerebral ischemia in murine animal models (Simon et al., 1984), providing the first hint that 
glutamate, and particularly its action on the NMDARs, is a condition necessary for ischemic 
brain damage. 
Apparent agreement from recent studies claims that NMDARs may fulfil a dual-effect 
depending on the level of receptor activity. As shown in both in vitro and in vivo assays, high 
levels of NMDA stimulation induce neuronal death, while survival is promoted by low levels 
of NMDA stimulation (Brassai et al., 2015). The specific function and localization of many 
synaptic and extra-synaptic proteins further corroborated the hypothesis that, in turn, synaptic 
and extra-synaptic NMDARs can be functionally coupled to different downstream pathways, 
conferring such differential functional outputs on neurons.  
To confirm, the propensity for synaptic NMDARs to support synaptic activity and thereby 
neuronal survival is accompanied by the activity-driven activation of the downstream survival 
pathway involving the ERK kinase, the transcription factor CREB and the survival-promoting 
protein BDNF (Brassai et al., 2015). Conversely, extra-synaptic NMDARs have been 
correlated with downstream death pathways and are persistently activated when abrupt 
glutamate spillover circulates within the brain, such as during cerebral ischemia. As a 
consequence, extra-synaptic NMDARs induce the shut-off of CREB and BDNF production, 
while PTEN, cdk5, DAPK1, calpains and JNK are downstream activated, leading to neuronal 
failure (Lai et al., 2014) (Fig. 10).  
Recent findings however underlined a possible contribution also of synaptic NMDARs in 
excitotoxicity in primary hippocampal neurons (Wroge et al., 2012), underlining the urgency 
to clearly determine the mechanisms by which the location of these receptors may promote 
their coupling to specific downstream signaling proteins and biochemical cascades.  
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The molecular cloning of NMDAR subunits has provided improved understanding of the 
receptor pharmacology.  
The most accepted theory describes NMDARs as heterotetramers composed of an essential 
NR1 subunit that is functionally coupled to at least one of the NR2A-D subunits and, less 
commonly, to an NR3 subunit, in order to fully establish the ionotropic activity of the channel 
(Gambrill and Barria, 2011; Stephenson, 2006). The specific subunit composition confers 
specific channel kinetics, agonist affinity, sensitivity to channel blockers, and differential 
brain localization.  
 
 
 
Fig. 10 
Distinct subpopulations of the NMDA receptor mediate neuronal death and survival.  
A) Under normal conditions, synaptic activity maintains neuronal survival via activation of the synaptic 
NMDAR. This pro-survival effect is dependent on the calcium influx through the receptors.  
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B) During cerebral ischemia, excessive release of glutamate into the synapses and extra-synaptic sites causes 
global stimulation of NMDAR at both locations. The C-terminal domain of the GluN2B (NR2B) subunit acts as 
a major hub for recruiting death-signaling proteins, which in turn is activated by calcium influx through the 
receptors to induce neuronal death. 
(Adapted from Lai et al., 2014). 
 
 
 
Additionally, the physiological role of NMDAR subunits depends expressly on their large and 
distinct cytoplasmic tails that mediate intracellular signaling (Ryan et al., 2008). 
On this line, synaptic receptors containing the NR2B subunit proved to be sufficient for the 
induction of neuronal death, whereas the synaptic NR2A protects against the excitotoxic 
insult. Similarly, extra-synaptic NR2A subunit is pro-survival while NR2B yields widespread 
neuropathy (Liu et al., 2007).  
Consistent with the extra-synaptic localization of the NR2B-containing NMDAR, there may 
be several advantages in selectively inhibiting the NR2B receptor subtype and its downstream 
death signaling pathways (Hardingham et al., 2002; Vizi et al., 2010, 2013).  
Ifenprodil
®
 and derived compounds (i.e. eliprodil
®
, traxoprodil
®
) are for instance a distinct 
class of NMDAR antagonists that act non-competitively at the NR2B NMDAR with high 
subunit specificity (Tajima et al., 2016; Williams, 1993). These NR2B-selective compounds 
provided therapeutic efficacy against ischemic neuronal death in vitro and in vivo, 
circumventing nonspecific blockade of the pro-survival NR2A NMDAR and without 
presenting the psychotomimetic side effects commonly seen with conventional NMDAR 
antagonists (Kalia et al., 2008).  
Nevertheless, a major pitfall affecting such selective blockade is the non-trivial physiological 
function developed also by NR2B NMDAR, including their role in the extinction of fear 
memory, the manifestation of stress responses, and the learning of new memory. Secondly, 
also these specific NMDAR blockers are only effective when administered immediately 
following stroke, and they quickly lose their efficacy when treatment is delayed, thereby 
limiting the time window for effective drug administration.  
Overall, this emerging evidence points to distinct NMDAR subpopulations that may 
differentially promote either neuronal death or survival.  
A deeper identification of those distinct intracellular pathways may lead to the development 
of novel and more therapeutically practical pharmacological agents able to convincingly 
target the molecular pathways affecting the ischemic brain. 
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2.4 The role of calcium toward death or survival  
Calcium is a crucial signaling molecule in cell biology and its tight regulation via 
sequestration or extrusion is fundamental for cellular function. Additionally, this cation plays 
an essential role in glutamate-mediated excitotoxicity, therefore any dysfunction of calcium 
homeostatic machinery is expected to exacerbate neuronal overload and to contribute to the 
ischemic injury.  
In particular, the initial calcium overload following excitotoxic glutamate spillover is the 
signal that triggers the secondary intracellular calcium influx in an NMDAR-mediated 
mechanism, actually correlating with neuronal death. In this context, also the sodium-calcium 
exchanger (NCX), an important regulator of intracellular Ca
2+
 levels that extrudes calcium 
using the driving force from sodium influx, fails in recovering the intracellular calcium 
concentration back to physiological levels (Chen and Li, 2012). Additionally, the 
mitochondrial maintenance of intracellular calcium homeostasis collapses, due to the failure 
of direct calcium uptake or indirect facilitation of ATP-dependent calcium extrusion 
(Szydlowska and Tymianski, 2010). As a result, upon excitotoxic stimulation, the 
mitochondrial uptake of calcium results in reactive oxygen species production, breach of the 
permeability transition pore followed by mitochondrial depolarization, worsening of calcium 
deregulation, and final induction of neuronal death (Khatuh et al., 2013; Nishio et al., 2013). 
In a fashion similar to the mechanisms previously described, high calcium loading induced by 
glutamate via NMDARs results to be neurotoxic when compared with the equivalent transient 
overflow induced by tonic depolarization via voltage-gated calcium channels that is instead 
neuroprotective. Such divergent effects on neuronal death or survival may again be explained 
by the differential effects of Ca
2+
 inputs on gene expression, as well as by the diverse sources 
of the calcium (Szydlowska and Tymianski, 2010). It might be possible that some calcium-
dependent death-signaling proteins are closely associated or rather physically bound to the C-
terminal domain of NMDARs, thereby generating these opposing functional outputs at the 
basis of neuronal functionality in physiological and/or pathological conditions. 
 
 
2.5 Oxidative stress and inflammation as secondary ischemia contributors 
As a consequence of such deranged orchestra of glutamate-driven detrimental signaling, 
several downstream pathways peaking in oxidative stress and phlogosis deeply compromise 
and challenge brain integrity. 
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Upon the ischemic insult, the conspicuous Ca
2+
 released progressively accumulates into the 
mitochondrial matrix, promoting the production of ROS, inhibiting the synthesis of ATP and 
enhancing mitochondrial membrane permeability. Contextually, due to neuronal phospholipid 
membrane damage, free fatty acids and arachidonic acid are released during ischemia upon 
phospholipase C and phospholipase A2 activation, in turn activated following NMDAR 
stimulation respectively by depolarization and increased Ca
2+
 concentration, contributing to 
failure of ion partitioning and free radical–mediated cytotoxicity (White et al., 2000). 
Besides the critical involvement in energy production, mitochondria are also primary 
mediators of apoptosis due to death factors located in the mitochondrial matrix, including 
cytochrome c, caspases and the apoptosis inducing factor (AIF) (Singh et al., 2010). 
Considering the substantial amount of oxygen consumed by the brain, its high propensity in 
generating ROS, the relative low levels of endogenous antioxidants, and the large amount of 
polyunsaturated fatty acids and transition metals available to fuel Haber Weiss and Fenton 
reactions, brain vulnerability to oxidative stress appears obvious. Thereby, the disruption of 
neuronal bioenergetics leads to the opening of the mitochondrial permeability transition pore, 
with release of cytochrome c, and finally, apoptotic cell death (Abeti and Abramov, 2015; 
Giorgio et al., 2013).  
Toxic free radicals including superoxide anion (O2
•−
), hydrogen peroxide (H2O2), hydroxyl 
radical (HO
•
), nitrogen dioxide (NO2
•
) and peroxynitrite (ONOO
−
) are readily produced by 
infiltrating phagocytes, pericytes and glial cells mostly in penumbral regions, further 
prompted during reperfusion, thus perpetrating neurotoxicity (Nishio et al., 2013; Ramos et 
al., 2017) (Fig. 11).  
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Fig. 11 
Deleterious role of the mediators of oxidative and nitrosative stress in cerebral ischemia. 
Calcium overload within mitochondria promote the increased generation of superoxide anion (O2
•−
), hydrogen 
peroxide (H2O2), hydroxyl radical (OH
–
), nitric oxide (NO
•
), or peroxynitrite (OONO
–
) in the core and 
penumbral tissue. Hydroxyl radicals and peroxynitrite, which results from the interaction between nitric oxide 
and superoxide, lead to protein oxidation and nitration, lipid peroxidation, mitochondrial and cellular DNA 
damage, activation or inhibition of various signaling pathways that ultimately favour inflammatory responses, 
apoptosis, and necrosis.  
(Adapted from Chamorro et al., 2016). 
 
 
 
On the other hand, the production of the metastable free radical nitric oxide (NO
•
), may result 
both beneficial and detrimental, depending upon source, location and duration of release 
(Förstermann et al., 1998; Pacher et al., 2007). This diffusible neurotransmitter plays indeed 
important physiological roles in vasodilation, blood pressure regulation and facilitated 
neurotransmission when produced by the endothelial nitric oxide synthase (eNOS). 
Conversely, high intracellular concentrations promoted by neuronal (nNOS) and inducible 
(iNOS) synthases have been related to depletion of cellular NAD
+
 and energy stores and 
further production of ONOO
−
, which in turn elicits single-strand DNA breakage, harmful 
protein nitration and oxidation, stimulation of mitogen-activated protein kinases, lipid 
peroxidation and breakdown of blood brain barrier (del Zoppo et al., 2000; Shi et al., 2013; 
Yenari and Han, 2012).  
Under this perspective, the association between the neuronal NOS isoform with excitotoxic 
cell death is corroborated by the fact that nNOS is physically tethered to the NMDA receptor 
and activated by Ca
2+
 influx, thereby explaining the increased levels of nitric oxide found in 
stroke animal models (Lipton, 2004). Thereupon, increased nNOS activity is related to 
excitotoxic cell death.  
In this frame of damaging biological events, phlogosis is generally triggered as well, with 
acute inflammatory events secondarily participating in the injurious process, while delayed 
chronic inflammation may rather be reparative (Bethea and Dietrich, 2002; Dziedzic, 2015). 
The infiltration of immune cells into the brain parenchyma begins from microglia and 
neutrophils, and is orchestrated by time-related release of different cytokines and chemokines 
including  IL-1β, IL-6, and TNF-α that promote matrix metalloproteases activity and further 
aggravate oxidative stress and BBB damage (Gelderblom et al., 2009; Kolaczkowska and 
Kubes, 2013). Platelets, in turn, interact with the endothelium and facilitate pro-thrombotic 
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pathways through the altered expression of cell surface signaling molecules and adhesion 
molecules such as selectins and ICAM-1, complicating the ongoing microvascular obstruction 
operated by neutrophils (del Zoppo et al., 2000). Additionally, activated glial cells release 
mediators that further attract neutrophils, monocytes, and lymphocytes, dramatically 
aggravating the lesion and contributing to endothelial and parenchyma damage via increased 
production of nitrites, myeloperoxidases, prostaglandins, and proinflammatory cytokines, in a 
vicious circle (Jiang et al., 2017; Taylor and Sansing, 2013) (Fig. 12). 
 
 
 
Fig. 12 
Inflammation in the pathogenesis of cerebral ischemia. 
Circulating monocytes, monocyte-derived macrophages, dendritic cells, natural killer cells, and lymphocytes 
regulate inflammatory responses and might favour thrombo-inflammation, which defines the dysfunction of the 
cerebral microvasculature caused by increased interaction of leucocytes with the ischemic brain endothelium and 
platelets. The first cells to respond to excitotoxicity are brain-intrinsic microglia, which release mediators that 
further attract neutrophils, monocytes, and lymphocytes, followed by neutrophils that exacerbate oxidative stress 
(O2
•−
), and damage the BBB. Cerebral antigens released during brain ischemia might reach regional lymph nodes 
through the drainage pathways of the interstitial and cerebrospinal fluid, favouring either tolerogenic or 
autoimmune responses. This process also enables the recognition of cerebral antigens during ischemia to locally 
activate autoreactive memory T cells.  
DAMPs = damage-associated molecular patterns. PVM = perivascular macrophage. 
(Adapted from Chamorro et al., 2016). 
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2.6 Reperfusion injury 
Although the ultimate therapeutic goal in ischemic stroke is addressed, as said, toward 
thrombolysis or mechanical recanalization, restoration of blood flow may at times collapse in 
the so-called “cerebral reperfusion injury”. Indeed, while reperfusion may reduce infarct size 
and improve clinical outcome in some subjects, a subset of patients paradoxically experience 
disastrous outcomes in the form of fatal edema or intracranial hemorrhage that extend beyond 
the sole failure of cellular energy supply to neurons (Chen and Nuñez, 2010; Eltzschig and 
Eckle, 2011) (Fig. 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13 
Reperfusion injury. 
When a cerebral artery is occluded, brain tissue becomes ischemic (blue rectangle), and death spreads 
exponentially. If the vessel is not reperfused using appropriate treatment, a huge brain area will be injured (blue 
line). If reperfusion occurs in a reasonable time, the infarct size is reduced (pink line). However, if reperfusion 
occurs together with neuroprotection to reduce reperfusion injury (pink shading), the infarct size is further 
attenuated (red line). 
(Adapted from Sanz-Rosa et al., 2012).  
 
 
 
Reperfusion is characterized by vascular restoration and concomitant reoxygenation of 
ischemic tissues that may nevertheless undergo cellular changes including nuclear 
fragmentation, chromatin condensation and neuronal cell body shrinkage, often accompanied 
by phospholipidic membrane alteration (Balasubramanian and Schroit, 2003; Broughton et 
Treatment 
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al., 2009). Multiple pathological molecular mechanisms are believed to be implicated in this 
injurious process, involving both innate and adaptive immune responses as well as 
complement system, platelets and coagulation factors (Nour et al., 2013). As a consequence, 
cell death can occur either by necrosis or apoptosis (Hotchkiss et al., 2009), thereby further 
stimulating the inflammatory system and exacerbating the ongoing injury (Chen and Nuñez, 
2010; Elliott et al., 2009). 
In the frame of such impaired cellular milieu, activated leukocytes interact with endothelial 
cells and extravasate from capillaries, infiltrating brain tissue and releasing leukotrienes, 
prostaglandins and other proinflammatory cytokines.  
Several studies also suggested a negative involvement of platelets after cerebral ischemia and 
reperfusion (Ishikawa et al., 2004; Pan et al., 2007). Beside the mechanical obstruction, 
platelets can cause vasospasm through serotonin, thromboxane A2, and free radicals release. 
In addition, activated platelets promote chemotaxis and migration of leukocytes, emphasizing 
the inflammatory cascade. 
The plunge into the inflammatory cascade and the release of neutrophil-derived oxidants and 
proteolytic enzymes increase the permeability of the vascular bed and eventually disrupt BBB 
integrity, ultimately deteriorating also the salvageable ischemic penumbra.  
Moreover, excitotoxicity-mediated inhibition of astrocytic repair function also disables the 
BBB, functionally correlating with the severity of patients outcome (Liu and Chopp, 2016; 
Schaller and Graf, 2004). 
In this inward spiral, the depletion of cellular metabolic resources leads to anaerobic 
glycolysis and lactic acidosis, further release of glutamate, cytotoxic edema, and excessive 
generation of free radicals that overwhelm the system, collapsing in irretrievable cellular 
demise (Dirnagl et al., 1999; Lee et al., 2000).  
Reactive radical oxide species play a major role in this hypoxic context (Olmez and Ozyurt, 
2012). Inducible nitric oxide synthase (iNOS) is activated during cerebral ischemia, leading to 
nitric oxide and peroxynitrite production, DNA damage, fall of ATP production and, 
ultimately, either p53 upregulation or Bcl-2 downregulation in case of, respectively, necrotic 
or apoptotic cell death (Shen et al., 2003).  
Besides the oxidant harm, ROS may directly alter BBB permeability, causing long-lasting 
edema and exacerbating the impedance to adequate tissue perfusion, possibly contributing to 
the hemorrhagic transformation of ischemic stroke (Bektas et al., 2010; Wang and Lo, 2003). 
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Although no study has so far finely quantified these events in stroke patients, animal stroke 
models have extensively recapitulated the concept of reperfusion injury at molecular and 
cellular level. Injury from reperfusion has been indeed observed to last beyond the period of 
ischemia and to extend wider in the penumbra, with evidence of sustained oxidative stress on 
pericytes in the microvasculature, and in spite of arterial recanalization in MCAo (Middle 
Cerebral Artery occlusion) murine models (Yemisci et al., 2009). Furthermore, neutrophil 
accumulation at the site of neuronal injury with consequent increase in infarct volume has 
been shown to occur earlier and to greater extent in reperfused areas than in tissue 
permanently deprived of blood supply, starting already 6 hours after restoration of cerebral 
circulation (Zhang et al., 1994).  
As current revascularization approaches have become highly successful and continue to 
improve, reperfusion injury has obtained a prominent interest for patient treatment and 
supportive care. On purpose, a better understanding of the mechanisms undermining cerebral 
ischemia and reperfusion injury has provided several potential strategies to limit or rather 
prevent further brain damage during reperfusion. Clinical trials ranged from inhibition of 
apoptosis to promotion of angiogenesis, targeting T-cells, inhibiting reactive oxygen species 
production and modulating cellular metabolic apparatus (Eltzschig and Eckle, 2011).  
Several interventions have targeted leukocyte infiltration by means of anti-neutrophil 
antiserum or anti-neutrophil monoclonal antibodies, showing improved recovery and reduced 
infarct size after cerebral reperfusion in both rats and rabbits (Pan et al., 2007). On the same 
line, monoclonal antibodies anti-adhesion molecules like ICAM-1 (i.e. enlimomab
®
) reduced 
neutrophil infiltration and lesion size after reperfusion in rats, although the translation of these 
promising agents into effective therapies in humans has been disappointing (Enlimomab 
Acute Stroke Trial Investigators, 2001).  
Additionally, given the major role of free radicals in hypoxic reperfusion, several studies have 
tailored neuroprotective interventions to target these players. Among those, modulation of 
superoxide dismutase and NADPH oxidase proved to limit injury in animal models of 
ischemia-reperfusion (Kahles and Brandes, 2012; Radermacher et al., 2013). 
Dextran sulfate, unfractionated heparin and fingolimod, a sphingosine-1 phosphate receptor 
agonist, also reduced infarct volume after reperfusion and provided improved functional 
neurological outcomes, paving a potential role for these agents alongside conventional 
therapeutic options (Wei et al., 2011). 
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Besides these drug therapies, management strategies including inhalation of hydrogen or 
nitric oxide gases, brain cooling and conditioned blood perfusion are under clinical evaluation 
due to the possibility to modulate several pathways involved in reperfusion injury (Stowe et 
al., 2011; Yenari and Hemmen, 2010).  
In this context, neuroimaging is currently being effectively used to provide real-time, clear-
cut, non-invasive, easily reproducible measures of potential success for therapeutic strategies 
implied in injury recovery (Nour et al., 2013; Pan et al., 2007).  
However, despite preclinical success of several previously described agents, clinically 
convincing benefits are still far from attainment, therefore a deeper understanding of 
revascularization beyond the concept of recanalization alone is strongly required.  
 
 
 
3. Symptomatic and disease modifying treatments 
The main reasonable aim of acute stroke treatment is the rescue of hypoperfused yet still 
viable ischemic penumbra surrounding the infarcted core. Indeed, since 1974 when Hossmann 
and Zimmermann demonstrated that ischemia induced in mammalian brains for up to an hour 
can be at least partially recovered, the possibility of intervening after the ischemic insult but 
before the damage becomes irreversible has been multifariously addressed (Raichle, 1983).  
On purpose, similarly to what previously said regarding reperfusion injury, relevant areas of 
interest include the search for safe and effective treatment strategies that combine 
neuroprotection, reperfusion, better use of advanced brain imaging for patient selection, and 
wider implementation of pre-hospital conducted trials.  
Despite this pressing clinical emphasis, acute thrombolysis using intravenous rt-PA is the 
only therapeutic strategy currently approved by the Food and Drug Administration, at least in 
the subpopulation of stroke patients that reperfuse adequately in the brain microvasculature. 
Indeed, as said before, rt-PA administered within 3 hours after stroke onset succeeded at 
lysing the arterial thrombus and restoring cerebral blood flow, although no additional 
implementations have been so far achieved.  
Thereupon, excitotoxicity, inflammation, and oxidative stress are key ischemia culprits to be 
targeted. Frustratingly, despite promising preclinical results, several hundred phase II studies 
and dozens of phase III randomized clinical trials failed to confirm the therapeutic benefits of 
the related pharmacological agents (Chamorro et al., 2016; Lo et al., 2005; O'Collins et al., 
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2006). An implemented search for new treatments appears thereby imperative to overcome 
these barriers and progress in stroke research (Fig. 14). 
 
 
 
Fig. 14 
Potential therapeutic targets to manage ischemia pathophysiology. 
The graph represents the temporal profile of the main pathophysiological mechanisms underlying acute focal 
cerebral ischemia and their impact on the final ischemic damage. In the absence of early reperfusion or 
appropriate treatment, neurons in the ischemic penumbra (yellow brain areas) subside due to ongoing injury, 
resulting in expansion of the infarcted core (red brain areas). Excitotoxicity, inflammation, oxidative stress, 
bioenergetics failure and BBB and microvasculature injury are promising targets to address for effective 
therapeutic approaches. (Adapted from Brouns and De Smedt, 2012).  
 
 
 
3.1 NMDARs and glutamate-driven excitotoxicity as therapeutic targets 
The prevention of glutamate-mediated neurotoxicity has been a central therapeutic target in 
numerous RCTs (Randomized Clinical Trials). Nevertheless, a long list of drugs with assorted 
mechanisms of action addressing glutamatergic pathways sadly failed when assessed in 
clinical trials (Chamorro et al., 2016).  
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Given that glutamate receptor activation and Ca
2+
 influx promptly occur at the very onset of 
the ischemic cascade, the therapeutic time window for intervention is supposed to be in this 
case extremely narrow. Consequently, neither AMPA receptor antagonists (i.e. YM872, 
MPQX), nor NMDA receptor antagonists (i.e. MK-801, Selfotel
®
) met their clinical targets 
(Lee et al., 2000; Yam et al., 2000), not unexpectedly leading to side effects respectively 
embracing sedation or alterations in motor and cognitive functions.  
Ifenprodil
®
, a NR2B subunit-selective antagonist of NMDARs mostly expressed in forebrain 
compared to hindbrain offered modest neuroprotection along with less interference with 
motor function compared to subtype-unselective NMDAR antagonists (Doğgan et al., 1997; 
Tadano et al., 1995).  
On the same line, memantine (1-amino-3,5-dimethyladamantane), an uncompetitive open-
channel NMDAR blocker with fast on/off kinetics and low-moderate receptor affinity, was 
able to block the deleterious effects of excessive glutamate release without interfering with 
the physiologic activation of NMDA receptors (Johnson and Kotermanski, 2006).  
Since 2002 memantine has been approved for the treatment of moderate to severe 
Alzheimer’s disease (Allgaier and Allgaier, 2014), also demonstrating some additional 
benefits for pathologies like vascular dementia (Orgogozo et al., 2002). Recent evidence from 
in vitro and in vivo studies underlined memantine as an attractive candidate for clinical 
translation also in stroke therapy, due to good biological availability and tolerability profile. 
The restoration of brain functionality provided by memantine occurs indeed in a dose-
dependent manner, with low memantine concentrations significantly rescuing neurons and 
glia via excitotoxic cascade interruption, while high concentrations significantly enhanced cell 
death (Trotman et al., 2015). In particular, memantine apparently acts via non-neuroprotective 
mechanisms, but rather involving increased BDNF/TrkB signaling, reduced reactive 
astrogliosis and improved vascularization, associated with better recovery of sensory and 
motor cortical function after MCAo (Lopez-Valdes et al., 2014). To date, a deeper evaluation 
of memantine in the clinical setting is warranted, particularly concerning the prophylactic 
administration in those patients identified as being at risk of ischemic stroke. 
Overall, in spite of initial tiny but encouraging results, glutamate receptor antagonists as well 
as postsynaptic Ca
2+
 channel blockers (i.e. nimodipine, ziconotide), Na
+
 channel blockers (i.e. 
sipatrigine, fosphenytoin), or GABA mimetics (i.e. clomethiazole) were all rejected because 
of toxic drawbacks, including nausea, vomiting, and severe psychotomimetic side effects 
(Gladstone et al., 2002; Lai et al., 2014).  
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Some other relevant clinical attempts to target excitotoxicity are summarized below. 
 
- Magnesium sulfate: 
Magnesium is an endogenous calcium channel antagonist, and its putative neuroprotective 
properties have been variously ascribed to NMDA receptor uncompetitive blockade, calcium 
channel blockade, excitatory neurotransmitter release inhibition, and smooth muscle 
vasodilation (Ginsberg, 2008).  
The FAST-MAG randomized double-blind trial was run as a pre-hospital therapy initiated in 
the ambulance as an IV bolus of magnesium sulfate followed by 24 h infusion. Not 
surprisingly, lack of clinical benefit resulted (Saver et al., 2015). 
 
- PSD-95: 
Intravenous NA-1 (Tat-NR2B9c), an inhibitor of postsynaptic density-95 (PSD95) protein 
that links NMDA receptors to neurotoxic signaling in neurons, proved to halt glutamate 
excitotoxicity and reduce infarct volume in non-human primates after transient or permanent 
brain ischemia (Cook et al., 2012; Sattler et al., 1999). In the ENACT trial, NA-1 showed to 
be safe, although no difference was noted by MRI analysis with respect to placebo concerning 
the volume of lesions (Hill et al., 2012). Further studies are currently ongoing. 
 
- Ca2+ channel antagonists: 
Calcium influx is a downstream event into the signaling pathway of glutamate. Therefore, 
receptor-operated calcium channel antagonists have been targeted as well.  
The calcium channel antagonist Ginsenoside-Rd has been for instance assessed in a Chinese 
RCT on patients with acute ischemic stroke treated within 72 h (Liu et al., 2012). 
Ginsenoside-Rd displayed no substantial adverse effects and showed better functional 
recovery in the treated group, although many previous trials indicated no clinical benefits. 
Further confirmation is warranted.  
 
- Peritoneal dialysis: 
In order to reduce blood glutamate concentrations without further affecting normal brain 
neurophysiology, peritoneal dialysis has been shown to efficiently reduce hematic glutamate 
levels in a rat model of cerebral ischemia (Godino et al., 2013), consequently the EUDRA 
clinical trial is ongoing on patients with acute ischemic stroke. 
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3.2 Oxidative stress as therapeutic target 
The neutralization of oxidative and nitrosative stresses is undoubtedly a potential therapeutic 
strategy to attempt, due to the brain high susceptibility to oxidative damage, its rich content of 
iron and unsaturated lipids, and its relatively low endogenous antioxidant capacity.  
As a consequence, the prevention of ROS and RNS (reactive nitrogen species) generation at 
penumbra sites proved to be an effective measure to limit the expansion of the ischemic lesion 
in preclinical stroke models (Fukuyama et al., 1998). 
 
- NXY-059: 
Peroxynitrite among other RNS gained particular interest due to its harmful activity on lipid 
peroxidation, mitochondrial damage, protein nitration and oxidation, depletion of antioxidant 
reserves, and breakdown of the BBB (Beckman, 1996). Peroxynitrite scavengers such as the 
nitrone disufenton sodium (NXY-059), the disulfonyl derivative of the radical-scavenging 
phenylbutylnitrone, provided controversial results, resulting efficiently neuroprotective from 
one large-scale trial (i.e. SAINT I) (Lees et al., 2006) but lacking reproducibility in a second 
trial (i.e. SAINT II) (Shuaib et al., 2007).  
 
- Edaravone: 
Edaravone is an antioxidant able to scavenge hydroxyl, peroxyl, and superoxide radicals. In 
both in vitro and in vivo assays, this drug inhibited a plethora of pathogenic mechanisms 
associated with ischemic cell death including microglia-induced neurotoxicity, chronic 
inflammation, oxidation of low-density lipoproteins, and altered expression of endothelial and 
neuronal proteins (Lapchak, 2010). Several trials on edaravone, however, reported no 
conclusive evidence for its therapeutic efficacy in stroke patients, although marked 
neurological improvement was more recently obtained when given in combination with 
standard therapy (Feng et al., 2011).  
Since 2001 edaravone has been approved in Japan for patients with acute stroke. 
 
- Melatonin: 
Melatonin is a neurohormone produced by the pineal gland, known to exert a wide variety of 
biological actions besides the control of circadian rhythms. So far, the neurotherapeutic 
potential of melatonin in brain ischemia has emerged thank to the success of its use in animal 
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stroke models, exhibiting a reduction in infarct volume by 40% and significantly improving 
neurologic deficits (De Butte et al., 2002).  
Melatonin was indeed demonstrated to possess a plethora of functions, ranging from direct 
free radical scavenger activity against ROS/RNS, indirect antioxidant properties via increased 
expression of antioxidant enzymes and NO synthesis suppression (Liu et al., 2015; 
Manchester et al., 2015; Reiter et al., 2009), up to anti-inflammatory, neuromodulatory, anti-
apoptotic and anti-excitotoxic effects, also via prevention of Ca
2+
 dyshomeostasis (Ramos et 
al., 2017). Additionally, melatonin is worth to note as a versatile modulator of multiple 
signaling pathways involved in neuronal tissue damage, promoting cell proliferation and 
neurogenesis, maintaining the integrity and permeability of BBB, as well as improving 
electrophysiological recovery, either alone or in combination therapy with thrombolytic 
agents (Ramos et al., 2017). 
Considering the low toxicity even in very high doses and the good efficacy in spite of low 
bioavailability, these beneficial properties makes melatonin a suitable option for potential 
treatment against brain ischemia (Andersen et al., 2016; Harpsøe et al., 2015). 
 
- Citicoline: 
Citicoline, a phosphatidylcholine precursor, may stabilize neuronal cell membrane due to its 
scavenging activity and brain bioenergetics modulation. Given the favourable outcomes 
observed in rat models of ischemic stroke, citicoline has been also tested in humans in several 
trials (Clark et al., 2001; Dávalos et al., 2002). Unfortunately, the benefits observed in 
previous meta-analyses were not confirmed in a conclusive prospective trial (Dávalos et al., 
2012). 
 
- Uric acid: 
Uric acid represents the endogenous final oxidation product from purine catabolism and 
accounts for roughly two-thirds of the whole plasmatic antioxidant capacity (Squadrito et al., 
2000). As such, uric acid prevented glutamate-induced cell death and suppressed ROS and 
RNS generation, conclusively improving the functional outcome in rats with hyperemia 
following focal ischemia (Onetti et al., 2015). Additionally, a synergistic neuroprotection 
when combined with alteplase
®
 was exhibited in a thromboembolic rodent model of stroke 
(Romanos et al., 2007). 
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The URICO-ICTUS phase III clinical trial tried to assess the effect of uric acid combined with 
IV rt-PA within 4.5 h from stroke onset. No supplemental benefits over rt-PA alone have been 
obtained (Chamorro et al., 2014), although a post-hoc analysis reported some improved 
outcome in the female subgroup (Llull et al., 2015). 
 
 
3.3 Inflammation as therapeutic target 
The immune-mediated inflammatory response that follows acute ischemic stroke has also 
provided promising therapeutic targets. Several RCTs have been therefore conducted or 
proceed under current investigation. 
 
- Fingolimod: 
Fingolimod is a high-affinity agonist of the sphingosine-1-phosphate receptor, able to prevent 
lymphocytes egress from lymph nodes, thereby limiting their infiltration into the brain. 
Moreover, fingolimod inhibits local activation of microglia and macrophages, reducing 
number of dying cells, infarcted area, neurological deficits, and edema in several rodent 
models of brain ischemia (Liu et al., 2013; Wei et al., 2011).  
The efficacy of oral fingolimod in improving functional outcome in stroke patients has been 
assessed in a small open-label pilot study (Fu et al., 2014). Administration within 72 h from 
stroke onset exhibited no severe adverse effects together with decreased microvascular 
permeability and attenuated neurological deficits. Additionally, the combination of 
fingolimod with alteplase
®
 given within 4.5 h after stroke onset presented synergistically 
improved clinical results, according to the National Institutes of Health Stroke Scale (Zhu et 
al., 2015). 
 
- Natalizumab: 
Natalizumab is a humanized CD49d antibody that blocks α4-integrin, attenuating leukocytes 
infiltration into the brain. Preclinical studies investigating natalizumab on brain ischemia led 
to contrasting results (Langhauser et al., 2014; Liesz et al., 2011; Llovera et al., 2015), 
therefore research efforts still have to be paid before landing onto the clinic. 
A related compound, Rovelizumab (LeukArrest
®
) is a monoclonal antibody against 
CD11/CD18 neutrophil CAM designed to prevent neutrophil invasion of the ischemic bed and 
subsequent inflammatory injury (Rhee et al., 2000). After establishing safety in humans, a 
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phase III trial (HALT) on acute ischemic stroke patients was run, but no suggestion of benefit 
has been cited. 
 
- Anakinra: 
Interleukin-1 receptor antagonist (IL-1ra) is a naturally occurring competitive antagonist of 
the proinflammatory cytokine IL-1 (Allan et al., 2005). Anakinra, the recombinant form of IL-
1ra, has been so far widely used in chronic inflammatory disorders due to its powerful 
antiphlogistic activity associated with good safety profile (Dinarello and van der Meer, 2013). 
Treatment with recombinant IL-1ra already showed neuroprotective effects in rodent models 
of stroke (Mulcahy et al., 2003). An ongoing phase II study will soon unveil any potential 
therapeutic action in stroke patients as well, in spite of the increased risk of infection 
manifested so far (Becker et al., 2014). 
 
- Minocycline: 
Minocycline, a tetracycline derivative, proved to attenuate apoptosis and inhibit 
metalloproteases expression following focal cerebral ischemia in animal models of stroke 
(Murata et al., 2008). The acceptable safety profile observed in an open-label, dose-escalation 
study together with the wider therapeutic window and the inhibition of matrix 
metalloproteases-driven inflammatory response offered by the combination with alteplase
®
 
(up to 6 h) have strongly encouraged on the potentialities of this drug (Fagan et al., 2010; 
Kohler et al., 2013). The results of a further RCT on minocycline with thrombolytic treatment 
are awaited. 
 
- Miscellaneous strategies: 
Ultimately, the exogenous administration of growth factors including nerve growth factor 
(NGF), brain-derived neurotrophic factor (BDNF), neurotrophins 4/5 (NT-4/5), basic 
fibroblast growth factor (FGF-β), and insulin-like growth factor 1 (IGF-1) accomplished some 
beneficial effects in the functional recovery of rats subjected to cerebral ischemia (Lee et al., 
2000), however a clear-cut evidence for satisfying therapeutic outcomes is still missing.   
Some of the principal randomized trials run so far have been summarized in Tab. 1.  
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Tab. 1 
Main randomized controlled trials assessing neuroprotective strategies to manage ischemia pathophysiology.  
mRS: modified Rankin Scale; OD: Odd Ratio; CI: Confidence Interval.   
 
 
 
3.4 Non-pharmacological approaches 
Various non-pharmacological strategies have been approached. 
In a subset of patients, angioplasty and stenting could be surgical viable options in the 
treatment of acute ischemic stroke. The rate of technical success for intra-cranial stenting 
ranged around 90-98% in relieving symptomatic intracranial arterial stenosis. The rates of re-
stenosis and recurrent strokes following the treatment were also favourable (Ansari et al., 
2011; Derdeyn and Chimowitz, 2007; Francoeur and Mayer, 2016) but further data are still 
required. Hyperbaric oxygen therapy has been studied as a possible protective measure, since 
multiple putative clinical benefits could be attained, including mitochondrial rescue, 
attenuation of cortical spreading depression, and salutary effects on endothelial-leukocyte 
interactions (Kumaria and Tolias, 2009). A recent meta-analysis of animal studies suggested 
that hyperoxia may reduce infarct size and improve neurological function, particularly when 
administered promptly following MCA occlusion (Xu et al., 2016), although additional 
studies haven’t been undertaken so far. 
Conclusively, the targeted temperature management has gained increasing momentum for 
clinical translation to stroke intervention (Chamorro et al., 2016; Lee et al., 2017). 
Compelling evidence from preclinical research in animal models demonstrated marked 
protective effects of mild to moderate therapeutic hypothermia in ameliorating functional 
outcomes via the downregulation of multiple pathogenic pathways including oxidative stress, 
inflammatory responses, metabolic disruption, and cell death signaling (Choi et al., 2012; Lee 
et al., 2014). Indeed, therapeutic hypothermia provided promising options for neuroprotection, 
correlating with diminished free radicals production (Hall, 1997), impaired neuronal apoptosis 
via modulation of p53 and Bcl-2, shutdown of matrix metalloproteases and cytochrome c 
pathways (Lee et al., 2014), decreased expressions of proinflammatory mediators such as 
TNF-α, NF-κB and IL-1β (Lee et al., 2016). 
Notably, glutamate release proved to be temperature-dependent (Campos et al., 2012; Yenari 
and Han, 2012), possibly due to a plethora of underlying mechanisms such as modulation of 
the GluR2 subunit of AMPA receptors (Colbourne et al., 2003), reduction of the number of 
40 
 
AMPA and NMDA receptors expressed (Friedman et al., 2001), decreased calcium influx and 
brain glycine levels (Hall, 1997; Kvrivishvili, 2002).  
In spite of all these obvious beneficial effects of therapeutic hypothermia, its clinical 
application is still limited due to multiple shortcomings. For instance, current hypothermia 
protocols contemplate procedures both slow and impractical (ice cooling may require up to 8 
hours) or invasive in the case of endovascular cooling, eventually providing tremendous need 
for optimization. On this line, the pharmacologically induced hypothermia can directly target 
the peripheral or central thermoregulatory mechanisms and is currently emerging as a more 
efficient and safer treatment (Cao et al., 2014; Wei et al., 2013). 
Several pilot studies have clearly indicated the clinical benefits offered by pharmacological 
thermoregulatory agents like neurotensin, transient receptor potential vanilloid 1 (TRPV1), 
cannabinoids and opioids, thyroxine derivatives, dopamine, gases, and adenosine derivatives 
(Feigin et al., 2002; Muzzi et al., 2012), although more incisive results are still needed. 
 
 
3.5 The translational roadblock 
Overall, cytoprotective strategies including anti-excitotoxic drugs, free radical scavengers, 
anti-inflammatory or anti-apoptotic agents as well as non-pharmacological approaches did not 
show the expected beneficial results (Chamorro et al., 2016).  
A plausible explanation for these discrepancies of translatability from bench to bedside in 
ischemic stroke could been ascribed to the difficulty of conducting clinical trials with stroke 
patients, due to the lack of a fitting linearity between lesion size and clinical deficits assessed 
by clinical scales, as well as to shortcoming in proper patients randomization to afford 
heterogeneity of study populations in relation to duration and severity of ischemia, gender 
differences, age and underlying or co-morbid diseases. Likewise, timing of drug 
administration, drug dosage, pharmacokinetics and bioavailability in the target area, 
concealed side effects, suitable therapeutic window for effective neuroprotection and clinical 
trials design itself might be sharply taken into consideration and, implemented, where needed, 
in order to avoid bias or contrived outcomes (Grupke et al., 2015; Howells et al., 2013; Landis 
et al., 2012). Increased awareness of the relevance of rigorous testing and appropriate 
selection for clinical inclusion criteria seem to offer the key for the search of safer and more 
effective treatment strategies (Fig. 15). 
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Fig. 15  
Stroke: a global problem with unmet medical needs. 
A) Translational roadblock: the focus of basic stroke researchers, clinicians, and pharmaceutical industry is on 
the failure to translate purportedly neuroprotective preclinical therapies into improved treatment of patients with 
stroke.  
B) A more comprehensive strategy toward ischemia clinical management may include several successful bench-
to-bedside translations in neuroprotection and stroke pathophysiology. 
(Adapted from Dirnagl and Endres, 2014). 
 
 
 
Among the several therapeutic options tried over the past three decades, strategies directly 
targeting excitotoxic mechanisms rather than collateral signaling including inflammation and 
oxidative stress have received great scientific concern. 
In particular, NMDAR antagonism, whether competitive, uncompetitive or occurring via 
inhibition of the glutamate-binding site, the glycine-binding site, or the channel pore, 
exhibited effective therapeutic potential in the treatment of ischemic stroke damage, although 
without any drug succeeding the approval in trials.  
The reason for this lack of clinical success is likely multifactorial. NMDAR blockers merely 
have a short therapeutic window, resulting effective only if administered before or 
immediately following stroke.  
Moreover, due to the involvement in neurophysiological functions, unselective NMDAR 
blockade may obviously produce multifarious unwanted effects as well as neuronal 
pathomorphological changes, as reported already from preclinical testing.  
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Due to such concerns, a great number of NMDAR antagonists under clinical evaluation have 
been painfully discontinued from further human clinical studies. 
 
 
3.6 Animal models for ischemic stroke: potentialities, capstones and issues 
The use of pertinent animal models for cerebral ischemia is currently matter of vibrant debate, 
being animal models strong predictors of clinical value, drug tolerance and side effects for 
translational therapeutic approaches in human subjects.  
The main aim of cerebral ischemia models is the induction of hypoxia and hypoglycemia to 
the brain, in order to recapitulate that variety of cellular and molecular mechanisms that 
impair neuronal energetics and lead to cerebral infarction, as observed in humans.  
Thereby, most focal cerebral ischemia models have been produced since early ‘60s, 
conveniently focusing on both large and small animals depending on the respective 
advantages regarding affinity with the human brain in terms of anatomic structure and 
function, financial costs, public animal welfare concerns, transgenic manipulation 
reproducibility, and compatibility with imaging techniques, physiological monitoring, 
behavioural assessments, and surgical procedures (reviewed in Sommer, 2017 and Traystman, 
2003). 
Experimental models for ischemia may be global, focal, or multifocal, depending on the 
pattern and severity of reduction in cerebral blood flow.  
To fit the purposes of this dissertation, only mice models of focal transient cerebral ischemia 
will be taken into account among the huge variety of possible experimental animals.  
Focal cerebral ischemia is widely achieved by clogging a major cerebral blood vessel like the 
middle cerebral artery (MCA), by means of intraluminal filament suture (Engel et al., 2011), 
electrocoagulation (Llovera et al., 2014) or photochemical approaches (Sugimori et al., 2004). 
MCA occlusion (MCAo) results in the absolute shutdown of oxygen and glucose supply in 
the very central infarcted area, while peripheral areas may be still sustained by collateral 
circulation from the circle of Willis and/or from leptomeningeal anastomoses.  
This procedure mostly induces injury at striatal and cortical level in the ischemic core, 
whereas shades of severity in the penumbra depend on the duration and site of occlusion 
along the artery, as well as on subsequent potential reperfusion and adequate systemic blood 
pressure.   
43 
 
So far, both transient and permanent MCAo models have been involved in the majority of 
studies investigating pathophysiological processes and potential novel neuroprotective agents, 
due to their close emulation of human ischemic stroke, and to reliability and reproducibility of 
generated infarcts.  
A wealth of fruitful insights later recognized also in the setting of human stroke have been 
unveiled from those experimental models, including the concept of penumbra, the 
identification of spreading cortical depolarization, the detection of post-stroke neurogenesis 
and the phenomenon of preconditioning (Dirnagl and Endres, 2014). 
Nevertheless, it appears immediately obvious how such experimental models can cover only 
individual specific aspects of this multifaceted disease, due to man/mouse discrepancies in 
molecular pathogenic mechanisms, genetics and epigenetics, brain anatomy and functional 
organization, vascular anatomy, immune system, behavioural and psychiatric outcomes, 
features of populations analysed (Sommer, 2017) (Fig. 16). 
 
 
 
 
 
Fig. 16 
Anatomy of brain across species. 
Illustration of connectivity as obtained by 3D-polarized light imaging (3D-PLI). Coronal sections from a human 
brain, a vervet and a rat brain. The colour sphere indicates the direction of fibers; black corresponds to a steep 
course of fibers in the third dimension, within the physical section. The comparison illustrates that not only the 
absolute volume of brains differs among the three species, but also the relative amount with a much higher 
proportion of white matter in human brains as compared to vervet and rodent brains. 
(Adapted from Sommer, 2017). 
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In addition, target endpoints in animal models generally account for infarct volume rather 
than long-term functional outcome which is instead the most relevant parameter in human 
patients, with special concern for the penumbral salvageable areas (Gladstone et al., 2002). 
Consequently, the deep gap between ischemic stroke in experimental models and the reality 
of stroke in human patients is sadly illustrated by the resoundingly failure that followed the 
moment of translation into human trials, with recanalization of occluded vessels being the 
only successful exception (Jickling and Sharp, 2015). 
Besides the issues of internal validity, external validity of preclinical stroke research has also 
been burdened by insufficient methodological zeal. Many drugs, for instance, have been 
tested in inbred adolescent healthy male mice with no co-morbidity or co-medication, rather 
fed on a diet high in antioxidants and housed under optimal pathogen-free conditions.  
This situation is in stark contrast to human reality where stroke patients are often old, with co-
morbidities, and under poly-pharmacology treatments (Dirnagl and Endres, 2014; Sena et al., 
2010). 
This poor translational power of preclinical stroke models has led to the establishment of the 
Stroke Therapy Academic Industry Roundtable (STAIR) that brought together basic and 
clinical science researchers, industry, regulators and NIH representatives with the goal of 
predispose landmarks and recommendations to optimize the quality of preclinical stroke 
research and the design of trials for neuroprotective drugs before moving to clinical trials. 
Moreover the STAIR aims at providing appropriate stroke models in the experimental setting 
for a future more incisive translatability, and to discourage overstated preclinical evidence of 
efficacy (Fisher et al., 2009; Stroke Therapy Academic Industry Roundtable (STAIR), 1999).  
Among the items listed in the guidelines, emphasis should be put on age, gender, co-
morbidities, replication in gyrencephalic non-human primates, drug pharmacokinetics and 
pharmacodynamics, acute and long-term histological and functional outcomes, sample size 
calculation, random and blinded animal allocation (Moretti et al., 2015). 
 
 
4. Looking for novel therapeutic molecular targets 
Due to such resoundingly discouraging scenario, further approaches pursued a dual line of 
neuroprotective strategies, focusing at extending the therapeutic time window for 
pharmacological intervention on one hand, while simultaneously targeting the signaling 
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events further downstream in the excitotoxic cascade, with the aim of being more selective 
and allow even delayed therapeutic operations to be effective.  
In an effort to circumvent the limitations reported above, recent studies have attempted to 
target the highly conserved intracellular signaling of mitogen-activated protein kinases 
(MAPK), including JNKs, p38 and ERKs kinases, so far mentioned among the biochemical 
pathways critically contributing to neuronal death following the ischemic induction. 
MAPKs are activated via the dual phosphorylation of a tripeptide motif (Thr-X -Tyr) located 
in the activation loop. These phosphorylations are mediated by a MAPK kinase (MAPKK) 
that is in turn activated via phosphorylation by another MAPKK kinase (MAPKKK) in the 
context of a kinases signaling cascade (Davis, 2000). 
Treatment with the selective p38 inhibitor SB203580 or ERK inhibitor PD98059 
demonstrated to reduce neuronal demise respectively after transient global and focal ischemia 
(Alessandrini et al., 1999; Sugino et al., 2000).  
Current work is emphasizing the utmost relevant role of the JNKs (c-Jun N-terminal kinases), 
also known as SAPK (stress-activated MAP kinases), in mediating neurotransmission in both 
physiological and, upon further activation, pathological conditions.  
 
 
4.1 JNK signaling pathway 
Three mammalian genes are known to encode the JNK isoforms, namely JNK1 and JNK2 that 
present ubiquitous patterns of expression, and JNK3 mostly restricted at neuronal, cardiac and 
testis level, with an activity up to 30 folds higher in the brain with respect to other tissues 
(Davis, 2000; Gupta et al., 1996). Those genes are additionally subjected to alternative mRNA 
splicing  to yield ten isoforms which nearly all fall into two molecular weight categories of 54 
and 46 kDa, characterized by distinct repertoires of brain expression (Coffey, 2014). 
The very first studies coming from ‘90s identified JNK as a “p54 microtubule-associated 
kinase”, activated upon cytokines input (TNF and IL-1) or environmental stressors (hypoxia, 
redox stress, heat shock, UV irradiation, inflammation, Aβ toxicity) via MKK4 or MKK7-
mediated phosphorylation within the Thr-Pro-Tyr motif (Centeno et al., 2007; Mukherjee et 
al., 1999; Nisticò et al., 2015; Sclip et al., 2014). To date, MAP kinases MKK4 and MKK7 
are the only known JNK activators, although their contribution in neuronal excitotoxicity has 
not yet been fully elucidated (Centeno et al., 2007). In turn, activated JNK may bind to and 
phosphorylate the c-Jun target, starting its downstream signaling (Pulverer et al., 1991). 
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Conversely, JNK inactivation is mediated by a group of phosphatases that determine the 
magnitude and duration of this MAPK activity, including Ser/Thr and Tyr phosphatases like 
PP2Cα and MKP-1 (Davis, 2000; Kondoh and Nishida, 2007) (Fig . 17). 
 
 
 
 
 
Fig. 17 
MAP kinases cascade and JNK isoforms splicing and distribution into the brain. 
A) JNK proteins belong to a classical MAPK signaling cascade. JNKs are activated by dual phosphorylation of 
the T-P-Y motif within their activation loop by two MAPK kinases MKK4 and MKK7. Upstream, various MKK 
kinases (MEKKs, ASK1, TAOK2, TRAF2, DLK, TNIK) phosphorylate and thereby activate MKK7 and/or 
MKK4. 
B) In the brain, JNK1, JNK2 and JNK3 are alternatively spliced to yield ten proteins, which nearly all fall into 
two molecular weight categories of 54 and 46 kDa, depending on the variants formed at the C-terminal. 
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C) An overview of JNKs subcellular distribution in the mouse brain. In the cortex and hippocampus, JNK1 
expression is largely cytosolic and found in the neuropile, whereas JNK3 expression is predominantly nuclear 
and found in approximately 30% of cells in layers III and V. Of note, JNK3 is the dominant JNK isoform 
expressed throughout the hippocampus. In the cerebellum, JNK3 is found in nuclei of Purkinje cells and 
cerebellar granule neurons, whereas JNK1 expression is prominent in Purkinje cell dendrites. JNK2 expression is 
similar to JNK1 and JNK3 expression in the cortex, although this isoform is found in both nuclei and soma of 
neurons in the hippocampus and cerebellum. 
(Adapted from Coffey, 2014).  
 
 
 
JNKs tuned expression and subsequent substrate phosphorylation is essential to govern brain 
morphogenesis and axodendritic architecture during development (i.e. neuronal migration, 
axonal sprouting, spines elongation and maintenance), as well as to regulate important 
neuronal specific functions (i.e. synaptic plasticity, memory formation) (Coffey, 2014; 
Weston and Davis, 2007; Yamasaki et al., 2012). Coherently, mutations in JNK1 and JNK2 
genes, as well as MKK4 and MKK7 knock-out mice are not viable or associated with 
exencephaly, indicating the crucial role of activated phospho-JNK for nervous system 
development.  
Furthermore, although very few is known about JNKs specific involvement in cognitive and 
behavioural functions, the pronounced basal expression, the regulation of gross and fine brain 
architecture and the central control of gene expression and metabolic homeostasis strongly 
suggest a relevant role for JNKs in higher brain functions (Reinecke et al., 2013).  
A recent study analysed the effects of single JNK deficient mice, reporting that the 
constitutive genetic deletion of JNK isoforms does not substantially affect memory 
consolidation but does elicit different phenotypic explorative behaviours, with JNK1 knock-
out mice displaying a stronger explorative behaviour whereas JNK2 or JNK3 knock-out 
showed opposite tendencies (Reinecke et al., 2013). 
On the other hand, JNKs signaling has been strongly correlated to several types of injurious 
processes, with particular concern upon neurodegenerative diseases (Sclip et al., 2014, 2011), 
psychiatric disorders (Coffey, 2014), cerebral ischemia (Borsello et al., 2003a; Repici et al., 
2007) and traumatic brain injury (Tran et al., 2012), possibly mediated by transcription-
dependent apoptotic pathways involving p53 and c-Myc as JNK targets (Davis, 2000).  
JNK has also been proposed to be required for stress-induced release of mitochondrial 
cytochrome c via Bcl2 inactivation, via phosphorylation and consequent caspase-driven 
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apoptotic death (Tournier et al., 2000; Wei et al., 2008), strengthening the hypothesis of a 
JNK-mediated neuronal demise following ischemia. 
 
 
4.2 JNK role in ischemia 
In response to the excitotoxic paradigm, JNK is known to be activated after focal or global 
ischemia during both permanent and transient events (Borsello et al., 2003a), with the 
phosphorylated fraction increasing 3 hours after the occlusion and peaking at 6 hours. This 
trend correlates well with c-Jun and caspase-3 time course in the ischemic core but not in the 
penumbra, emphasizing an interesting correlation with ischemia-induced apoptotic neuronal 
death (Repici et al., 2007).  
Given the relevant association between JNK and NMDARs at postsynaptic sites, NMDA-
induced excitotoxicity has been classically entailed as a potent JNKs signaling activator, 
operated through the rapid and selective phosphorylation carried by MAP kinases, although 
divergent results have not identified whether MKK7 or MKK4 contributes the most (Centeno 
et al., 2007; Repici et al., 2007). 
Moving beyond this evidence, several studies have been conducted in order to thoroughly 
unveil the involvement of JNK in ischemic excitotoxicity, looking at feasible therapeutic 
avenues. Coherently, JNK inhibition was shown to prevent NMDAR-mediated neuronal death 
in both cortical neurons and organotypic hippocampal slice cultures (Borsello et al., 2003a, 
2003b; Centeno et al., 2007). In particular, JNK3 is currently associated with protection from 
excitotoxicity and hypoxia since adult JNK3-deficient mice exhibit reduced seizure outbreak 
and apoptotic avoidance (Kuan et al., 2003; Yang et al., 1997). JNK1 and JNK2 seem instead 
to be important for apoptosis during brain development (Kuan et al., 1999). Mice lacking c-
Jun gene are also less prone to the excitotoxic insult, overall raising JNK signaling pathway 
blockade as a promising target for neuroprotection.  
Notably, as previously reported, addressing to this delayed downstream pathway may 
crucially extend the therapeutic window for intervention, allowing a more opportune chance 
for ischemic patients reaching the emergency room later than 3 h after stroke onset, i.e. 
beyond the effective temporal range for thrombolysis. 
On this line, D-JNKI1, a D-retro-inverse cell-penetrating peptide able to block JNK access to 
its phosphorylatable substrates was the first drug to achieve remarkable reduction in infarct 
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volume and neuroprotection even when administered 6 to 12 h after both transient and 
permanent cerebral artery occlusion in MCAo models (Borsello et al., 2003a). 
Recent evidences are furthermore shedding new light on the biological involvement of JNK 
and its scaffold proteins JIP (JNK interacting protein) (Kennedy et al., 2007) also at 
presynaptic sites (Biggi et al., 2017; Nisticò et al., 2015), and particularly under the 
perspective of their potential association with presynaptic NMDARs (Corlew et al., 2007). 
Indeed, JIP proteins have been implicated in the assembly and coordination of JNK signaling 
partners, and mice lacking JIP expression were found to exhibit severe defects in NMDAR 
function, including decreased NMDA-evoked current amplitude, aberrant regulatory 
phosphorylation of NR1 and NR2 subunits, impaired cytoplasmic Ca
2+
 homeostasis, and 
altered gene expression (Kennedy et al., 2007).  
Contextually, JIP1 was also required for JNK activation and neuronal death in response to 
ischemia in in vitro and in vivo stroke models (Whitmarsh et al., 2001). 
Concurrently, presynaptic NMDARs have been newly characterized as important key players 
implicated in brain development, neurotransmitter release, synaptic strength modulation, and 
memory consolidation (Banerjee et al., 2016; Larsen et al., 2014), but also in pathologies 
including ischemia and Alzheimer’s disease (Biggi et al., 2017; Frasca et al., 2011).  
As a matter of fact, the existence of glutamate receptors at presynaptic terminals has been 
suggested by immunochemical localization experiments, functional studies, ultrastructural 
fractionation and receptor subunit trafficking analyses, bridging a gap on the lack of evidence 
for NMDARs and JNK implication in glutamate release at this synaptic compartment in both 
physiological and pathological settings (Biggi et al., 2017; Feligioni et al., 2006; Grilli et al., 
2012; Nisticò et al., 2015). 
In a recent work, our group employed transgenic knock-out mice for single JNK isoforms, 
underlining a unique and specific contribution of the JNK2 subtype in mediating such 
presynaptic events at cortical nerve endings (Nisticò et al., 2015).  
Indeed, JNK2 knock-out mice displayed a dramatic reduction of NMDA-evoked glutamate 
release as direct consequence of the decreased NMDA-elicited JNK activation, thereby 
suggesting a striking mechanism by which glutamate overflow might be controlled via the 
upstream presynaptic interaction among NMDAR, JNK2, JIP1 and other protein partners of 
the release machinery.  
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4.3 Presynaptic JNK modulates glutamate release 
Protein–protein interactions and formation of protein complexes are thought to be critical for 
the normal function of the JNK signaling pathway. Thereby, our research effort is exploring 
the role of JNK in the presynaptic modulation of vesicle release, focusing on the interaction 
between JNK and SNARE proteins.  
A work by Biggi and coworkers (Biggi et al., 2017) just confirmed JNK localization at 
presynaptic compartments, as well as its activation upon presynaptic NMDARs stimulation. 
Additionally, the presence of putative JNK-binding domains (JBDs) in some proteins 
belonging to the presynaptic release machinery let authors hypothesize a possible physical 
interaction of those proteins with JNK. Basically, a JNK-dependent phosphorylation of t-
SNARE proteins may be involved in neurotransmitter release at presynaptic sites, with 
potential application in both synaptic plasticity and ischemic events. 
On purpose, we examined whether JNK may act as an effector for the SNARE complex 
formation, in order to regulate glutamate vesicle release. 
 
 
4.4 SNARE complex assembly in the synaptic vesicles machinery 
In the central nervous system, neurotransmitter release in both physiological and pathological 
conditions is mediated by exocytosis of synaptic vesicles from electron-dense regions called 
active zones in the presynaptic plasma membrane of nerve terminals. These specialized 
biochemically insoluble, disk-like structures are embedded with multidomain proteins that 
provide a scaffold for synaptic vesicles, i.e. 40–100 nm spherical lipid-bilayer organelles 
generated from the endoplasmic reticulum or presynaptic plasma membrane, filled with 
molecules of neurotransmitter via a vacuolar proton pump and transported by cellular 
trafficking toward the presynaptic active zone (Ramakrishnan et al., 2012; Südhof, 2004).  
Exocytosis at fast synapses is a calcium-dependent event that occurs on a millisecond 
timescale (0.5 ms or less) following transient calcium current into nerve terminals during 
incoming action potentials (Jahn and Fasshauer, 2012). Under resting conditions, synaptic 
vesicles are referred to as “readily-releasable pool” and get tethered in the nerve terminal in 
close proximity to the voltage-gated calcium channels that cluster around the active zone to 
regulate exocytosis and endocytosis in the frame of rapid and repeated rounds of transmitter 
release. 
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When action potentials induce the opening of Ca
2+
 channels (mostly CaV2.1 P/Q- or CaV2.2 
N-type Ca
2+
 channels), the resulting Ca
2+
 influx effectively triggers exocytosis. 
For the sake of clarity, it appears obvious that these fine-tuned mechanisms may deregulate 
and exacerbate during the spreading depolarizing waves characterizing the ischemic 
progression and culminating into excitotoxic demise.  
Presynaptic neurosecretion is traditionally divided into three stages preceding vesicles 
endocytosis and recycling, namely:  
- docking at the active zone, as morphologically observed by electron microscopy; 
- priming of vesicles to become electrophysiologically Ca
2+
 responsive and competent for 
fusion; 
- fusion of vesicular-presynaptic bilayers and opening of an aqueous channel termed fusion 
pore to release ready vesicles into the synaptic cleft (Acuna et al., 2014). 
A major goal in structural and functional neurobiology studies during the past two decades 
has been to gain insight into the molecular machinery that mediates neurotransmitter release, 
in order to yield a unified picture for the key players crowding at the presynapse. 
Several genes and protein families have been so far identified and likely targeted to modulate 
the dynamics of neuronal exocytosis, and particularly upon pathologic conditions such as 
cerebral ischemia. Many of them belong to an array of structurally conserved proteins, 
collectively called SNARE (Soluble-N-ethylmaleimide-sensitive factor Attachment protein 
REceptors) and SM (Sec1/Munc18 like) proteins (Südhof, 2012).  
SNARE proteins are defined by an extended homologous 70-residue coiled-coil stretch, 
referred to as a SNARE motif, and include the vesicular v-SNARE protein 
synaptobrevin/VAMP (vesicle-associated membrane protein) and the target t-SNARE 
proteins Syntaxin and SNAP25 (synaptosomal-associated protein 25) on neuronal presynaptic 
membrane. On the other hand, SM proteins Munc18 and Munc13 are generally clustered with 
the assembling complexes via the interaction with Syntaxin, bearing a fundamental role in 
orientation and localization of the vesicles at the active zone (Dawidowski and Cafiso, 2016; 
Südhof, 2013a). Indeed, deletion of either Munc18 or Munc13 completely inhibits neuronal 
exocytosis (Jahn and Fasshauer, 2012). 
The first step in neurotransmitter exocytosis is the tethering of vesicles at the presynaptic 
membrane via the formation of protein complexes (Whyte and Munro, 2002). In the active 
zone, Syntaxin is generally found strongly attached to Munc18 in a close conformation in 
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which its Habc-domain folds against the N-terminal part of the SNARE motif, mutually 
excluding further interaction with other SNARE proteins (Smyth et al., 2010) (Fig. 18).  
 
 
 
 
 
Fig. 18 
Open/closed state of Syntaxin in presence of SNAP25 and Munc18. 
Syntaxin readily forms oligomers in solution that dissociate to form a 1:1 complex in a closed configuration with 
Munc18 (form 1). Conversely, Syntaxin preferentially forms a 2:1 Syntaxin/SNAP25 complex (form 2) with 
excess of SNAP in solution, switching to the open conformation. Further addition of Munc18 dissociates this 2:1 
complex, yielding a 1:1:1 Syntaxin/SNAP25/Munc18 complex where Syntaxin goes back to the closed 
configuration (form 3). The equilibrium between complexes (1) and (3) favours form (3) that is supposed to be 
the starting point for SNARE assembly. 
(Adapted from Dawidowski and Cafiso, 2016).  
. 
 
 
The regulatory interaction between Syntaxin and Munc18 has been intensely debated due to 
controversial findings. So far it is recognized a dual mechanism to explain the distinct fates of 
this protein interplay. As said above, in the inhibitory mode Munc18 envelopes Syntaxin, 
sequestering it from SNARE protein interactions. On the other hand, the direct binding of 
Munc18 to the evolutionarily conserved N-terminal domain of Syntaxin has been proposed to 
promote the priming in the fusion reaction, ultimately fostering transmitter release (Deák et 
al., 2009; Rickman and Duncan, 2010; Rickman et al., 2007). In parallel, also Munc13 might 
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switch Syntaxin into the open conformation, unmasking its SNARE motif and making it 
competent for SNARE-complex assembly (Dawidowski and Cafiso, 2016). 
Interestingly, transgenic mice modified for constitutively open Syntaxin are viable but 
succumb to generalized seizures in young age, due to impaired binding to Munc18 and 
dramatically enhanced rate of synaptic vesicle fusion (Gerber et al., 2008), as a proof of the 
inevitably supervised switch between closed/open state for the normal SNARE assembly. 
The “SNARE hypothesis” describes a mechanistic model for priming and fusion based on the 
specific and high-affinity interactions between the highly conserved SNARE domains present 
in v- and t-SNAREs proteins. The leucine-zipper-like assembly of the SNARE motifs consists 
of a highly twisted and parallel four-helical trans bundle wherein Synaptobrevin and Syntaxin 
respectively share two individual helices while SNAP25 contributes with other two helices, as 
seen by high-resolution analysis (Brunger et al., 1998; Li et al., 2007). The resulting 
SNAREpin is a competent and thermodynamically stable core fusion machinery that bridges 
and spans through vesicle/target bilayers, catalyses the steps involved in the release by 
reducing the energy barrier, and ultimately drives to membranes fusion (Acuna et al., 2014; Li 
et al., 2007). 
The number of assembled SNARE complexes per vesicle during fusion determines the 
presynaptic discharge probability and the fusion kinetics, with only 1 to 3 SNARE complexes 
supposed to be minimally required for a fusion reaction (Acuna et al., 2014).  
Following transmitter release, vesicles detache from the presynaptic membrane by 
dissociation of the SNARE complex in an ATP-dependent process and recycle to the reserve 
pool, which serves to replenish the readily releasable pool upon its depletion. 
Besides forcing membranes close together, SNARE nucleation importantly ensures the spatial 
and temporal specificity of fusion reactions, in a tightly coordinated and finely regulated 
process. 
However, this unique orchestra of calcium-triggered exocytosis is not mediated by the direct 
binding of Ca
2+
 to the SNARE engine, but rather primarily encoded by calcium-binding 
proteins located near active zones. Among these, Synaptotagmins are specialized vesicle-
bound proteins that constitute the dominant calcium sensors at synaptic terminals (Südhof, 
2013a; Südhof, 2013b) and whose deletion results in a complete loss of fast, synchronous 
calcium-triggered exocytosis (Kochubey et al., 2011). In parallel, Complexins are small 
calcium-dependent neuronal regulators of exocytosis that facilitate synchronized vesicle 
fusion via their interaction with SNARE proteins (Giraudo et al., 2006) (Fig. 19).  
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Fig. 19 
Paradigmatic diagram of the SNARE–SM protein cycle during synaptic vesicle fusion and 
neurotransmitter release. 
Synaptic vesicles are primed for fusion via a switch of the Munc18-binding mode on Syntaxin from the closed to 
the open conformation (step 1). This partial assembly of trans-SNARE complexes is facilitated by recently 
discovered chaperones CSPs and synucleins.  
The fusion pore opens following a full trans-SNARE complex assembly (step 2) and expands converting trans-
SNARE into cis-SNARE complexes (step 3), permitting neurotransmitter release. Ultimately, NSF and SNAPs 
mediate the disassembly of the SNARE complex, leading to vesicle recycling (step 4).  
(Adapted from Südhof, 2013b). 
 
 
 
Several other proteins actually contribute to the engine of membrane fusion, representing 
potential targets for the machinery manipulation. Indeed, many forms of neurodegeneration 
initiate presynaptically, where nerve endings release neurotransmitters thousands of times per 
minute. During each release event, SNARE-complex assembly and disassembly may render 
the terminals potentially vulnerable to activity-dependent degeneration, especially in cases of 
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disproportionate neurotransmitter overflow, as seen with glutamate-based excitotoxicity in 
cerebral ischemia. A deeper knowledge of the individual players belonging to the release 
machinery may thereby provide useful insights in the search for novel therapeutic strategies. 
  
 
4.5 Syntaxin involvement in neurotransmitter vesicle release 
Syntaxins are t-SNARE transmembrane proteins that play a central role in synaptic vesicle 
exocytosis.  
16 members are known to characterize this protein family in mammalian cells. Among them, 
Syntaxins 1–4 are localized into the plasma membrane, although Syntaxin-1a and -1b are the 
major variants expressed in the brain.  
Hereby, Syntaxin-1a is the isoform taken into consideration, due to its pivotal contribution in 
neurotransmitter release at presynaptic terminals (Südhof, 2004). 
Different Syntaxin functional domains are known take part to different steps during calcium-
triggered membrane fusion. The amino-terminal regulatory domain consists of an antiparallel 
three-helix bundle termed the Habc domain, connected to the SNARE motif (H3) by a flexible 
linker (Jahn and Fasshauer, 2012). The Habc domain may fold to form a closed configuration 
or unfold to expose the H3 SNARE motif for interaction during vesicle fusion, thereby 
regulating, as previously seen, Syntaxin pertinence to the SNARE complex nucleation (Fig. 
20). 
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Fig. 20 
Schematic representation of domain and crystal structures of core proteins of the neuronal fusion 
machine.  
Domain structures of Syntaxin-1a, Munc18 and SNAP25 are here depicted. 
The dashed lines between the N-peptide and Habc domain represent flexible regions in Syntaxin-1a.  
Syntaxin-1a is shown assembled with Mun18 (left) and in the SNARE complex (right) with SNAP25, 
Complexin (Cpx) and Synaptobrevin (Syb).  
(Adapted from Jahn and Fasshauer, 2012). 
 
 
 
Besides assembling with Synaptobrevin and SNAP25 for the indisputable role in synaptic 
transmission, Syntaxin also interacts with a number of regulatory proteins such as Munc18, 
Synaptotagmin, and calcium channels, providing essential additional cues to that fine-tuning 
of the fusion process discussed above.  
In the engine of the exocytotic apparatus, it is reasonable to speculate that the 
phosphorylation/dephosphorylation state of synaptic proteins may be another critical 
mechanism accounting for the regulation of the biochemical pathways leading from vesicle 
docking to neurotransmitter release, in the context of either normal synaptic plasticity or 
possible disease conditions (Südhof, 1995). Obviously, the time course between action 
potential arrival at nerve terminal and the consequent vesicle fusion is roughly too short for 
protein phosphorylation to exert a direct and acute effect upon a single exocytotic event. 
Nevertheless, both protein kinases and phosphatases deserve influential roles on subsequent 
neurotransmitter release events. 
The N-terminal of Syntaxin-1a contains, for instance, a highly conserved consensus site for 
the ubiquitous Ser/Thr casein kinase II (CKII). Serine 14 has been observed to be the target 
for in vivo phosphorylation (Foletti et al., 2000; Risinger and Bennett, 1999), and mutagenesis 
assays also proved that this residue is the sole CKII phosphorilatable site for Syntaxin-1a. 
Notably, this phosphorylation is rather specific for Syntaxin-1a and poorly conserved in other 
mammalian Syntaxin paralogs, suggesting a patterning for specific differential modulation of 
downstream functions. 
Previous studies underlined that the amount of phospho-Syntaxin in the rat brain increases 
during development from 4% in embryos to 40% in adult animals, bearing a potential 
regulatory implication in development, in parallel with synapse development and maturation. 
Immunoprecipitation assays have also shown that phosphorylated Syntaxin can form 
complexes with SNAP25, VAMP and Synaptotagmin, although it results mostly enriched in 
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complexes with SNAP25 and localizes into discrete domains of the axonal plasma membrane 
that do not necessarily colocalize with pools of synaptic vesicles, rather defining fusion sites 
outside classical active zones (Foletti et al., 2000).   
A more recent study pointed out the key regulatory role of phosphorylation at serine 14 for 
priming–based interaction between Syntaxin-1a and Munc18 at the plasma membrane, 
evidencing the utmost relevance of this phosphorylation for downstream vesicle motion and 
efficacy of the fusion apparatus (Rickman and Duncan, 2010).  
On the other hand, the Ca
2+
-dependent phosphorylation by DAP (death-associated protein) 
kinase at serine 188 in the C-terminal domain significantly decreases Syntaxin-1a binding to 
Munc18, providing and additional mechanism for the modulation of Syntaxin binding 
properties in response to elevated intracellular Ca
2+
 concentrations and synaptic activity (Tian 
et al., 2003).  
 
 
4.6 Beyond molecular biology: clinical implications for Syntaxin1a 
Neurotransmitter release is irreproachably recognized as the milestone for synaptic 
communication. Consequently, impairment engaging any of the proteins involved in any 
release step may lay the foundation for an array of pathologies, including neurodegenerative 
(Alzheimer’s and Parkinson’s diseases), neurodevelopmental (autism), neurovascular 
(migraine, ischemia) and psychiatric (schizophrenia, depression) disorders (Cao et al., 2009; 
Castillo et al., 2010; Corominas et al., 2009; Durdiaková et al., 2014; Nakamura et al., 2008).  
Besides the well documented involvement in the SNARE complex-mediated exocytosis, 
Syntaxin has been found to directly impact on mental well-being, due to its variegated 
implication in pathways underlying functional/behavioural entailment. 
Consequently, the analysis of the human genome has been prompted, looking for possible 
associations between Syntaxin and genetic-based disorders.  
The genomic structure of STX1A is based on the UCSC May 2004 draft assembly of the 
human genome (OMIM 186590) (www.genome.ucsc.edu). The gene STX1A consists of 10 
exons spanning a 20.42 kb region (mRNA 2064 bases) and lies at 7q11.23, a locus found to 
be duplicated in some individuals with autism, and associated with delayed speech and 
autistic behaviour (Berg et al., 2007) (Fig. 21). 
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Fig. 21 
Genomic structure of STX1A and location of SNPs. 
Exons are indicated by boxes, with translated regions in closed boxes, and untranslated regions in open boxes. 
Introns are indicated by lines. SNP positions are denoted by arrows (from http://www.genome.ucsc.edu). 
 
 
 
Overexpression of Syntaxin-1a has been indeed implicated in Asperger syndrome, a high-
functioning form of autism characterized by pervasive difficulties in social interaction and 
impaired communication, alongside unusually narrow interests and repetitive, stereotyped 
behaviour, although lacking delay in language and cognitive development (Kanner, 1968; 
McPartland and Klin, 2006).  
Abnormalities in serotoninergic neurotransmission have extensively been reported in autism 
(Betancur et al., 2002; McDougle et al., 2005) and, in parallel, Syntaxin regulates subcellular 
localization and expression of the serotonin transporter 5-HTT, which in turn modulates 
serotonin brain levels, particularly during neurodevelopment (Quick, 2002). Furthermore, 
Syntaxin-1a has been thought to interact with the glutamatergic system, via promotion of the 
endocytic sorting of the glutamate transporter EAAC1, leading to deregulation of glutamate 
transport (Yu et al., 2006), already associated with the pathophysiology of autism (McDougle 
et al., 2005). Finally, Syntaxin-1a is an important component of the GABAergic system, due 
to its involvement in the transport of glutamate and its conversion to GABA (gamma-
aminobutyric acid) (Yu et al., 2006), another targeted network in autism (Coghlan et al., 
2012). The rational for a potential correlation between Syntaxin and autism, as well as other 
neurological disorders, is thereby justified. Consistently, in transmission disequilibrium test 
analyses, two Single Nucleotide Polymorphisms (SNPs) for STX1A (i.e. rs2293485 and 
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rs4717806) showed nominal association with Asperger syndrome and were therefore related 
to the pathogenesis of early developmental abnormalities in the Caucasian population 
(Nakamura et al., 2008). In a similar vein, a more recent study restricted to the Japanese 
population showed the nominal association of the rs69510130 SNP with autism. In addition, 
authors further evidenced in post-mortem specimens from autistic patients compared to non-
autistic controls a significantly lower Syntaxin-1a expression in the anterior cingulate gyrus, a 
region of the brain associated with rational function and social cognition, suggesting another 
hint to the possible role of Syntaxin-1a in the pathogenesis of autism (Nakamura et al., 2011).  
rs941298 is another intronic SNP that showed significant association with Asperger 
syndrome, confirming the role of Syntaxin-1a as an important candidate gene in autism 
spectrum disorders (Durdiaková et al., 2014). Interestingly, it is likely that the expression of 
STX1A may be putatively regulated by these SNPs via alteration of transcription factor 
binding sites both directly or through other variants in high linkage disequilibrium 
(Durdiaková et al., 2014).  
The latter polymorphisms, rs6951030 and rs941298, are also susceptibility factors associated 
with increased risk of migraine, a common neurological disorder with a complex inheritance 
pattern, characterized by recurrent episodes of invalidating headache, that affects more than 
15% of the European population (Corominas et al., 2009; Lemos et al., 2010; Stovner et al., 
2006). Besides the presynaptic reduction of serotonin and GABA reuptake, there is some 
evidence suggesting that ion channel subunits might also be involved in the more common 
forms of migraine, and Syntaxin-1a is known to physically interacts with the α1A and α1B 
subunits of the voltage-dependent calcium channel, enabling the rapid glutamatergic secretory 
response to cortical spreading membrane depolarization, incriminated as the underlying 
mechanism for visual, sensory, or motor aura in migraine pathophysiology (Zamponi, 2003).  
A significant genetic association has also been reported between an intron 7 SNP in the 
STX1A gene and schizophrenia, a psychiatric disorder described as a “disease of the synapse” 
(Mirnics et al., 2001; Wong et al., 2004). Post-mortem studies provided evidence for 
increased Syntaxin immunoreactivity in the cingulate cortex, but not in other brain regions of 
schizophrenic subjects when compared with controls (Gabriel et al., 1997; Honer et al., 1997). 
Interestingly, the altered phosphorylation of this key presynaptic protein has been related to 
the pathophysiology of schizophrenia. Previous studies reported a significant reduction in the 
levels and activity of CKII in the brain of patients with schizophrenia, with no apparent 
correlation with any antipsychotic drug treatment (Aksenova et al., 1991). This deficit 
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correlates with the 25% decrease in CKII-mediated phosphorylation of Syntaxin-1a observed 
in schizophrenia, and potentially affects Syntaxin-1a binding to the protein partners for the 
SNARE complex assembly, ultimately wrecking synaptic transmission (Castillo et al., 2010). 
Given the pivotal functional role fulfilled by Syntaxin-1a at neuronal level, and moreover 
considering its prominent implication in neurotransmitter exocytosis, we wonder how and to 
what extent this protein could be involved in the presynaptic excitotoxic glutamate release 
defining neuronal cell death after ischemia, aiming at the precise molecular mechanisms 
governing this unknown signaling. 
Evidence from previous studies in permanent focal ischemia rat models already revealed a 
significant acute up-regulation of Syntaxin-1a immunoreactivity, but not synaptotagmin, in 
the core cortex and peri-ischemic cortex at 1 day after infarction (Cao et al., 2009). Authors 
hypothesized a possible protective contribution of Syntaxin-1a to neuronal demise via 
inhibition of the Kv2.1 potassium channel, leading to a reduced K
+ 
efflux-induced apoptotic 
death after cerebral ischemia. 
However, a concretely compelling evidence for Syntaxin-1a involvement in ischemia 
pathogenesis would be the demonstration of a pathophysiologic mechanism in addition to the 
prominent association between the gene and the disease. By this approach, as science 
progresses in the understanding of biochemical mechanisms and potential genetic 
predisposition at the basis of certain illnesses, the possibility for convenient chances of 
therapeutic intervention, in turn, increases. 
This is what our work yearns for. 
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AIM OF THE WORK 
 
In the frame of the discouraging scenario concerning the clinical failure of almost every 
therapeutic avenue approached so far, our purpose was to provide a novel tool to be 
efficiently exploited in the clinical setting of the ischemic pathology. 
To date, besides rt-PAs, the most promising therapeutics have pointed to the inhibition of 
NMDA receptors, with more or less subunits specificity, thereby directly targeting the 
upstream culprit in excitotoxicity. The major drawback undermining these disappointing 
attempts is the limited time to opportune intervention, as well as a plethora of unwanted side 
effects deriving from the multifarious involvement of the glutamatergic receptors in normal 
neurophysiology, together with the trivial pathological implications.  
On the other hand, a new direction for therapeutic possibilities has been the pursuit of 
downstream signaling in order to permit delayed intervention and to dam off-target undesired 
outcomes. 
In this context, we aimed at identifying potential yet undisclosed molecular mechanisms 
involved in the excitotoxic cascade following ischemia. 
Our investigation contribution so far evidenced the role of JNK proteins also at presynaptic 
sites, besides their well-known role in the postsynapse. In particular, we unveiled a JNK2 
specifically mediated role in NMDA-evoked glutamate release during excitotoxic conditions 
(Nisticò et al., 2015). 
Considering this new subset of data deriving from our previous work, we hereby present an 
interesting molecular interplay between the JNK2 isoform and STX1a, a key player in the 
SNARE complex assembly and neurotransmitter vesicular release. We hypothesized that this 
interaction should support an essential role in synaptic transmission in times of excessive 
glutamatergic storm, given the deep involvement at presynaptic sites of these two proteins. 
In order to verify and subsequently counteract the occurrence of this sordid partnership, we 
took advantage of bioinformatics analyses to identify the protein regions physically contacting 
and, on the basis of this knowledge, to design the appropriate sequence of a novel peptide able 
to competitively disrupt this contact. We additionally provided the peptide with the HIV-Tat 
portion in order to let it pass through membranes, according to our experimental objectives.  
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Following several experiments ranging from biochemistry to molecular biology, from 
electrophysiology, to in vivo manipulation and human genotyping, we collected a bulk of data 
emphasizing that: 
 a physical interaction between JNK2 and STX1a does occur, and is more robust during 
excitotoxicity; 
 this interaction is causally implicated in the presynaptic release of glutamate during 
ischemic injury and, more in general, in the context of excitotoxicity; 
 this interaction can be itemized as novel molecular pathway to target, in order to 
specifically inhibit the presynaptic NMDA receptor overactivation; 
 our cell-permeable Tat-linked peptide resembling the N-terminal portion of STX1a 
proved to be able to disrupt JNK2/STX1a interplay with high selectivity of action in 
several experimental paradigms, proving to be a suitable neuroprotective drug; 
 genetic studies focusing on the SNPs of STX1A gene from human blood samples of 
stroke patients demonstrated the occurrence of a haplotype significantly associated 
with increased susceptibility to stroke. 
 
 
Future perspectives: 
Encouraged by the therapeutic neuroprotective potential of our peptide, we are currently 
planning further sets of experiments with the aim of deepening the findings already obtained 
and, at the same time, widening the translational possibilities of JGRi1. 
On purpose, we would like to broaden the number of ischemia animal models employed for 
the experiments, as well as the samples genotyped from stroke patients, in order to rely on a 
still more consistent statistics. 
We are additionally interested in evaluating our peptide efficacy upon several paradigms and 
time windows of reperfusion, being reperfusion injury an important issue to consider in the 
context of neuroprotection. 
Under a more clinical perspective, behavioural tests will be also taken into consideration to 
assess the rescue from neurotoxicity provided by JGRi1 concerning functional sensorimotor 
and cognitive outcomes. Among the most plausible, rotarod, pole, wire-hanging, corner, open 
field, Morris water maze and radial arm maze tests will be worth of attention.         
Functional testing is indeed a crucial achievement for cutting-edge evaluation of experimental 
procedures in animal stroke models in that it provides an alternative analysis of the 
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therapeutic intervention, particularly in the direction of bridging the gap between the 
evaluation criteria used in animal studies with respect to human clinical trials.  
The difficulty in translating preclinical findings to humans, conventionally referred to as the 
translational roadblock, still represents a major challenge in cerebrovascular research. The 
importance of this issue resides in the fact that many pathologies associated with 
excitotoxicity still lie under the burden of the lack of innovative medicaments to tackle brain 
damage. 
In the context of the double-edged sword represented by glutamatergic neurotransmission, the 
pressing need to find new pharmacological targets to be more specifically and convincingly 
addresses is of utmost urgency. We are consequently moving at dissecting the role of JGRi1 
in the wide universe of the excitotoxicity-mediated pathologies, including traumatic brain 
injury, epilepsy, perinatal asphyxia, diabetic retinopathy and glaucoma. 
In addition, the neurotoxicity of glutamate can also be involved, at least partially, in the 
pathogenesis of various late-onset and chronic diseases that are classified in the context of 
neurodegeneration and neuroinflammation such as Alzheimer's and Parkinson's diseases, 
amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, as well as various 
psychiatric disturbances (i.e. major depressive disorder, schizophrenia, anxiety disorders), 
migraine, autism, chronic neuropathic pain. 
By blocking the NMDA glutamate receptor, the drugs on the market today may be initially 
effective on one hand, but on the long-term produce side effects that may even be severe.  
Our preclinical research on the intracellular partners of the NMDA receptor brought about a 
new druggable tool to overcome these limitations and fulfil the medical and human longing of 
novel specific and less toxic therapeutics. 
Gazing to this overflowing medical crossroads, we wish to make clear that we are not yet 
holding the keystone for neuroprotection. Nevertheless, we are working hard to empower our 
ambitious future research with the best direction for best scientific achievements. 
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MATERIALS AND METHODS 
 
Animal handling, brain tissue preparation and drug administration 
Two and three months old C57BL/6 mice (Charles River Laboratories, Calco, Italy) 
weighting 20-25 g and pregnant Wistar rats (Charles River Laboratories, Calco, Italy) at 
gestational age 17-18 (E17-18) were used for the experiments, kept with standard food and 
water ad libitum, on a 12 hours light/dark cycle, under environmentally monitored conditions 
(room temperature set at 22 ± 1 °C; relative humidity 40 ± 5%). 
Animal care procedures and testing have been disciplined by the guidelines established by the 
European Communities Council Directive (Directive 2010/63/EU of 22/09/2010), and 
accepted by the Italian Ministry of Health (D.L. 26/2014 of 04/03/2014). According to the 
ethical care and handling of animals, all experiments were performed in conformity with the 
“International Guiding Principles for Biomedical Research involving animals” (Council for 
the International Organizations of Medical Sciences, Geneva, CH) and approved by the 
Ethical Committee on animal experiments of EBRI (European Brain Research Institute - 
“Rita Levi-Montalcini” Foundation, Rome, Italy).  
All adequate measures were taken to minimize animal suffering or discomfort, and to reduce 
the number of animals used to obtain statistically trustworthy results. 
Mice were anesthetized with proper drugs and killed by decapitation. Brains were rapidly 
dissected out on ice in order to collect the tissues to use in the various experiments. All the 
procedures necessary to prepare the brain fractions were done at 0–4 °C.  
Systemic intraperitoneal and intracerebroventricular injections were performed to administer 
JGRi1 peptide variants for subsequent analysis. Surgery for transient MCAo induction was 
performed under 5% isoflurane anaesthesia and maintained on 1.5% isoflurane.   
 
Synaptosomes preparation  
Synaptosomes are artificial, membranous sacs of purified intact nerve endings, firstly 
prepared in the late 1950s by Whittaker and colleagues to define the functional components of 
the synapse and to study the synaptic signaling (Gray and Whittaker, 1962).  
Synaptosomes are generated by the subcellular fractionation of homogenized nerve tissue and 
contain the complete presynaptic terminal enriched with mitochondria and synaptic vesicles, 
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along with a portion of the postsynaptic membrane, as observed through electron microscopy. 
This “pinched-off nerve endings” preparation is currently established as an amenable and 
elegant in vitro model system to analyse the molecular mechanisms that coordinate the 
temporal and spatial synaptic activity in the brain. Indeed synaptosomes maintain intact 
membrane potential and metabolic activity, contain the molecular machinery of presynaptic 
proteins, and, upon convenient exogenous stimulation, may release neurotransmitters 
including glutamate in a Ca
2+
-dependent manner (Evans, 2015). Synaptosomes purification is 
additionally an essential tool to study synaptic proteomics and phospho-proteomics and to 
finely dissect the networks of synaptic protein–protein interactions in either normal or disease 
conditions (Munton et al., 2007; Wilhelm et al., 2014).  
The basis of synaptosomal preparations is the starting homogenization of fresh cerebral tissue 
under isotonic conditions to generate shear forces that physically detach nerve terminals from 
the axons, but still allow the lipid bilayers to naturally reseal together in closed synaptosomes 
(Fig. 22). 
 
 
 
 
 
Fig. 22 
Preparation and composition of synaptosomes.  
A) Schematic representation of a synaptic cleft, comprehending the presynaptic nerve terminal (upper dotted 
line) and the attached postsynaptic density (lower dotted line) that result pinched off following homogenization 
of brain tissue. 
B) Representation of the typical appearance of a centrifuge tube at the end of the centrifugation step of the 
Percoll density gradient. The synaptosomal fraction is isolated between 10 and 20% Percoll layers (see below). 
C) Electron micrograph of a mouse brain synaptosome, illustrating a synaptic vesicle (S), mitochondria (M), and 
the postsynaptic density (P). Scale bar = 100 nm. 
(Adapted from Bai and Witzmann, 2007; Dunkley et al., 2008; Evans, 2015). 
 
 
The protocol used in the present work has already been described in Marcelli et al., 2016. 
Briefly, dissected C57BL/6 mice cortices were homogenized at 4 °C using a glass/Teflon 
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grinder (clearance 0.25 mm) in 10 volumes of a preservative solution containing 0.32 M 
sucrose, buffered to pH 7.4 with 1 mM Tris-(hydroxymethyl)-amino methane. The 
homogenate was centrifuged 5 min at 1000 xg to remove nuclei and cellular debris and the 
supernatant was gently stratified on a discontinuous Percoll gradient (Sigma-Aldrich, USA) 
composed of 4 layers (2, 6, 10, 20% v/v in Tris-buffered glucose), then centrifuged 5 min at 
33500 xg to obtain a purer preparation (Dunkley et al., 2008; Nakamura et al., 1993). The 
synaptosomal fraction was isolated between 10 and 20% Percoll layers, washed by 
centrifugation and collected by centrifugation. The pellet was then resuspended in a 
physiological solution (saline buffer) pH 7.2-7.4 constituted by NaCl 140 mM, KCl 3 mM, 
MgSO4 1.2 mM, CaCl2 1.2 mM, NaHPO4 1.2 mM, NaHCO3 5 mM, HEPES 10 mM, glucose 
10 mM and used for subsequent biochemical and confocal analyses.  
  
Synaptosomal stimulation in biochemical studies 
Stimulation of synaptosomes was performed in batch, as previously reported (Nisticò et al., 
2015).  
Resuspended synaptosomes were divided into 0.2 ml aliquots and gently agitated at 37 °C for 
10 min to allow full restoration of the enzymatic machinery. Synaptosomal suspensions were 
subjected to differential stimulation with either NMDA (100 μM) + glycine (1 μM) or KCl (8 
mM), respectively for 10 min or 90 seconds at 37 °C. 
0.2 ml of warm saline buffer containing proteases and phosphatases inhibitors was added at 
the end to stop the stimulation. JGRi1 (1 μM) was added, where needed, and left for 30 min at 
37 °C before the NMDA stimulus and till the end of the experiments. The experiments were 
terminated by immediate centrifugation at 12000 ×g to pellet the synaptosomes. In NMDA 
stimulation experiments, external Mg
2+
 ions were omitted from the resuspension buffer to 
avoid the functional inactivation of the receptor. 
The final pellets were lysed in ~100 μl of Lysis Buffer solution (LB) made up of 1% Triton 
X-100 (Serva, Germany), complete proteases inhibitor cocktail solution (Serva, Germany), 
phosphatases inhibitor cocktail solution (Serva, Germany) and the following components 
(mM): TRIS acetate, 20; sucrose, 0.27; EDTA, 1; EGTA, 1; NaF, 50; Na Orthovanadate, 1; 
Na Pyrophosphate, 5; Na β-glycerophosphate, 10; DTT, 1. 
Protein concentration was ultimately quantified by Bradford assay and samples directly 
analysed by Western blot, following 5 min heating at 95 °C upon resuspension in Laemmli 
Sample Buffer 2x containing 10% β-mercaptoethanol. 
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Immunoprecipitation experiments 
In order to study JNK2/STX1a interaction and JGRi1 activity on that, cortical synaptosomes 
were stimulated and treated as previously described, and samples quantified for protein 
content via Bradford assay.  
Magnetic beads (Protein G Mag Sepharose
™
, GE Healthcare, UK) were washed three times in 
Binding Buffer (Tris Base 50 mM, NaCl 150 mM) and 15 µl were added to each sample tube, 
composed of 350 µg of protein extract from synaptosome lysate diluted in Lysis Buffer. This 
pre-clearing step was performed over 30 min at 4 °C upon gentle agitation.  
The supernatant was then collected by means of a rack that allows easy beads separation via 
magnetic holding. p-JNK antibody (1:200, rabbit Cell Signaling, USA) was added in each 
sample, excluding the one for the ‘Input’ total synaptosomes lysate and the ‘Beads’ alone, 
before leaving them at 4 °C overnight. 
The day after, 25 µl of freshly washed beads were added to each sample and left for 3 h at 4 
°C in mild agitation. After the indicated time, the supernatant was removed and the beads 
were washed four times in Binding Buffer enriched with phosphatases and proteases 
inhibitors (Serva, Germany). The immunoprecipitated complexes were resuspended in Sample 
Buffer 1x, incubated 30 min at 50 °C and loaded on gels for immunoblot analysis. 
 
Western Blot  
10% SDS polyacrylamide gels were used to resolve 15 µg of proteins (equal amount in each 
condition) and then blotted onto PVDF membranes (Amersham Hybond 0.2 µm; GE 
Healthcare, UK) previously activated in methanol. The resulting membranes were incubated 1 
h at room temperature in blocking buffer (5% skim milk diluted in tween-Tris-buffered saline 
(t-TBS) (M) Tris, 0.02; NaCl, 0.15; Tween 20, 0.1%). After several washes in t-TBS, 
membranes were incubated overnight at 4 °C with specific primary antibodies: rabbit anti 
STX1a 1:1000 (Synaptic System, Germany), rabbit anti p-STX1a 1:1000 (AbCam, USA), 
rabbit anti JNK 1:1000 (Cell Signaling, USA), rabbit anti p-JNK 1:1000 (Cell Signaling, 
USA), rabbit anti JNK2 1:1000 (AbCam, USA), mouse anti SNAP25 1:1000  (BioLegend, 
USA), rabbit anti Munc18 1:1000 (Cell Signaling, USA), mouse anti Actin 1:1000 (Sigma-
Aldrich, USA), and mouse anti HA 1:1000 (Sigma-Aldrich, USA). 
Membranes were washed for 50 min in t-TBS before incubation with peroxidase-conjugated 
goat anti-rabbit or anti-mouse IgG secondary antibodies (UCS Diagnostic) 1:3000 for 1 h at 
room temperature. Several washes with t-TBS for 50 min were performed again before the 
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membranes were exposed to chemiluminescence reagents (ECL; WESTAR, Cyanagen, Italy) 
and the resulting signals acquired on blue X-Ray films (Aurogene, Italy). 
 
Bioinformatics analysis and computational details   
Coordinates and structures for JNK2 and the N-terminal domain of Syntaxin-1a were obtained 
from Protein Data Bank (PDB) with ID(s) accession number respectively 3NPC (Kuglstatter 
et al., 2010) and 1BR0 (Fernandez et al., 1998). Docking simulations were performed using 
the Rosetta 3.4 software (Sircar et al., 2010), allowing backbone movements and side-chain 
optimization. One hundred thousand docking decoys were generated and ranked according to 
the total score, taking into account the contributions from Van der Waals interactions, 
solvation, hydrogen bonds, electrostatic interactions, probability of side-chain rotamers, and 
interface score (i.e. the difference between the total score of the complex and the total score of 
isolated protomers). Three top structures were selected according to higher scores and 
considered for further analysis. Buried surface area upon complex formation for each 
structure has been evaluated with NACCESS (NACCESS Computer Program 
http://www.bioinf.manchester.ac.uk/naccess), a stand-alone program that calculates the 
atomic and residue accessibility area for proteins in PDB format file. 
Multiple sequence alignment for JNK1, JNK2 and JNK3 was virtually performed with Clustal 
Omega (Sievers et al., 2011) using default options. Buried surface and sequence alignment 
data outlined that one among the selected structures exhibited peculiar features, making it the 
most plausible for protein-protein interaction. 
Indeed, although the three JNK isoforms on their whole display high sequence identity, the 
sole JNK2 domain binding to Syntaxin-1a showed a unique distinctiveness with respect to 
analogue domains in JNK1 and JNK3, also accompanied by the highest buried surface upon 
complex formation. The good shape complementarity between the two binding partners 
sustained the hypothesis of a possible interaction linking JNK2/STX1a.  
 
JGRi1 peptides synthesis 
In order to selectively disrupt the possible JNK2/STX1a interaction, JGRi1, a novel cell 
permeable peptide, has been designed and synthetized on the basis of the above presented 
computational data.  
Therapeutic approaches involving the administration of proteins as druggable agents is 
actually gaining increasing momentum for the management of disorders ranging from single 
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enzyme deficiencies to cancer. In this frame, protein transduction via peptides able to 
ubiquitously cross both cellular membranes and BBB launched a novel field in molecular 
delivery based on non-invasive small vectors generally referred to as cell-penetrating peptides 
(CPPs) (Dinca et al., 2016; Guidotti et al., 2017).  
Over the past twenty years, CPPs showed to efficiently transport various biologically active 
cargoes with valuable results in both in vitro and in vivo experimental systems, being 
therefore established as feasible and promising devices for medical and biotechnological drug 
development (Bechara and Sagan, 2013; Dinca et al., 2016) (Fig. 23). 
 
 
 
 
Fig. 23 
Schematic representation of Cell-Penetrating Peptide (CPP)-based technologies.  
Due to their hydrophilic nature, cargoes (blue) including peptides, proteins, nucleic acids, or small drugs cannot 
generally be uptaken by the cell to reach eventual intracellular targets. Conjugation to a CPP (orange) by 
covalent bond or non-covalent complex formation enables the CPP–effector conjugate to cross the cell 
membrane and reach the intracellular milieu, providing an enhancement of the therapeutic effectiveness. 
(Adapted from Guidotti et al., 2017). 
 
 
The ﬁrst CPP discovered serendipitously in the late 1980s is the trans-activator of 
transcription protein (Tat), belonging to the human immunodeﬁciency virus (HIV) (Green et 
al., 1989). 
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Tat sequence generally consists of a basic domain coding region of 9-11 amino acids from 
residue 48 to 56 within the first exon (Choi et al., 2002). The variants mostly used are the 
cationic Tat48-60 (sequence: GRKKRRQRRRPPQ) and the Tat49-57 (sequence: 
RKKRRQRRR). 
Several others CPPs have been lately identified, like the Antennapedia homeodomain from 
Drosophila melanogaster, providing new appeal in the cellular uptake of exogenously 
delivered active conjugates, including proteins as large as 110 kDa that would have been 
otherwise hampered without cellular entry.  
To date, no CPP-tagged protein has yet succeeded in clinical trials. Nevertheless, several 
evidences are underlining the extensive use of CPPs in experimental diseases. In a recent 
work, for instance, delivery via the Tat-linked Aβ1-6A2V(D) was able to confer 
neuroprotection against both in vitro and in vivo TgCNRD8 Alzheimer disease synaptopathy 
models, suggesting that the abovementioned CPP-conjugated peptide can cross the BBB, 
penetrate the brain parenchyma, and finally reach its therapeutic target (Cimini et al., 2016). 
Data from another group also reported the impact of D-JNKI1, a CPP acting as JNK inhibitor 
in MCAo animal models. This Tat-linked peptide has emerged as a potent in vivo 
neuroprotectant, with a remarkably long therapeutic window and a strong effect on both 
functional outcome and ischemic lesion size (Borsello et al., 2003a). 
In a parallel vein, we have produced our 26 amino acids long JGRi1, composed by 12 amino 
residues (GRKKRRQRRRPP) belonging to the HIV-1 Tat48-59 protein in order to provide cell 
permeability (Chauhan et al., 2007). This arginine rich domain has been covalently linked to 
the effector sequence (IEQSIEQEEGLNRS) able to competitively induce JNK2/STX1a 
unbinding.  
The exact sequence was assessed by HPLC chromatographic analysis.  
For peptide synthesis, pre-loaded Wang resin, Fmoc-protected amino acids, 2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 1-
hydroxybenzotriazole (HOBt) and Diisopropylethylamine (DIEA) were purchased from Iris 
Biotech Gmbh (Germany). Solvents, piperidine and other reagents were purchased from 
Sigma-Aldrich (USA). All peptides were synthesized using a CEM Liberty peptide 
synthesizer and purified using RP-HPLC with a Jasco BS-997-01 instrument and a DENALI 
C-18 column from GRACE VYDAC (10 μm, 250 × 22 mm). ESI mass spectra were recorded 
on an LCQ Advantage spectrometer from Thermo Finnigan.  
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Overall, several structures of the peptide have been synthetized for the experimental purposes 
of the present work, including full-length effector and scrambled JGRi1 sequences, a Tat-
JGRi1-FITC peptide (able to penetrate through membranes) and a ΔTat-JGRi1-FITC form 
(unable to penetrate through membranes due to the lack of Tat). In particular, the FITC 
peptides have been covalently coupled to a fluorophore that enables the indirect detection 
through the fluorescein fluorescent label. Due to the fact that, in general, fluorimetry detection 
does not allow defining if the peptide is still linked to the fluorescent probe once inside cells, 
we designed the peptide in the sequence Tat-cargo-FITC, so that the fluorescence detection 
should represent only internalized integral entities. 
 
- Solid phase peptide synthesis: 
JGRi1 peptides were prepared by microwave-assisted solid phase synthesis (Pellegrino et al., 
2012), based on 9-Fluorenylmethyloxycarbonyl (Fmoc) chemistry on pre-loaded Wang resin 
(0.4 meq/g substitution), choosing a five-fold molar excess of 0.2 M Fmoc-protected amino 
acids dissolved in N-methyl pyrrolidinone, and using HOBt/HBTU/DIEA (5 : 5 : 10 eq) as 
activators. Coupling reactions were performed for 5 min at 40 W with a maximum 
temperature of 75 °C. Deprotection was performed in two stages using 20% piperidine in 
dimethylformamide (5 and 10 min each).  
Cleavage from the resin was performed using 10 ml of Reagent K (trifluoroacetic 
acid/phenol/water/thioanisole/ 1,2-ethanedithiol; 82.5 : 5 : 5 : 5 : 2.5) for 180 min. Following 
cleavage, labeled peptides were precipitated and washed using ice-cold anhydrous ethyl ether. 
The peptides were therefore purified by RP-HPLC (Reversed phase High-performance liquid 
chromatography) using a gradient elution of 5–70% solvent A-B (solvent A: 
water/acetonitrile/trifluoroacetic acid 95 : 5 : 0.1; solvent B: water/acetonitrile/trifluoroacetic 
acid 5 : 95 : 0.1) over 20 min at a flow rate of 20 ml/min. The purified peptide was freeze-
dried and stored at 0 °C. 
 
- N-terminal labeling with FITC: 
FITC (Fluorescein isothiocyanate) labeling at the N-terminal of JGRi1 was performed on 
resin, before the cleavage, using 10 eq of 5(6)-carboxyfluorescein and HOBt/DIC (10 eq) as 
activators. The coupling reaction was performed twice for 1 h each, in the dark under 
vigorous shaking. 20% piperidine in dimethylformamide was then added and the mixture was 
shaken for 1 h.  
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- C-terminal labeling with FITC: 
C-terminal labeling of JGRi1 was done by addition of an orthogonal protected lysine residue 
at the C-terminal of the peptide sequence. The peptide was synthesized as above described. 
Lysine side chain deprotection was performed on resin. FITC was linked to the side chain 
lysine amino group as described for the N-terminal. 
 
HEK-293 cell cultures and transfection 
Human embryonic kidney cells (HEK) -293 were seeded into 6-well plates with a density of 
4×10
5
 the day before treatments and maintained in complete medium with the following 
composition: DMEM (LONZA Group LTD, Switzerland) 4.5 g/l glucose, 10% fetal bovine 
serum (LONZA Group LTD, Switzerland), 1% L-glutamine (Gibco, Invitrogen, USA), 1% 
penicillin/streptomycin antibiotics (Gibco, Invitrogen, USA), 1% MEM non-essential amino 
acids solution 100× (Sigma-Aldrich, USA). Cells were incubated at 37 °C under 5% CO2. 
Transfections were performed in serum-free culture medium using 2 µl/sample 
Lipofectamine
® 
2000 (Invitrogen, USA) as transfection reagent. Cells were co-transfected 
with 1 µg/sample of full length non-tagged STX1a plasmid (pCMV5 backbone) and one of 
the following plasmid DNAs: HA-JNK1, HA-JNK2, or HA-JNK3. Incubation with 
exogenous DNAs was maintained over 3 h, then the medium was replaced with fresh 
complete DMEM, and cells incubated overnight to let DNAs to be expressed. The following 
day, treatment with JGRi1 (40 µM) was performed during 1 h 30 min. Cells were then 
scraped in Lysis Buffer solution, harvested in test tubes, sonicated and quantified via 
Bradford assay. 350 µg of protein extract from each sample was immunoprecipitated for anti-
HA (mouse 1:1000; Sigma-Aldrich, USA), following the protocol previously reported.  
 
SNARE complex assay 
The SNARE complex is a detergent resistant clustering that can be analysed by Western 
blotting on unboiled non-denatured samples (Burré et al., 2010). The modulation of the 
complex assembly upon NMDA (100 µM) + glycine (1 μM) or JGRi1 (1 µM) stimulation has 
been tested on cortical synaptosomes and evaluated via Western blotting, comparing unboiled 
with boiled (5 min, 95 °C) samples. The immunoreactive bands identified by anti STX1a 
primary antibody (1:1000; Synaptic System, Germany) at approximately 50–100 kDa were 
quantified as an indicator of the SNARE complex assembly upon treatment. The band at 33 
kDa indicates instead free unassembled STX1a. 
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Measurements of synaptic release 
Synaptogreen (Sigma-Aldrich, USA), also known as FM1-43, is a green fluorescent dye 
widely used to track synaptic release activity by synaptic vesicles staining. Due to the two 
peculiar cationic charges located in their headgroup, the styryl dye molecules are able to 
partition into the outer leaflet of surface membranes without permeating. Upon a proper 
stimulus, FM1-43 molecules are internalized so that newly formed synaptic vesicles become 
stained with the dye. By evoking exocytosis, FM1-43 molecules ultimately dissociate from 
the membranes and lose fluorescence following the concentration gradient, with the 
destaining being directly proportional to the exocytosis rate (Amaral et al., 2011).  
We used here a protocol already reported in Marcelli et al., 2016. 
Cortical synaptosomes (0.3 mg/ml) obtained from mice following 2 or 24 h JGRi1 (20 mg/kg) 
intraperitoneal (Ip) injection were incubated in 2 ml of Saline Buffer for 2 min at 37 °C in 
mild agitation. Synaptogreen (50 μM) was added 1 min after stimulation with NMDA (100 
μM) and glycine (1 μM) to load the fluorescent dye. After 3 min of stimulation, synaptosomes 
were washed twice to remove non-internalized Synaptogreen in a Saline Buffer containing 
BSA 1 mg/ml. Synaptosomes (200 μg of proteins) were then seeded on poly-L-lysine (50 
ug/ml) treated coverslips and let sediment over 40 min in the dark. Two washes were then 
performed to remove not seeded synaptosomes. The coverslips were placed on a time-lapse 
system mounted on an inverted fluorescence microscope (TiE; Nikon, Japan), equipped with 
an incubation chamber (Okolab), a cooled CCD camera (Clara; Andor), Perfect Focus System 
to avoid z-axis focus fluctuations and a Niss Elements imaging software (Nikon). Video 
recordings were performed with a 40× oil objective (N.A 1.4) for 6 min (upon 30 mM KCl 
stimulation) or 30 min (upon NMDA 100 μM + glycine 1 μM stimulation), by taking 14 bit 
images every 2 s at room temperature (25 °C). Fluorescence was recorded and video images 
were analysed by using the Spot module of the Imaris
®
 Suite 7.6 software (Bitplane A.G., 
Zurich, Switzerland) by selecting a 1.5 μm radius diameter of fluorescent puncta. 
Fluorescence intensity was measured in 15–20 randomly selected synaptosomes within the 
microscopic field. The criteria for fluorescence puncta inclusion in the data analysis were the 
spherical shape ranging between 0.5-1.5 μm and the stimulation-dependent destaining 
response. Destaining time-courses were generated by normalization of each fluorescence spot 
trace. Quantification of FM1-43 responses was accomplished by calculating the average 
percentage of fluorescence loss. A group of control experiments was run to test the specificity 
of Synaptogreen loading and destaining. Ca
2+
 free medium drastically reduced the dye loading 
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and inhibited the stimulus-induced dye release. The Synaptogreen photobleaching rate was 
also measured in absence of the stimulus and compared to the stimulated Synaptogreen 
destaining traces for each experimental group. 
 
Glutamate release experiments 
Release experiments were performed on synaptosomes in a superfusion system (Pittaluga et 
al., 2006) where each event affecting glutamate release is attributable only to the functional 
presynaptic compartment.  
Cortical synaptosomes were incubated for 45 min at 37 °C in a rotary water bath in the 
presence of the radioactive tracer [
3
H]D-aspartate ([
3
H]D-Asp, final concentration 50 nM). 
JGRi1 was added at different concentrations (2, 5, 10 µM) in the incubation medium for 30 
min. After the labeling period, synaptosomes were maintained and superfused with 
physiological solution at 37 °C, layered in the superfusion system (Ugo Basile, Comerio, 
Varese, Italy) for 48 min. After 36 min of re-equilibration period, four consecutive 3 min 
fractions (termed b1 to b4) were collected. N-methyl-D-aspartic acid (NMDA) (100 μM) plus 
glycine (1 μM), or (S)-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) (50 
μM) were applied at the end of the first fraction collected (b1) and maintained in the 
superfusion medium till the end of the superfusion period. In NMDA experiments the medium 
was replaced, at t= 20 min, with a Mg
2+
 ion-free solution to permit NMDAR activation.  
In KCl experiments synaptosomes were transiently (90 s) exposed, at t= 39 min, to high K
+
 
containing medium (8 mM). In these experiments, fractions were collected according to the 
following scheme: two 3 min fractions (basal release), one before (t= 36–39 min) and one 
after (t= 45–48 min) the 6 min fraction stimulation (t= 39–45 min; evoked release). Fractions 
collected and superfused synaptosomes were counted for radioactivity. The amount of 
radioactivity released by each superfusate fraction was expressed as a percentage on the total 
synaptosomal tritium content at the start of the fraction collected (fractional efflux). Agonists 
and K
+
-induced effects were estimated by subtracting the neurotransmitter content into the 
fractions corresponding to the basal release from those corresponding to the evoked release. 
 
Electrophysiology 
The effect of JGRi1 on NMDA receptor-dependent presynaptic glutamate release was 
evaluated by measuring miniature Excitatory Postsynaptic Currents (mEPSCs), according to a 
protocol previously described (Nisticò et al., 2015).  
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mEPSCs are small currents deriving from the vesicular release of neurotransmitter that 
represents the presynaptic terminal activity reaching the patched postsynaptic neuron. The 
higher the frequency of mEPSCs, the stronger the connectivity of the cell tested. Conversely, 
mEPSCs amplitude relies on the amount of neurotransmitter filling the vesicles.     
For the experiments, two months old C57BL/6 mice were anesthetized with halothane and 
killed by decapitation. The brain was rapidly removed from the skull and combined 
entorhinal-hippocampal slices were cut (250 µm) using a vibratome (Leica) in cold artificial 
cerebrospinal fluid (aCSF) consisting of (mM) NaCl, 124; KCl, 3.0; MgCl2, 1.0; CaCl2, 2.0; 
NaH2PO4, 1.25; NaHCO3, 26; glucose, 10, saturated with 95% O2 and 5% CO2 (pH 7.4) 
(Jones and Heinemann, 1988; Nisticò et al., 2015). 
After an incubation period of 1 h in saturated aCSF at 33.5 °C, slices were maintained at room 
temperature or transferred to a submerged recording chamber (2.5–3 ml min-1, 33.5 °C) on the 
stage of an upright microscope (Eclipse FN1, Nikon, Italy), equipped for infrared video 
microscopy (Hamamatsu, Japan). 
Layer II neurons of the entorhinal cortex were recorded in whole-cell patch-clamp 
configuration using 1.5 mm borosilicate glass electrodes (3–4 mOhm) pulled with a vertical 
puller (PP-83 Narishige, Japan) in voltage-clamp mode, filled with (mM) CsMeSO4, 130; 
HEPES, 5; EGTA, 0.5; MgCl2, 1; NaCl, 1; CaCl2, 0.34; QX-314, 5 and MK-801, 1; adjusted 
to pH 7.3 with CsOH. QX-314 is a Na
+
 channel blocker used to block action potentials in the 
patched neurons, whereas the antagonist MK-801 was used to prevent NMDAR activation. 
Neurons were held in hyperpolarized voltage-clamp conditions, at -70 mV. Current signals 
were filtered at 2 kHz and digitized at 10 kHz using a Multiclamp 700 B differential amplifier 
linked to a Digidata 1440A, operated by the pClamp10 software (Molecular Devices, USA).  
No series resistance compensation was implemented, in order to keep a low signal-to-noise 
ratio, however, series resistance and whole-cell capacitance were monitored continuously 
during the experiment and recordings were discarded if series resistance changed by more 
than 15% from control conditions. Spontaneous synaptic events were analysed offline using 
the pClamp10 software package (Molecular Devices, USA). The spontaneous events were 
detected from 3 min trace records, through an algorithm based on the minimization of the sum 
of squared errors between data and a template function. Single template waveforms were 
created by averaging a number of spontaneous events following a visual inspection of a 
representative trace in each cell. The template-matching threshold was set between 5 and 5.5, 
providing a good balance to avoid detection of false events. 
76 
 
Rat neuronal cultures and assessment of cell viability  
Cortical primary neurons were obtained from E17-18 rat embryos, dissociated in trypsin, and 
seeded into 24-well poly-L-lysine-coated plates with a density of 1.5×10
6
. Neurons were 
maintained in complete medium containing Neurobasal (Gibco, Invitrogen, USA), 2% B-27 
supplement (Gibco, Invitrogen, USA), 1% penicillin/streptomycin antibiotics (Gibco, 
Invitrogen, USA), incubated at 37 °C under 5% CO2 and maintained for ten days before 
further use.  
NMDA stimulus (100 µM) was applied over 3 h, preceded, where needed, by 1 h pretreatment 
with JGRi1 at increasing concentrations (0.1, 0.5 and 1 µM). Cellular viability was assessed 
following 24 h from drugs administration, by counting the number of intact nuclei upon 
neuronal lysis in a detergent-containing solution (Esposito et al., 2012). The culture medium 
was removed and replaced over 2 min with 0.5 ml of a lysing solution (0.5% 
ethylhexadecyldimethylammonium bromide, 0.28% acetic acid, 0.5% Triton X-100, 3 mM 
NaCl, 2 mM MgCl2 in PBS pH 7.4 diluted 1/10). The resulting uniform suspension of single, 
intact, viable cells was then collected and nuclei counted and quantified in a hemocytometer. 
Nuclei from viable cells appeared as phase-bright intact circles surrounded by a dark ring. 
Broken or damaged nuclei could not be included in the count since the detergent solution 
selectively dissolves nuclei of broken or dying cells (Pieri et al., 2010). 
 
Confocal images 
Among JGRi1 peptide variants, one was designed and synthetized to contain a FITC tag, i.e. a 
green fluorescent dye with excitation wavelength at 495 nm and emission wavelength at 519 
nm. Contextually, it was possible to evaluate whether and to what extent the FITC-peptides 
could reach brain regions driven by their HIV-Tat domain, without requirement of any 
antibody.  
Mice treated with Ip and ICV injection were sacrificed after 1, 3, 6, 24 h and cortex slices 
were analysed.  
ICV injections were performed at hippocampal level; the site of infusion was located 1 mm 
mediolateral, 0.2 mm anteroposterior and 2 mm dorsoventral with respect to the Bregma. 
Animals were deeply anesthetized with tribromoethanol (Avertin
®
) and perfused through the 
aorta with ice-cold 4% paraformaldehyde. Brains were post-fixed for at least 4 h at 4 °C and 
equilibrated with 30% sucrose overnight. 30 µm thick sections were permeabilized in PBS 
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with Triton-X 0.25% (t-PBS) and preincubated with 10% normal donkey serum solution for 1 
h at room temperature containing DAPI 0.01 mg/ml.  
Sections were mounted with Vectashield (Vector Labs, USA) on poly-L-lysine coated slides, 
air-dried and coverslipped.  
Slides were examined under a confocal laser scanning microscope (Leica SP5, Leica 
Microsystems, Wetzlar, Germany) equipped with 4 laser lines and a transmitted light detector 
for differential interference contrast (DIC; Nomarski) imaging. Confocal acquisition setting 
was kept identical among the slides and throughout the whole acquisition.  
 
Organotypic slice preparation and oxygen/glucose deprivation 
Brain slice models are an ex vivo system that extensively replicates several aspects of the in 
vivo biology, offering unique advantages over in vitro platforms. Slices indeed preserve brain 
tissue architecture and functional local synaptic circuitry, additionally providing surrogate 
screening systems for pharmacological agents, without recourse to whole animal studies (Cho 
et al., 2007). 
Oxygen/glucose deprivation (OGD) is a simple yet highly useful technique chiefly validated 
as an in vitro model for ischemia. By mimicking the key pathophysiological events occurring 
in in vivo stroke (Cimarosti and Henley, 2008; Dennis et al., 2011), OGD provides a chance to 
dissect those cellular and molecular pathways, besides offering a useful setting for 
development and testing of novel neuroprotective strategies, as is the case.  
OGD can be experimentally obtained by exposing brain slices to simultaneous anoxic and 
aglycemic conditions (Cimarosti et al., 2001; Frantseva et al., 1999) in order to recapitulate 
the interruption of oxygen and nutrients supply to cerebral parenchyma, as well as the stroke-
like energy failure. Importantly, the insult achieved via OGD proved to be consistent and 
largely reproducible to be so far the most widely used method to simulate the in vivo injury. 
For our experimental purposes, acute cortical slices were obtained from 3 months old 
C57BL/6 mice, killed by decapitation under anaesthesia with halothane. The brains were 
rapidly removed and placed in an ice-cold, oxygenated (95% O2 and 5% CO2) artificial 
cerebral spinal fluid (aCSF) composed by (mM): NaCl, 126; KCl, 2.5; MgCl2, 1.2; CaCl2, 2.4; 
NaH2PO4, 1.2; NaHCO3, 24; glucose, 10 (pH 7.4). Coronal slices (300 µm thickness) were cut 
in the same conditions using a vibratome (Leica). Cortices were microdissected (~2 mm from 
bregma) and then kept in oxygenated aCSF for 1 h at room temperature to restore synaptic 
circuitry. 
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In vitro oxygen/glucose deprivation (OGD) was obtained by switching the slices into a 
hypoglycemic solution obtained by omitting glucose from standard aCSF, bubbled with 
nitrogen (95% N2 and 5% CO2) for 15 min at room temperature (Nisticò et al., 2008). For 
slice treatment, JGRi1 (10 µM) was added in the incubation plate 1 h before the OGD and 
maintained until the end of the experiment. At the end of the ischemic induction, the slices 
were not reperfused but immediately collected in Lysis buffer solution, and homogenized at 4 
°C using a glass/Teflon grinder. The protein fraction was obtained upon centrifugation and 
quantified by Bradford assay. Samples were directly analysed by Western blot, or used for 
immunoprecipitation, as explained above. 
 
Transient MCAo induction and ischemic damage evaluation 
Since its inception in the late 1980s, MCA occlusion (MCAo) by means of the intraluminal 
filament has become an established, quite simple and relatively non-invasive technique to 
produce either permanent or transient ischemic animal models.  
Proximal focal vessel closure is generally obtained by inserting a 4-0 nylon surgical suture 
with an acryl-thickened tip into the internal carotid artery of murine models, and advancing 
orthogradely toward the cranium to occlude both the MCA and the collateral circulation from 
the anterior communicating arteries. In this way, cerebral blood flow may be reduced up to 
80% in the cortex, as confirmed by Laser-Doppler flowmetry (Ansari et al., 2011; Engel et al., 
2011). In this way it is possible to closely simulate the real in vivo infarction occurrence, also 
thanks to the fact that most thromboembolic events in humans occur in the territory of the 
MCA.  
Reperfusion may easily follow by thread withdrawal after a specified period of time 
(generally 30 to 90 min for transient models), permitting animal survival and enabling further 
functional outcome measurements (Traystman, 2003) (Fig. 24). 
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Fig. 24 
Middle cerebral artery occlusion in animal models. 
A) Vascular brain anatomy of the rat. 
B) Induction of middle cerebral artery occlusion (MCAo) by insertion of a filament into the common carotid 
artery, as reported in Koizumi’s method. (ACA = anterior carotid artery; AchA = anterior choroidal artery; CCA 
= common carotid artery; ECA = external carotid artery; ICA = internal carotid artery; HTA = hypothalamic 
artery; PPA = pterygopalatine artery; PCOM = posterior communicating artery). 
C) Schematic illustration of typical cerebral lesion and relative size insult following different time points of 
reperfusion in the proximal MCAo mouse model. The graph in the middle illustrates a representing time-course 
of functional activity and cerebral blood flow after MCAo (LDF = Laser-Doppler flowmetry). 
(Adapted from Canazza et al., 2014; Engel et al., 2011). 
 
 
Avoiding craniectomy is a great advantage of this technique that eliminates possible 
influences of surgical manipulation on blood brain barrier permeability and intracranial 
pressure. On the other hand, many other factors can lead to inconsistency in this model, 
including strain-related differences, housing conditions, size of suture tip, duration of 
occlusion, body temperature, anaesthesia (Ansari et al., 2011). 
For the sake of our experimental protocol, C57BL/6 mice were anesthetized with 5% 
isoflurane and maintained on 1.5% isoflurane in 70% nitrous oxide and 30% oxygen. 
Regional cerebral blood flow was measured by Laser-Doppler flowmetry (PF2B; Perimed, 
Stockholm, Sweden), using a flexible skull probe. In randomly selected animals, the left 
femoral artery was cannulated with a PE-10 polyethylene tube for blood gas determination 
and arterial blood pressure measurement. Rectal temperature was maintained between 36.5 
and 37.5 °C with a homeothermic blanket (Frederick Haer and Co., Brunswick, Maine, USA). 
Mice were randomized and Middle Cerebral Artery (MCA) was occluded proximally for 1 h 
using the classical intraluminal filament technique (Muzzi et al., 2012).  
JGRi1 was injected intracerebroventricularly (ICV) at the dose of 16ng/5µl 30 min before 
artery occlusion, to determine eventual prophylactic therapeutic efficacy. Animals were 
sacrificed after 24 h of MCA reperfusion and the brains snap frozen in N2 vapour for cryostat 
sectioning. Infarction areas were quantified by a blind evaluator by means of MCID M4 
image analysis software (Imaging Research Inc., St. Catharine’s, Ontario, Canada) on 
toluidine blue stained sections. In order to account for and eliminate swelling/edema 
alterations, infarction volume was calculated using an indirect measurement, summing the 
area of each section using the following formula: Corrected Infarct Volume (CIV) = 
contralateral hemisphere volume (mm
3
) – undamaged ipsilateral hemisphere volume (mm3). 
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Human experiments: patients and controls 
Eight patients (5 females and 3 males, mean age 69.66 years; SD= 12.71 years) from the 
Department of NeuroRehabilitation at “Casa di Cura Privata del Policlinico” (Milan, Italy) 
were included in this study in order to take part to the Biobank project, after subscribing a 
written consent approved by the Ethic Committee.  
All patients are Caucasian with a clinical diagnosis of Acute Ischemic Stroke (AIS), 
previously tested for neurological scales, including the National Institute of Health and Stroke 
scale (NIHSS), Mini-Mental State Examination (MMSE), Cumulative Illness Rating Scale 
(CIRS) and Barthel Index (BI). The only inclusion criterion was a CIRS severity index < 2. 
In addition, seventeen Caucasian healthy controls (HC) (10 females and 7 males, mean age 
69.66 years; SD= 7.67 years) age- and gender-matched with patients, were enrolled in this 
study. Notably, also their cognitive status was assessed by MMSE. 
 
SNP typing on human blood samples 
Human blood samples of a group of stroke patients were analysed in a pilot study in order to 
assess the eventual implications of STX1A SNPs on ischemia susceptibility.  
Due to the reliable correlation with the functions of central nervous system, lymphocytes are 
considered as convenient neural probes and easily accessible alternative to brain samples for 
biochemical and genetic investigations (Gladkevich et al., 2004). Genomic DNA was 
therefore isolated from peripheral blood lymphocytes of patients and healthy controls using 
Chemagic blood 10k (Perkin-Elmer, GmbH) following the manufacturer instructions.  
SNPs rs4717806 and rs6951030 respectively located in intron 9 and intron 2 of STX1A, and 
SNP rs2293489 located in WBSCR22 gene, ~6 kbp upstream to 5' UTR STX1A gene (Fig. 
40A) were typed using the Taqman SNP Genotyping Assays (Applied Biosystems Inc., CA, 
USA) on Bio-Rad CFX96
™
 Real-Time PCR system. 
For rs2293489, rs4717806 and rs6951030 respectively the C__15971044_10, 
C__27872627_10 and C__29194787_10 Human Pre-Designed Assays (Applied Biosystems) 
were used. 
 
Statistical Analysis  
- Biochemical and animal experiments:  
ANOVA was used to carry out variance analysis together with Newman-Keuls multiple-
comparison test in the experiments for neurotransmitter release. A Student’s two-tailed t-test 
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was chosen when it was about to compare a single treatment group. A value of *p < 0.05 was 
the minimum accounted to validate our data. Appropriate controls were always run in parallel 
with enzyme inhibitors. GraphPad PRISM 4 (GraphPad software, USA) was used to analyse 
all biochemical experiments. Values shown represent the mean ± SEM of a different number 
of separated experiments (as indicated in figure legends). In case of intergroup comparisons, 
one-way or two-ways ANOVA were used, followed by Newman-Keuls test.  
- Human experiments:  
Chi-squared (χ2) analysis was used to exclude any deviation of SNPs genotype distribution 
from Hardy-Weinberg equilibrium (HWE); p value was > 0.05 both in cases and in controls. 
χ2 statistics or Pearson's exact test, appropriately needed, were applied to 2XN table to 
compare case-control differences of SNPs distributions. p value was considered significant 
after Bonferroni correction for multiple SNPs testing (pc). The Kolmogorov-Smirnov (K-S) 
test was applied to verify normal distribution of numerical variable scores.  
MMSE, a cognitive score which resulted normally distributed, was shown as mean and 
standard deviation (SD) and analysis of variance ANOVA was calculated in relationship with 
SNPs distribution.  
Statistical analysis was performed using commercial software (IBM SPSS Statistics 23.0, 
IBM Inc., Chicago, IL, USA). Haplotype analyses were performed using the SHEsis software 
freely available at http://analysis.bio-x.cn (Li et al., 2009; Yong and He, 2005). Haplotype 
association analysis was performed using PLINK software (Purcell et al., 2007) by logistic 
regression analysis. Age, sex and pathology were incorporated as covariates in the regression 
model which estimated the Beta value associated with MMSE. 
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RESULTS 
 
Modulation of presynaptic JNK isoforms and STX1a activity by NMDA or KCl stimuli   
It is widely recognized that the apoptotic cascade following excitotoxicity is transmitted 
through postsynaptic NMDA receptors, via the intracellular activation of JNK protein-
mediated signaling in both brain (Centeno et al., 2007) and spinal cord (Guo et al., 2009). 
This postsynaptic interaction between NMDA receptors and JNK proteins is ensured by the 
JNK scaffolding protein JIP (Kennedy et al., 2007).  
We recently showed that, also in the presynaptic side, the excitotoxic input induced by 
NMDA stimulation provokes the phosphorylation of JNK proteins and that, interestingly, 
JNK2 is the isoform preferentially implicated in this mechanism (Nisticò et al., 2015).  
As already reported (Dong et al., 1998; Nisticò et al., 2015), JNK proteins are present as 
double isoforms with different molecular weights, i.e. JNK1 46 kDa and JNK2 54 kDa, 
respectively.  
It is therefore possible to estimate their specific isoform phosphorylation by measuring the 
relative band densitometry at the corresponding molecular weight.  
In cortical synaptosomes under NMDA (100 µM) + glycine (1 µM) or KCl (8 mM) stimulus, 
JNK1 phosphorylation (Thr183/Tyr185 p-JNK) was not changed while JNK2 
phosphorylation, as expected, was augmented only by the NMDA stimulus (1.58 ± 0.12 vs. 
control, ***p < 0.001) and not by KCl (Fig. 25A). 
As previously said, the phosphorylation of STX1a (Ser14 p-STX1a) is a fundamental step 
toward the SNARE complex assembly leading to neurotransmitter release (Ramakrishnan et 
al., 2012; Südhof, 2004).  
Accordingly, both NMDA (1.38 ± 0.07 vs. control =1, **p < 0.01) and KCl (1.22 ± 0.11 vs. 
control =1, *p < 0.05) stimuli increased the levels of phosphorylated STX1a (p-STX1a) in 
mouse cortical synaptosomes (Fig. 25B). 
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Fig. 25 
Presynaptic JNKs and STX1a activity by NMDA or KCl stimuli. 
A) Cortical synaptosomes prepared from 3 months old wild-type mice have been stimulated either with NMDA 
(100 µM) + glycine (1 µM) for 10 min or with KCl (8 mM) for 90 seconds, and subsequently lysed. 
Quantification of the phosphorylation state for both JNK1 and JNK2 isoforms has been separately evaluated. 
The top histogram shows that JNK1 phosphorylation was not affected by both stimuli. The lower histogram 
shows instead an increased and significant phosphorylation of JNK2 corresponding to NMDA stimulus (n= 6, 
***p < 0.001 vs. control, Newman-Keuls multiple-comparison test).  
B) The same cortical synaptosome preparation has been used for the quantification of STX1a phosphorylation. 
Ser14 phosphorylation of STX1a was increased from both NMDA (n= 6, **p < 0.01 vs. control, Newman-Keuls 
multiple-comparison test) and KCl stimuli (*p < 0.05 vs. control, Newman-Keuls multiple-comparison test). 
 
 
 
JNK interacts with STX1a  
To test whether the presynaptic STX1a physically interacts with JNK, mouse cortical 
synaptosomes previously stimulated with NMDA (100 µM) to induce JNK phosphorylation, 
were immunoprecipitated (IP) by using a specific p-JNK antibody (Thr183/Tyr185 p-JNK). 
The IP experiment demonstrated that JNK and STX1a actually interact, since p-JNK pulled 
down STX1a already in basal conditions. Noteworthy, the NMDA stimulus increased the 
level of p-JNK level without significant modifications of total JNK level. This finding was 
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moreover accompanied by an augmented level of p-STX1a, thereby suggesting that upon 
excitotoxic stimuli the release of glutamate is likely controlled by the interaction between the 
phosphorylated forms of JNK and STX1a (Fig. 26 left panel). 
IP performed with a specific JNK2 antibody confirmed the increased p-JNK levels under the 
NMDA stimulus (Fig. 26 right panel).  
 
 
 
 
Fig. 26 
IP after stimulus.  
Cortical synaptosomes underwent NMDA (100 µM) + glycine (1 µM) stimulus for 10 min and, together with 
respective controls, were IP either for p-JNK (left panel) or JNK2 (right panel). p-JNK resulted to be augmented 
by NMDA stimulus and beside the interaction with STX1a. On the other hand, the phosphorylation of STX1a 
was also increased by NMDA with respect to control. 
‘Input’ lane corresponds to the total lysate from untreated synaptosomes. ‘Beads’ lane shows the quality of the 
IP procedure, since no unspecific immunoreactivity was detected.  
 
 
 
Docking results for JNK isoforms and JNKs alignment  
A JNK2-STX1a complex model has been built in silico using the protein-protein docking 
software Rosetta 3.4 (Sircar et al., 2010) (Fig. 27A-1) (see computational details). STX1a 
binds to JNK2 through the groove formed by two of the three alpha helices that form its 
structure, namely helix B and helix C, which have been therefore proposed as the most 
plausible binding site for Syntaxin-1a partners (Fernandez et al., 1998). The contact surface 
between the two proteins comprehends an area of 2680 Å highlighted in red (Fig. 27A-2).  
The sequence alignment of the three known JNK isoforms shows that although the JNK 
isoforms (-1, -2, -3) present a high sequence homology among them, the amino acid sequence 
at the interface between JNK2 and STX1a (in red) clearly differs from both JNK1 and JNK3, 
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making it a potential specific site for STX1a interaction (Fig. 27B). This finding may 
therefore explain the high specificity of STX1a binding with JNK2 when compared to other 
JNK isoforms. 
In order to selectively disrupt JNK2/STX1a interaction, JGRi1, a novel cell permeable peptide 
long 26 amino acids has been designed, based on these computational data. The 12 amino 
residues (GRKKRRQRRRPP) of the HIV-1 Tat48-59 protein that confer cell permeability 
(Chauhan et al., 2007) have been linked to the effector portion (IEQSIEQEEGLNRS).  
Several peptide variants have been designed and produced in order to be used in the 
experiments (Fig. 27C).       
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Fig. 27 
Bioinformatics and docking experiments. 
A) 3D structures of the molecular docking resolving the possible interaction between JNK2 (grey) and the N-
terminal portion of STX1a (red) (1). The image originates from a computational analysis that allowed the 
determination of the minimum region of contact between the two proteins. The portion of STX1a that has been 
used to design JGRi1 has been coloured in red (2).  
B) Amino acid sequences corresponding to the region of contact between JNK and STX1a have been aligned for 
all 3 JNK isoforms. In the emphasized contact region, JNK2 has several distinguishing amino acids while JNK1 
and JNK3 are mostly equal among them. 
C) Figurative cartoon that summarizes the peptides variants that have been synthesized and used for the 
experiments.  
 
 
 
JGRi1 is able to specifically disrupt JNK2/STX1a interaction  
To verify the actual occurrence of the interaction between JNK2 and STX1a, we exploited 
HEK-293 cell cultures, an in vitro system useful for our purposes since it lacks of endogenous 
expression of STX1a (Toonen et al., 2005). HEK-293 cells have been transfected with HA-
tagged JNK1, JNK2 or JNK3 plasmids together with full length STX1a (non-tagged) plasmid. 
In the total lysate from cells harvested, endogenous JNK2 and exogenous STX1a levels were 
present in all the lanes while HA-JNK2 was present only in the JNK2 lane (Fig. 28 left blots). 
HEK-293 cells overexpressing HA-tagged JNK1, JNK2 or JNK3 proteins and STX1a further 
underwent treatment with JGRi1 40 µM and were subsequently immunoprecipitated (IP) with 
HA antibody. Beside the presence of all HA-JNKs protein, as expected, the treatment with 
JGRi1 prevented the interaction of STX1a with HA-JNK2 but not with HA-JNK1 and HA-
JNK3 (Fig. 28 right blots), confirming that this protein interplay does exist and that our 
peptide effectively disrupts it.    
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Fig. 28 
JGRi1 specifically interferes with JNK2/STX1a interaction. 
HEK-293 cells co-transfected with STX1a plus HA-JNK1, -JNK2, or -JNK3 were IP for HA and probed for HA 
and STX1a. Upon treatment with JGRi1, STX1a was pulled down in correspondence of JNK1 and JNK3 but not 
JNK2, as expected, confirming the specificity of action of our peptide. 
 
 
 
JGRi1 disrupts JNK/STX1a interaction in mouse cortical synaptosomes 
The JNK2/STX1a interaction has been evaluated also in cortical synaptosomes that were 
previously stimulated with NMDA (100 µM) + glycine (1 µM) and then immunoprecipitated 
for p-JNK. The treatment increased the phosphorylation of JNK, accompanied by an 
augmented interaction between p-JNK and STX1a, p-STX1a and Munc18. Interestingly, 
pretreatment with JGRi1 reduced p-JNK levels probably because a 30 min administration of 
the peptide given before NMDA stimulus was sufficient to induce the blockade of the NMDA 
receptor activity. Moreover, as expected, pretreatment with JGRi1 also reduced the interaction 
of p-JNK with SNARE complex proteins, like Munc18 (Südhof, 2004; Wan et al., 2010) and 
STX1a (Südhof, 2004). On the other hand, SNAP25 was not pulled down by p-JNK (data not 
shown), coherently with the observation that the assembly of SNAP25 intervenes in a second 
step with respect to Munc18-STX1a interaction (Cheng et al., 2013; Südhof, 2004).  
Presynaptic JNK2 presence in the p-JNK IP was confirmed by the JNK2 specific antibody 
(Fig. 29). 
 
 
 
Fig. 29 
p-JNK IP experiment.  
p-JNK was augmented by 10 min NMDA (100 µM) + glycine (1 µM) NMDA stimulus while it was reduced by 
30 min pretreatment with JGRi1 (1 µM). p-STX1a as well resulted increased under NMDA. In all conditions 
JNK2 was present. JGRi1 reduced both STX1a and p-STX1a level, as well as Munc18.   
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JGRi1 does not impair JNK phosphorylation but affects STX1a activation 
The differential activation of the various JNK isoforms has been evaluated in cortical 
synaptosomes that underwent NMDA stimulation. An increased level of JNK2 
phosphorylation was detected after NMDA treatment alone (1.58 ± 0.12 vs. control =1, ***p 
< 0.001). Interestingly, JGRi1 administered before the NMDA insult prevented the abrupt 
increase in JNK2 phosphorylation (1.40 ± 0.20 vs. control = 1, *p < 0.05), with a decrease of 
about 20% with respect to NMDA alone. Pretreatment with JGRi1 alone or the scrambled 
version sJGRi1 did not determine any change in p-JNK2 levels. On the other hand, JNK1 
phosphorylation level was not affected in any case (Fig. 30A).  
Conversely, NMDA increased STX1a phosphorylation (1.38 ± 0.07 vs. control = 1, *p < 0.05) 
while, as expected, JGRi1 prevented it. Scrambled JGRi1 and JGRi1 applied alone did not 
evoke STX1a phosphorylation (Fig. 30B). 
 
 
 
 
Fig. 30 
JGRi1 modulates JNK phosphorylation and STX1a activation. 
A) p-JNK1 was not affected by treatments while p-JNK2 was increased after 10 min NMDA (100 µM) + glycine 
(1 µM) alone or pretreated with JGRi1 (1 µM). JGRi1 (1 µM) or sJGRi1 (1 µM) alone did not affect the 
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phosphorylation state of JNK2 (n = 5, ***p < 0.001 NMDA stimulus vs. control, ***p < 0.001 JGRi1 alone vs. 
NMDA, *p < 0.05 NMDA + JGRi1 vs. JGRi1 alone, *p < 0.05 NMDA + JGRi1 vs. control, Newman-Keuls 
multiple-comparison test).  
B) NMDA stimulus increased STX1a phosphorylation that was in turn prevented by pretreatment with JGRi1 
(n= 5, *p < 0.05 NMDA stimulus vs. control, **p < 0.01 JGRi1 alone vs. NMDA, *p < 0.05 sJGRi1 alone vs. 
NMDA, Newman-Keuls multiple-comparison test). 
 
 
 
JGRi1 prevents the formation of the SNARE complex 
The biochemical evidence of the inhibitory effect of JGRi1 upon the release of glutamate was 
evaluated by performing a SNARE complex formation assay, being SNARE complex 
assembly a crucial step for the release of neurotransmitters (Jahn and Fasshauer, 2012). 
Indeed, by probing unboiled samples from cortical synaptosomes for STX1a it is possible to 
evaluate the formation of the SNARE complex, measuring the non-resolved higher molecular 
weight complexes that are evident in the smear from Western blot (Biggi et al., 2017; Burré et 
al., 2010).  
As expected, NMDA stimulus was able to increase the formation of the SNARE complex 
while JGRi1 prevented it. The higher levels of free STX1a in the boiled samples compared to 
the unboiled ones indicate the quality of the procedure, being STX1a no more engaged in the 
SNARE complex in boiled samples (Fig. 31).    
 
 
 
 
 
Fig. 31 
SNARE complex assay. 
JGRi1 (1 µM) was applied, as indicated, to cortical synaptosomes 30 min before 10 min NMDA (100 µM) + 
glycine (1 µM) stimulus. SNARE complex formation was evaluated by probing STX1a in unboiled samples 
comparing STX1a lanes smearing (from 50 to 100 kDa) with free STX1a. NMDA increased SNARE complex 
formation while JGRi1 prevented it. 
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JGRi1 reduces presynaptic NMDA-evoked neurotransmitter release  
Vesicular release has been tested by means of Synaptogreen destaining assay in cortical 
synaptosomal preparations, as previously described (Nisticò et al., 2015).  
Interestingly, NMDA-evoked vesicle release in basal experimental conditions (68% ± 10) was 
reduced by pretreatment with JGRi1 in a dose dependent manner (JGRi1 5 µM: 27% ± 8 vs. 0 
µM, **p < 0.01; JGRi1 10 µM: 18% ± 4 vs. 0 µM, **p < 0.01). On the other hand, KCl-
evoked release was not affected by JGRi1, overall indicating that JGRi1-mediated release 
inhibition is specific for NMDA receptors (Fig. 32A). 
The specific release evoked by tritiated aspartic acid ([
3
H]D-Asp) was also studied (Fig. 32B). 
In this experimental conditions JGRi1 reduced again the NMDA-evoked release in a dose 
dependent manner (2 µM: 41% ± 5 vs. 0 µM, **p < 0.01; 5 µM: 34% ± 4 vs. 0 µM, **p < 
0.01; 10 µM: 18% ± 4 vs. 0 µM, **p < 0.01), while KCl and AMPA-evoked release were not 
affected. 
 
 
 
 
 
Fig. 32 
Glutamate release experiments.  
A) Exocytosis evoked by KCl (8 mM) or NMDA (100 µM) + glycine (1 µM) stimulus has been evaluated in 
cortical synaptosomes as a measure of FM1-43 destaining in a time-lapse image setting. Pretreatment with 
JGRi1 at different concentrations given 30 min before the registration specifically reduced NMDA-evoked 
exocytosis. Average percentage of fluorescence loss has been reported in the histograms (n= 5, **p < 0.01 vs. 
control, Newman-Keuls test). In each experiment three coverslips for each experimental group were analysed.  
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B) Wild-type mice cortical synaptosomes preloaded with radioactive tracer were incubated with several stimuli 
in absence or presence of JGRi1, as indicated. The experiment demonstrated that, among the applied stimuli, 
JGRi1 was able to specifically inhibit the sole NMDA-evoked glutamate release in a dose dependent manner.  
Means ± SEM n= 3 experiments run in triplicate (three superfusion chambers for each experimental condition), 
(**p < 0.01 vs. basal release, Newman-Keuls test).  
 
 
 
JGRi1 blocks spontaneous presynaptic NMDA currents in patch-clamp experiments  
The effect of JGRi1 on NMDA receptor-dependent presynaptic glutamate release was 
evaluated by measuring mEPSCs, as already reported (Nisticò et al., 2015). 
In basal conditions, the tiny and rapid mEPSCs on the field are inward currents corresponding 
to depolarizing events linked to glutamatergic signaling through AMPA/Kainate receptor. 
Possibly, each spike observed corresponds to a single presynaptic vesicle released.  
Postsynaptic NMDARs in the recorded neurons were blocked by MK-801 (10 μM) in the 
patch-pipette, in the presence of extracellular tetrodotoxin (1 μM) and picrotoxin (100 μM). 
Application of the selective NMDA receptor antagonist D-AP5 in the same experimental 
conditions induced an increase of the inter-event interval (iei) (**p < 0.01, t-test, vehicle vs. 
D-AP5, n= 8; Fig. 33), whilst the amplitude of the same events was unaffected (*p > 0.05, 
Student t-test, vehicle vs. D-AP5, n= 8; Fig. 33).  
Inter-event interval can be considered an indirect measure of mEPSCs frequency. 
Consequently, the increase of iei indicates a decrease in NMDARs firing, confirming that 
NMDARs clearly contribute to the depolarization of the presynaptic terminal. 
Perfusion with D-AP5 did not lead to significant changes of iei in slices preincubated with 
JGRi1 for 30 min at 5 μM and 10 μM (*p > 0.05, t-test, JGRi1 5 μM vs. D-AP5, n = 7; *p > 
0.05, t-test, JGRi1 10 μM vs. D-AP5, n = 9; Fig. 33), indicating that presynaptic NMDAR 
inhibition has been effectively accomplished by JGRi1, since the pharmacological inhibition 
by D-AP5 did not further reduce the iei.  
On the other hand, no changes were observed in the amplitude of mEPSCs under the same 
conditions, suggesting that JGRi1 does not influence the biochemistry of glutamate release 
(i.e. neurotransmitter metabolism, vesicular filling).  
Overall these electrophysiological results indicate that JGRi1 specifically reduces glutamate 
release mediated by presynaptic NMDA receptors. 
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Fig. 33 
JGRi1 prevents spontaneous NMDA currents in the presynaptic site. 
Histograms show the median values expressed as percentage versus control (100%) of mEPSC amplitude (left) 
and iei (right) recorded in vehicle, JGRi1 (1-10 μM) or scrambled condition, in response to D-AP5. (**p < 0.01 
vs. ctrl, #p<0.05 vs. JGRi1 (1 μM) (t-test).  
 
 
 
NMDA-mediated neuronal death is prevented by JGRi1 
Rat cortical primary neurons pretreated with JGRi1 for 1 h were subjected to further NMDA 
excitotoxic stimulation (100 µM) for 3 h, in order to activate the cell death machinery. 
Neuronal viability was assessed 24 h after the drug treatment, by counting the number of 
nuclei non permeable to DAPI coloration (Fig. 34). Pretreatment of neuronal cells with JGRi1 
showed a neuroprotective effect, strongly reducing NMDA-driven cell death in a 
concentration-dependent manner. JGRi1 was efficacious at 1 µM (43.5 ± 1.62 vs. 0 µM, ***p 
< 0.001) or 0.5 µM (38 ± 0.98 vs. 0 µM, **p < 0.01) but not at 0.1 µM (28.4 ± 1.68 vs. 0 
µM).  
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Fig. 34 
Neuronal cell cultures were pretreated 1 h with JGRi1 at different concentrations before 3 h NMDA stimulation 
(100 µM). Following 24 h from the applied stimulus, neuronal cells nuclei have been counted to evaluate the 
degree of cell death. JGRi1 was able to protect from cell death in a dose dependent manner.  
Histograms show the number of cells alive in each well. A number of 3 triplicates per well has been counted for 
each experiments. (n= 6, ***p < 0.001 and **p < 0.01 vs. control, Newman-Keuls multiple-comparison test). 
 
 
 
JGRi1 brain distribution following in vivo administration 
Peptides containing HIV-Tat sequences (generally 47-57) are able to cross the BBB within 1 
h after injection (Bechara and Sagan, 2013; Stalmans et al., 2015).  
In addition, fluorescence-based protocols are the most common methods used to allow 
indirect quantification and localization of these probes inside living cells by observation of 
fluorimetry at confocal microscopy.  
On purpose, the fluorescent tag on the FITC-linked peptide variants was exploited to 
determine the cerebral distribution of JGRi1 upon administration through differential routes.  
As expected, FITC-JGRi1 was detectable in the cortex (Fig. 35A) from 1 h till 24 h post intra-
peritoneal (Ip) injection as well as in hippocampus (Fig. 35B). Since the fluorescein (FITC) 
tag is linked at the C-term of the Tat-peptide (Fig. 27C) we could rely on the belief that the 
whole peptide should be intact when it reaches the brain, in order to fluoresce. Coherently, the 
variant version lacking the Tat portion (FITC-JGRi1-ΔTat, Fig. 27C) did not show any green 
fluorescence under the same conditions of administration, indicating that it is definitely not 
able to cross the BBB and distribute within cortical tissues (Fig. 35C).  
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Fig. 35 
JGRi1 distribution in cerebral tissue. 
A) FITC-JGRi1 (20 mg/kg) was administered intraperitoneally and its brain distribution was detected by 
confocal microscopy. Cortical tissue has been examined at several time points and the FITC fluorescence was 
detected until 24 h after injection. Scale bar = 15 μm. 
B) FITC-JGRi1 (20 mg/kg) was intraperitoneally administered and its brain distribution was detected by 
confocal microscopy. Hippocampal tissue has been examined 3 h after injection and the FITC fluorescence was 
detected. Scale bar = 15 μm. 
C) FITC-JGRi1-ΔTat (20 mg/kg) was intraperitoneally administered and its brain distribution was detected by 
confocal microscopy. Cortical tissue has been examined 3 h after injection but no FITC fluorescence was 
detected in this case. Scale bar = 15 μm.   
 
 
 
JGRi1 distribution and activity following in vivo intraperitoneal injection  
Wild-type mice were injected in the peritoneum with a single dose of JGRi1 or vehicle and 
sacrificed to prepare cortical synaptosomes following 2 or 24 h post Ip injection. NMDA-
evoked vesicle release was measured through FM1-43 destaining. JGRi1 treated mice showed 
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lower neurotransmitter release with respect to vehicle alone (2h: -23% ± 7% JGRi1 vs. 
vehicle; 24h: -26% ± 4 JGRi1 vs. vehicle) (**p < 0.01) (Fig. 36A), demonstrating that a 
single injection of the peptide, up to 24 h, is already efficacious in inhibiting NMDA receptor 
activity.  
The p-JNK/STX1a interaction-disrupting efficacy of the peptide was tested also in 
synaptosomes prepared from mice injected intraperitoneally with a single dose of JGRi1 and 
sacrificed after 24 h. Synaptosomes were stimulated with NMDA (100 µM) + glycine (1 µM) 
and then immunoprecipitated for p-JNK.  
NMDA treatment induced a relevant increase in the level of p-JNK in synaptosomes from 
vehicle animal, moreover underlining a stronger interaction with STX1a with respect to 
control. p-STX1a levels were also increased by NMDA treatment, as expected.  
Notably, JGRi1 efficiently disrupted JNK/STX1a interaction as indicated by the drastically 
decreased level of STX1a, as well as of its phosphorylated form (Fig. 36B). 
In an additional experiment, a single dose of JGRi1 per day administered intraperitoneally for 
7 days demonstrated again that when mouse cortical synaptosomes are stimulated with 
NMDA, the p-JNK levels upon immunoprecipitation were increased in non-treated and 
treated animals, but the interaction with STX1a was completely abolished only in preparations 
from JGRi1 injected animals. This result once more demonstrated the efficacy of the peptide 
in disrupting JNK/STX1a interaction (Fig. 36C).   
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Fig. 36 
JGRi1 inhibits glutamate release and prevents JNK2/STX1a interaction following in vivo administration. 
A) JGRi1 (20 mg/kg) was intraperitoneally (Ip) administered to wild-type mice. After 2 h or 24 h from injection, 
cortices were used to prepare synaptosomes and to test the exocytosis evoked by NMDA (100 µM) + glycine (1 
µM) stimulus, measured as FM1-43 destaining in a time-lapse image setting. Injected JGRi1 was able to reduce 
NMDA-evoked exocytosis in both time points, with comparable efficiency (n = 3, **p < 0.01 vs. control, t-test).  
B) Mice were treated Ip with 1 injection of either vehicle or JGRi1 (20 mg/kg) and sacrificed after 24 h. The 
cortices were used to prepare synaptosomes, subsequently stimulated with NMDA (100 µM) + glycine (1 µM), 
as indicated. Synaptosomes were then IP for p-JNK and probed for p-JNK, STX1a and p-STX1a.  
NMDA stimulus alone, as expected, was able to increase the interaction between p-JNK and p-STX1a, as 
indicated by the increased bands signal from the two phosphorylated proteins. JGRi1 in turn was able to decrease 
the level of both STX1a and p-STX1a, confirming the efficacy of the disruption activity of the peptide.  
C) Mice were treated Ip with 1 injection per day of vehicle or JGRi1 (20 mg/kg) and after 7 days the cortices 
were used to prepare synaptosomes further stimulated by NMDA (100 µM) + glycine (1 µM), as indicated. 
Synaptosomes were then IP for p-JNK and probed for p-JNK and STX1a. NMDA alone increased the interaction 
between p-JNK and STX1a while JGRi1 reduced their interaction in both control and NMDA conditions. 
  
 
 
JGRi1 efficiently distributes in the cortex after ICV in vivo injection  
Single ICV injection of FITC-JGRi1 (16ng/5µl) showed that the peptide was able to reach the 
cortical tissue and be maintained there over 24 h. On the other hand, the peptide variant 
lacking the Tat portion (FITC-JGRi1-ΔTat), injected at the same concentration, was not. 
JGRi1 fluorescence was intensely found around cell nuclei stained by DAPI (Fig. 37).     
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Fig. 37 
JGRi1 distributes in the cortex following in vivo ICV administration. 
A) FITC-JGRi1 (16ng/5µl, ICV) and FITC-JGRi1-ΔTat (16ng/5µl, ICV) were administered with a single 
intracerebroventricular injection to wild-type mice. The brains were sliced after 24h. FITC-JGRi1-ΔTat was not 
able to reach the cortex as shown by the absence of FITC fluorescence (first row of confocal images) while 
FITC-JGRi1 was efficiently distributed in the cortex parenchyma as indicated by the green fluorescence 
presence (second row of confocal images). Scale bar = 25 μm. 
 
 
 
JGRi1 disrupts JNK/STX1a interaction and affects STX1a activation in the OGD 
ischemia model 
Preliminary data have been collected to define the JNK2/STX1a interaction also in mouse 
cortical slices under the OGD (oxygen/glucose deprivation) ischemic paradigm, followed by 
immunoprecipitation for p-JNK.  
As already observed in the synaptic compartment, excitotoxicity mimicked by the shortage of 
nutrient and oxygen supply to cortical neurons promoted a valuable increase in the 
phosphorylation of JNK, furthermore accompanied by the augmented interaction with the 
activated p-STX1a (Fig. 38A, unpublished data).  
SNAP25 was instead not pulled down in the JNK/STX complex, as already reported (Cheng 
et al., 2013).  
Notably, pretreatment with JGRi1 (10 µM) reduced both p-JNK levels as well as the 
interaction with the phosphorylated STX1a (Fig. 38A, unpublished data). 
To support this result, the same samples were analysed by Western blot in order to evaluate 
the activation of STX and JNK isoforms.  
OGD to cortical neurons promoted a valuable increase in JNK2 phosphorylation, and, 
interestingly, in this setting also the phosphorylation of JNK1 resulted augmented, possibly 
due to a major involvement of this isoform in apoptotic cell death (Dhanasekaran and Reddy, 
2008; Wang et al., 2007).  
On the other hand, pretreatment with JGRi1 (10 µM) rescued the increase in JNK 
phosphorylation compared to OGD alone (Fig. 38B, unpublished data). 
Coherently with previous findings, OGD additionally increased STX1a phosphorylation 
whereas, as expected, JGRi1 (10 µM) administered 1 h before the insult prevented it (Fig. 
38C, unpublished data). 
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Fig. 38  
JGRi1 disrupts JNK/STX1a interaction in the OGD ischemia model (unpublished data). 
A) p-JNK IP experiment on slices subjected to OGD. JNK phosphorylation was clearly augmented by 
deprivation of oxygen and glucose whilst it was restored by 1 h pretreatment with JGRi1 (10 µM). p-STX1a as 
well resulted increased under OGD injury, suggesting the occurrence of JNK/STX interaction also in this 
experimental model. By contrast, JGRi1 reduced p-STX1a level, whereas SNAP25 was not involved in p-JNK 
pull-down. 
B) Western blotting analysis on slices subjected to OGD. Under this experimental setting, both p-JNK1 and p-
JNK2 levels were augmented, as indicated by higher band reactivity. JGRi1 (10 µM) was able to rescue the 
phosphorylation state of both JNK isoforms. 
C) OGD insult on cortical neurons increased STX1a phosphorylation that was in turn prevented by pretreatment 
with JGRi1 (10 µM), confirming the data already observed in cortical synaptosomes. 
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In vivo brain ischemia is rescued by JGRi1 administration in the MCAo mouse model 
The neuroprotective effect of JGRi1 during brain ischemia was assessed in mice subjected to 
1 h of middle cerebral artery occlusion (MCAo), followed by 24 h of reperfusion. As shown 
in Fig. 39, ICV injection of JGRi1 (16ng/5µl) 30 minutes before the induction of ischemia 
effectively reduced both infarcted areas and volumes in cortical areas when compared to 
control mice (64 ± 9 and 43 ± 6 mm
3
 in saline- and JGRi1-treated mice, respectively; n = 8 
per group, *p < 0.05). 
 
 
 
 
Fig. 39 
JGRi1 rescues infarct insult in the MCAo mouse model. 
Visualization of infarct distribution (pale areas) in toluidine blue-stained coronal brain slices of representative 
saline- or JGRi1-treated mice (left). Effects of JGRi1 (16ng/5µl, ICV) administered 30 minutes before inducing 
ischemia upon infarcted areas (in mm
2
; centre) and infarcted volumes (in mm
3
; right) of mice subjected to 1 h 
MCAo followed by 24 h reperfusion. Data represent the mean ± SEM of 8 mice per group. *p < 0.05, Student's 
t-test. 
 
 
 
Genetic study of STX1A SNPs in blood human samples from stroke patients 
Taking into account the importance of the STX1a protein in the mechanism of SNARE 
trafficking so far described, a pilot study was conducted on human blood samples of a group 
of stroke patients, with the aim of assessing the presence and the implication of STX1A single 
nucleotide polymorphisms (SNPs).  
In the other hand, JNK2 sequence is strongly conserved and does not present any SNP.  
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The SNPs chosen for the gene STX1A have been already reported to be associated with 
pathologies in which excitotoxicity plays an important role, i.e. migraine and autism 
(Corominas et al., 2009; Nakamura et al., 2008). Analysing the STX1A gene sequence, three 
interesting polymorphisms have been identified within introns sequence, namely rs4717806, 
rs6951030 and rs2293489, with the latter being located in WBSCR22 gene, ~6 kbp upstream 
to 5' UTR STX1A gene (Fig. 40A). The analysis of rs2293489 and rs4717806 SNPs showed 
significant differences between Acute Ischemic Stroke (AIS) and Healthy Control (HC) 
subjects in both genotype distributions (pc= 0.024; pc= 0.048 respectively) and allele 
frequencies (p= 0.007; p= 0.012 respectively) (Tab. 2), while no significant association was 
found for rs6951030 (data not shown).  
The logistic regression analysis performed for rs2293489 and rs4717806 showed a correlation 
between T and A nucleotides respectively with high Mini Mental State Evaluation (MMSE) 
scores (pc= 0.004, β= 1.33; pc= 0.012, β= 1.17).  
Due to the strong Linkage disequilibrium (r
2
= 0.91) between rs2293489 and rs4717806, the 
haplotype analysis was performed excluding rs6951030 (Fig. 40B). T-A haplotype is more 
frequent in HC (p= 0.01) while C-T haplotype is more represented among AIS patients (p= 
0.01) (Tab. 3 and Fig. 40C). 
Plink analysis showed that rs2293489/rs4717806 T-A haplotype is significantly associated 
with higher MMSE scores (pc= 0.007; positive value β= 1.20) whereas C-T with lower 
MMSE scores (pc= 0.003; negative value β= -1.32) (Tab. 4).  
The results were confirmed after covariate (age, sex) correction. 
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Fig. 40 
A) Genomic sequence of STX1A and tested SNPs localization. Exons are indicated by boxes, introns are 
indicated by lines. SNPs positions are denoted by arrows.  
B) Linkage Disequilibrium Plot for tested SNPs; r² values are reported. 
C) Haplotype of STX1A rs2293489/rs4717806 frequencies distribution in AIS and HC subjects. **pc = 0.01 
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STX1A SNPs AIS HC pc value OR [95% CI] 
rs2293489     
Genotypes (%)   0.024  
CC 87.5 29.4 0.021 14.77 [1.72-409.2] 
CT 12.5 52.9 0.142 0.137 [0.005-1.156] 
TT 0 17.6 0.590 0 [0.0-3.633] 
Alleles (%)   0.007 11.842 [1.40-100.1] 
C 93.8 55.9 0.007 11.38 [1.719-267.2] 
T 6.2 44.1 0.007 0.088 [0.003-0.581] 
     
rs4717806     
Genotypes (%)   0.048  
AA 0 17.6 0.590 0 [0.0-3.633] 
AT 12.5 47.1 0.238 0.171 [0.006-1.458] 
TT 87.5 35.3 0.042 11.53 [1.361-315] 
Alleles (%)   0.012 0.095 [0.01-0.86] 
A 6.2 41.2 0.012 0.099 [0.004-0.657] 
T 93.8 58.8 0.012 10.11 [1.521-237.9] 
 
Tab. 2  
Genotype and allele distributions of STX1A SNPs rs2293489 and rs4717806 in AIS patients and HC.  
AIS: Acute Ischemic Stroke, HC: Healthy Controls, pc: Pearson’s p value; OR: odd ratio; 95% CI: interval of 
confidence.  
Significant pc values are reported in bold. 
 
 
 
 
 
Tab. 3  
Haplotype distribution of STX1A rs2293489/rs4717806 in AIS patients and HC.  
OR: odd ratio; 95% CI: interval of confidence. 
 
 
 
 
 
SNP1 SNP2 Haplotype Beta STAT pc value 
rs2293489 rs4717806 T-A 1.20 2.937 0.007 
  C-T -1.32 -3.327 0.003 
 
Tab. 4  
Analysis of STX1A haplotype rs2293489/rs4717806 in relation to MMSE score in AIS patients and HC 
subjects. 
 
SNP1 SNP2 Haplotype χ2 p value OR 95% CI 
rs2293489 rs4717806 T-A 6.64 0.01 0.09 0.01-0.76 
  C-T 6.64 0.01 11.05 1.30-93.82 
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DISCUSSION 
 
The breakthroughs achieved by virtue of a deeper scientific knowledge and an improved 
medico-technical expertise have so far attempted to find new therapeutic opportunities in the 
field of neuroprotection. 
Nevertheless, cerebral ischemia still represents a pathology with roughly no prophylaxis, 
limited clinical management, and almost poor prognosis. 
Stroke survivors are generally enslaved by two sequelae: either a second, possibly fatal acute 
stroke or multiple chronic ischemic events, with the risk of recurrence ranging between 5% 
and 20% per year (Gupta et al., 2014). Additionally, the damage correlated to the reperfusion 
injury may be as threatening as the ischemic injury itself. 
Consequently, besides monitoring risk factors in predisposed subjects, the principal goal in 
managing stroke patients is to prevent further cerebrovascular events, since no real primary 
prevention does exist.  
Recommended approaches for secondary prevention include addressing modifiable risk 
factors (high blood pressure and cholesterol), initiating long-term antithrombotic therapy, and 
intervening surgically, when indicated. Unfortunately, the majority of patients are not suitable 
candidates for mechanical or pharmacological thrombolysis, the intervention that presently 
represents the unique FDA-approved treatment for ischemia. In addition, the consensus in the 
stroke medical literature asserts that most of the neuronal demise arises because ischemia 
occurs within a dramatically brief time period, leaving behind a ridiculously narrow 
therapeutic window for neuroprotective cares. 
Combining preclinical and clinical evidence, the time from symptom onset to the provision of 
a feasible intervention for substantial reduction of damage might be as short as 1 hour, 
generally referred to as the “golden hour” (Chamorro et al., 2016). The rapid progression of 
brain damage seems indeed to be almost irreversible already following 3 to 4.5 hours from 
symptoms onset, as observed from MRI and CT scans. 
It appears therefore obvious how urgent and critical should be a robust identification of the 
biochemical mechanisms underlying the ischemic cascade, in order to develop and provide 
more effective and convincing treatments to improve recovery from brain damage or, 
hopefully, even prevent that damage. 
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The major regulatory site for neuronal activity-mediated chemical transmission is the 
presynaptic nerve terminal, embedded with a plethora of metabotropic and ionotropic 
receptors. Among those, NMDA receptors are well-known supporters of the excitotoxic 
glutamate spillover undermining neurons during cerebral ischemia (Lai et al., 2014).  
Sadly, the efforts of both preclinical research and pharmaceutical industries to develop an 
efficient NMDAR inhibitor to contrast excitotoxicity have been unsuccessful over the last 
decades (Chamorro et al., 2016; Ikonomidou and Turski, 2002). One of the possible 
explanation for such widespread discouraging clinical trials failure of NMDAR inhibitors 
might be the inappropriate pharmacological action of these molecules that generally directly 
block the receptor activity, thereby compromising also the normal neurotransmission in 
certain areas of the brain, ultimately leading to harmful adverse effects (Lipton, 2004).  
In an attempt to circumvent past reminiscences of ruinous experimental efforts, and moreover 
considering the poor risks-benefits ratio as well as the limited time widow for appropriate 
intervention in pan-NMDAR-mediated glutamate blockade, we focused our speculations on 
eventual intracellular partners of the NMDA receptors with the aim of disclosing novel 
therapeutic targets that might be more specific, safer and with a delayed opportunity for 
intervention. 
Additionally, beside several evidences reporting the effects of cerebral ischemia at 
postsynaptic sites (i.e. intracellular Ca
2+
 overload, activation of Ca
2+
-induced proteolytic 
enzymes, generation of free radicals), we chose to take into consideration the presynaptic 
terminal, specifically intervening on the modulation of the excessive release of excitatory 
neurotransmitter. 
Herein, we introduce a new molecule specifically designed and produced to inhibit the 
presynaptic NMDA receptor activity, via the blockade of an intracellular downstream 
pathway that we discovered. 
In a recent published work, we already demonstrated that the presynaptic release of glutamate 
evoked by NMDA during excitotoxic conditions is specifically mediated by the cooperation 
between NMDARs and the JNK2 isoform. For the purposes of these previous findings, the 
presynaptic expression of JNK was assessed by using a synaptic fractionation protocol 
supported by immunogold staining, while JNK protein activity was inhibited by means of a 
commercial cell-permeable peptide (L-JNKi1) containing a JNK-binding domain (JBD) 
effector linked to a cargo sequence. 
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Coherently, both L-JNKi1 treated synaptosomes and JNK2 knock-out mice exhibited a drastic 
reduction of glutamate release upon NMDA overstimulation in cortical nerve endings (Nisticò 
et al., 2015).  
Due to the fact that L-JNKi1 competes with JBDs to disrupt the interaction between all JNKs 
and their scaffolding protein JIP, and also considering that JNK2 appeared as the critical 
player involved in NMDAR overactivation, the present work is the natural prosecution of 
previous evidences.  
We indeed investigated a possible molecular mechanism to justify the specific involvement of 
JNK2 in this presynaptic phenomenon, unveiling for the first time that the mechanism by 
which NMDA controls glutamate overflow might pass through the interaction between JNK2, 
presynaptic JIP and other proteins of the release machinery, specifically addressing to the 
strong JNK2/STX1a interplay occurring upon the massive excitotoxic glutamate overflow. 
The observation that JNK2 is expressed in high proportion at synaptic puncta supports our 
functional data, demonstrating that JNK2 can actually interfere with the SNARE complex 
machinery and potentially modulate glutamate release (Nisticò et al., 2015). 
In parallel, STX1a is a presynaptic t-SNARE protein that belongs to the SNARE complex 
machinery and primarily regulates the presynaptic neurotransmitter release (Brunger et al., 
1998), including glutamate (Acuna et al., 2014). Although its physiological activity is 
complex and not yet fully elucidated, STX1a phosphorylation at Ser14 driven by casein 
kinase II is thought to be a crucial step for the protein activation and subsequent assembly of 
the SNARE complex. Furthermore, the raising of the intracellular Ca
2+
 concentration in 
charge of presynaptic membrane depolarization upon NMDA or KCl stimuli is likely the 
signal that triggers STX1a phosphorylation (Foletti et al., 2000; Tian et al., 2003). 
Considering the strong implication of both proteins in this intracellular signaling, we 
evaluated the possible interaction between JNK2 and STX1a as a novel molecular pathway to 
target to specifically inhibit presynaptic NMDA receptor overactivation in the frame of 
ischemic excitotoxicity.  
It is currently definitely ascertained that neuronal exposure to NMDA induces marked 
swelling of cell bodies within 1 hour, followed by total neuronal degeneration over the next 
48 hours (Centeno et al., 2007). 
In this frame, our biological inquiry began by confirming that the expression of both JNK2 
and phosphorylated STX1a is increased at synaptic level by convenient NMDA stimulation.  
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We assessed the actual occurrence of a physical contact between the two proteins by means of 
immunoprecipitation assays that proved the pull-down of STX1a carried by the activated 
JNK.  
In order to identify a possible region of contact between the two proteins, a protein docking 
approach led to the identification of an amino acidic sequence of STX1a univocally 
interacting with JNK2. This specific common contact surface was then exploited to produce 
JGRi1, a cell-permeable peptide (CPP) containing the Tat amino acid sequence to confer cell 
permeability (Chauhan et al., 2007).  
Taking advantage of the fluorescein-tagged version of the peptide, we were effectively able to 
assess the widespread diffusion of FITC-JGRi1 in cortical and hippocampal brain districts 
over 24 hours from intraperitoneal and intracerebroventricular administration. On the other 
hand, the FITC-JGRi1-ΔTat version lacked any evidence of fluorescence at confocal 
observation. 
Thus far, CPPs are becoming widely used pharmacological tools to specifically interfere with 
protein function at intracellular level (Borsello et al., 2003a; Cimini et al., 2016), so that some 
of them are prominently following the pharmaceutical clinical development for distinct 
human pathologies (Dinca et al., 2016a; Guidotti et al., 2017).  
In line with this panorama, our peptide JGRi1 demonstrated to be able to efficiently disrupt 
the presynaptic JNK2/STX1a protein-protein interaction, in turn impeding STX1a 
phosphorylation at Ser14, preventing the SNARE complex formation, and ultimately reducing 
the excitotoxic NMDA-evoked release of glutamate within the ischemic cascade. 
Parallel findings from another research group recently evidenced that both STX1a and STX2 
contain a JNK binding domain (JBD) respectively at 151-155 and 261-270 amino acid 
residues. In their experimental conditions, JNK1 was co-immunoprecipitated with both 
STX1a and 2 while JNK2 and 3 preferentially interacted with STX2 (Biggi et al., 2017). 
In our computational analysis we unveiled a different amino acid cluster (90-103 and 105-109 
amino acid residues) besides the classical JBD that appears highly conserved and specific for 
JNK2 compared to JNK1 and JNK3, being those two proteins more similar among them. 
We identified the JNK2/STX1a interaction in this specific sequence and, consequently, we 
designed and synthetized JGRi1 exactly on that. 
Coherently with our expectations, JGRi1 efficiently disrupted JNK2/STX1a interplay with 
high target specificity, without affecting JNK1/ nor JNK3/STX1a eventual interactions, as 
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evidenced in overexpressing experiments performed in HEK-293 cells and synaptosomal 
preparations.  
Moreover, we did not obtain any evidence of SNAP25 involvement in this initial stage of the 
SNARE complex formation, possibly due to its partial assembly in a primed structure with 
STX1a in resting states, followed by an only belated participation to the release machinery 
(Dawidowski and Cafiso, 2016; Vogel et al., 2000).   
Under a functional point of view, the strong neuroprotective efficacy of JGRi1 is especially 
worth to be mentioned. Indeed, we tested JGRi1 on several experimental paradigms, 
delineating an encouraging widespread activity of neuronal death rescue. 
 JGRi1 reduced presynaptic NMDA-evoked neurotransmitter release from synaptic vesicles in 
synaptosomal preparations, as evaluated via Synaptogreen destaining or tritiated [
3
H]D-
aspartate β–emitting radiation.  
Our peptide also blocked spontaneous presynaptic NMDA currents in electrophysiology 
experiments, and prevented NMDA-elicited neuronal death in neurochemical assays.  
In a more therapeutic perspective, we reproduced the oxygen/glucose deprivation (OGD) 
model of ischemia in mouse cortical slices. In shortage of nutrient and oxygen supply, JGRi1 
was again able to interfere with JNK2/STX1a interaction, restoring the levels of 
phosphorylated proteins back to the control undeprived ones.  
Finally, we performed an in vivo experiment using the well characterized model of transient 
focal brain ischemia produced in mouse via the occlusion of the middle cerebral artery 
(MCAo) (Muzzi et al., 2012). JGRi1 administered as intracerebroventricular injection 30 min 
before ischemia induction demonstrated a valuable neuroprotective effect on infarcted 
cerebral tissue. Upon JGRi1 pretreatment, indeed, both injured area and volume were 
significantly reduced, with an almost complete protection in cortical regions.  
This striking result, obtained for the first time with a specific presynaptic JNK2 inhibitor, 
suggests that prevention of excitotoxicity can really represent a valuable and efficient 
approach to reduce brain damage. Since glutamate blood levels can be easily measured and 
assessed as a biomarker for stroke (Jickling and Sharp, 2011), we believe that safe anti-
excitotoxic drugs like JGRi1 could be particularly useful in the clinical practice within a 
proper time window, aiming not only at the perspective of containing ongoing neuronal 
demise, but especially at preventing and protecting the brain from recurrent ischemic 
episodes.  
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In conclusion, the possibility to finely predict a pathology onset with specific biomarkers 
undoubtedly represents a major fundamental goal of preventive medicine, particularly when 
these pathologies plod along in finding a suitable therapeutic treatment.  
 The evaluation of genetic predisposition in this context is an important yet valuable issue to 
consider. 
Given the key role played by STX1a in the mechanism of vesicle release, we wonder whether 
there could be any genomic participation to stroke susceptibility, hypothesizing that it should 
be interesting to study the genetic variants of STX1A gene. 
We did not consider JNK2 in the genomic analysis since its sequence is conversely highly 
conserved. 
From a careful examination of the scientific literature, we identified three single nucleotide 
polymorphisms (SNPs) of STX1A already associated with migraine and autisms (Corominas 
et al., 2009; Nakamura et al., 2008), other pathologies wherein excitotoxicity contributes to 
the etiology. We therefore ran a pilot study to analyse the SNPs profiles from blood samples 
of a cohort of acute ischemic stroke (AIS) patients, in order to confirm the clinical relevance 
of our data. 
The genotype analysis evidenced that two of these polymorphisms (rs229489 C/T and 
rs4717806 A/T) are significantly associated with AIS both for alleles (C and T respectively) 
and for homozygous genotypes (CC and TT respectively). In line with these findings, the 
haplotype rs2293489/rs4717806 C-T is more frequent in AIS patients with a positive risk 
related to stroke and, as expected, is associated with lower MMSE scores. Conversely, the 
logistic regression analysis showed that rs2293489 (T) and rs4717806 (A) alleles are instead 
associated with higher MMSE scores, in agreement with the protective role already described 
for autism, concerning the rs4717806 (A) allele (Corominas et al., 2009). 
Overall, we have associated here for the first time these intronic SNPs on STX1A gene with 
the susceptibility to acute ischemic stroke in the Caucasian population, speculating a potential 
role for STX1a expression, in addition to cis- and trans-acting factors, to its implication in the 
excessive glutamate release from presynaptic sites in times of excitotoxicity (Durdiaková et 
al., 2014; Nakamura et al., 2011, 2008).  
 
Glutamate-mediated injury remains a fundamental yet unmet clinical target. So far, several 
research attempts tried to disclose novel drugs or pharmacological approaches in the field of 
neuroprotection for either preventive therapy or ongoing post-stroke clinical management.  
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At present, patients subjected to chronic stroke recurrence are mostly managed with 
anticoagulants like aspirin, either alone or in combination with some other cardiovascular 
drugs including clopidogrel or dipyridamole. The rate of clinical success remains in any case 
very modest, since no specific drug has be so far formulated to purposely tackle excitotoxicity 
(Diener, 2006). Even the promising NMDAR inhibitors failed in their goal, due to their lack 
of selectivity of action and consequent undesired adverse effects. 
In this demoralizing scenario sprinkled by the withdrawal of many new molecules from 
clinical trials, we yearn to propose a novel tool effectively able to address a precise 
intracellular molecular mechanism, in order to ensure the pharmacological safety and avoid 
any unpleasant off-target consequence. Additionally, we make it cell-permeable and we tested 
it in a plethora of different experimental paradigms mimicking in vivo human ischemia, in 
order to assess the real neuroprotective efficacy. 
In the present medical panorama poor in neuroprotective agents, we hope that JGRi1 could 
represent the difference. On purpose, JGRi1 was patented with the indication of “cell-
permeable peptide system for treating diseases caused by excitotoxicity” (n° WO 2015150934 
A1) and is presently following the pharmaceutical development for clinical translatability and 
trial inclusion in the setting of excitotoxicity-linked pathologies.  
If there is a reason in science, and undoubtedly there is, our present reason is the attempt to 
offer a chance for a respectable life to people torn apart by devastating ischemic attacks.  
JGRi1 could be the instrument to sublimate our reason. 
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